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Abstract 
 
Conventional approaches for the discovery of bioactive small 
molecules typically follow a cycle of design, synthesis, purification and 
testing. This workflow usually employs a narrow toolkit of robust chemical 
reactions, and places equal value on every chemical entity regardless of 
bioactivity. Consequently, significant effort is invested into designing, making 
and purifying large numbers of compounds with low levels of bioactivity.  
 
Activity-Directed Synthesis (ADS) places the focus exclusively on 
bioactive molecules during the discovery phase, using activity to guide 
syntheses through an iterative discovery cycle. ADS exploits chemistry that 
may yield multiple product outcomes and are not commonly integrated into 
traditional discovery workflows. The process is structure-blind and function-
driven, permitting the discovery of bioactive small molecules and their 
associated synthetic routes in parallel, mimicking elements of the process in 
which small molecule natural products are produced via biosynthetic 
pathways in nature. 
 
Integration of new chemistries into the ADS workflow would permit 
exploration of more diverse areas of chemical space using the approach. 
Organocatalysis was recognised to have potential to generate a wide range 
of scaffolds in a combinatorial manner and is robust enough to tolerate the 
miniaturised high-throughput format required for ADS. The potential for the 
use of organocatalysis in ADS was explored and successfully translated into 
a micro-scale format for application in ADS. Additionally, protocols were 
developed to remove undesirable functional groups from product mixtures 
prior to screening. 
 
The miniaturised organocatalytic chemistry was then applied in ADS 
to reaction arrays, seeking to use organocatalysis in ADS to discover novel 
androgen receptor agonists. Different strategies for reaction array design 
were developed, in addition to protocols for efficient execution of reaction 
arrays. Both conversion and bioactivity of product mixtures were assessed 
v 
using a TR-FRET assay and NMR, highlighting issues that significantly 
decreased the number of reactions that yielded intermolecular products. 
However, successful identification of bioactive components within product 
mixtures that were not the result of intermolecular reactions demonstrated 
the potential for the protocols developed to be successful in identifying 
bioactive small molecules. Consequently, ADS is now poised to utilise 
organocatalysis to attempt to generate bioactive molecules for alternative 
biological targets. 
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1 Introduction 
 
Nature has provided an invaluable number of biologically active small 
molecules that have served as great inspiration to medicinal chemists. The 
structural complexity and bioactive diversity of natural products is well 
documented, and their influence on drug design is evident. The FDA (US 
Food and Drug Administration) had approved a total of 547 natural products 
and associated derivatives as small molecule therapies by the end of 2013, 
representing more than one-third (38%) of all approved molecular entities.1  
 
In contrast, the efficient exploration of diverse areas of chemical 
space by medicinal chemists in recent years has been less effective. It has 
been proposed that this is largely due to an over-reliance on a well-
established but narrow set of synthetic methods, and compound libraries 
that have not managed to explore biologically relevant chemical space 
efficiently.2,3 An analysis of the CAS registry suggested that around half of all 
known compounds are based upon 0.25% of known molecular frameworks, 
demonstrating an evident lack of diversity between known compounds, and 
by consequence their inefficient exploration of biologically relevant chemical 
space.  
 
 
 
Figure 1.1 – An overview of the pipeline for the discovery and development 
of new drugs. 
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As the total spend on research and development costs increases year 
on year, with ever increasing rates of attrition of clinical candidates (Figure 
1.1), new strategies that result in the identification of high-quality bioactive 
hit molecules in the early stages of the drug discovery process are required. 
Higher quality starting points should help to avoid the massive expense of 
clinical candidate failures during the later stages of the drug discovery 
process.4  
 
Natural products have been optimised via an evolutionary natural 
selection process to possess functional benefit for the host organism. This 
process often results in natural products that have structures with high 
affinity for their intended biological targets.5 Analysis of the structural 
properties of natural products demonstrates there to be a greater number of 
chiral centres, bridgeheads, rings and rotatable bonds per molecule in 
natural products than in pharmaceutical compounds in development. This 
shows that they display more structural complexity in comparison to 
synthetic compounds designed by medicinal chemists.6 This structural 
complexity leads to an innate tendency for natural products to display potent 
bioactivity, as they can explore more diverse areas of chemical space in 
contrast to synthetic compounds. 
 
New strategies that increase the efficient development of bioactive 
molecules with similar characteristics to natural products are therefore of 
great importance, helping medicinal chemists move further away from 
compound libraries that do not explore chemical space efficiently. This 
introduction explores commonly used approaches that chemists use to 
discover bioactive molecules that are suitable as starting points in drug 
discovery. A new approach will then be discussed - Activity-Directed 
Synthesis (ADS): a function-driven, structure-blind approach to bioactive 
molecule discovery that mimics some aspects of the process used by nature 
to enable the emergence of natural products. 
 
3 
1.1 Current Approaches to Bioactive Molecule Discovery 
 
To discover a bioactive small molecule that is a suitable clinical 
candidate as a therapy for a disease, a suitable chemical starting point must 
be identified using a lead generation strategy. Recent analysis of hit-to-
candidate projects published in J. Med. Chem. in 2016-2017 shows that 
while 43% of clinical candidates were generated from previously known 
ligands, the remainder of clinical candidates were discovered using a range 
of de novo lead generation strategies.7 A selection of these strategies will be 
more discussed in more detail.  
 
 
 
1.1.1 Current Medicinal Chemistry Toolbox 
 
Medicinal chemists have gravitated towards the use of a narrow 
toolkit of reactions that prioritise synthetic accessibility and the ability to 
deliver compounds, over the efficient exploration of chemical space.2,8,9 
Despite unprecedented advances in the range of available synthetic 
methods, the reactions that medicinal chemists use during the drug 
discovery process have remained remarkably similar, demonstrating a high 
barrier to entry for new synthetic methodologies. The bias towards these 
reactions has led to development of compounds that have a low fraction of 
43.00%  Known
29.00%  Random Screen
14.00%  Structure-Based Drug Discovery
8.00%  Directed Screen
5.00%  Fragment-Based Drug Discovery
1.00%  DNA-Encoded Libraries
Figure 1.2 – Sources of hit-to-candidate pairs from articles in J. Med. Chem. 
during the period 2016-2017 (n = 66). Figure adapted from referenced 
article.7  
4 
sp3-hybridised carbon centres and are largely lipophilic: properties that are 
not usually observed in either successful drugs or natural products.10 
Medicinal chemists are also guided by Lipinski’s work linking his ‘Rule of 5’ 
for physiochemical properties to oral absorption of drug molecules. These 
parameters are often at odds with the chemistries commonly used within 
drug discovery, as they feature aromatic or unsaturated functionality that 
tends to increase lipophilicity.11 
 
As can be observed in Figure 1.3, an analysis of articles in the 
Journal of Medicinal Chemistry demonstrated that the palette of reactions 
that medicinal chemists have used has barely changed in 30 years. Of the 
top ten most commonly used reactions from articles in 2014, only the 
Suzuki-Miyaura coupling has been developed within the last 40 years. This 
clearly shows that uptake of newly discovered novel reactions has been 
poor, with the opportunity cost of this being structural diversity and potential 
bioactivity of compounds. Considering the extensive potential and novel 
reactivity of recently developed methods including, but not limited to, late-
stage functionalisation, C-H activation and photoredox coupling; it is 
surprising that these chemistries have not been added to the palette of 
reactions commonly used by synthetic medicinal chemists.12–14 However, 
there has been increased recognition that integration of such methods into 
discovery workflows could add significant value and lead to the accession of 
unexplored chemical space.15,16 
 
Additionally, commercially available building blocks are reflective of 
the currently used chemistries, offering great diversity and availability for 
starting reagents, but often no or very little diversity for reagents that are 
required for new methodologies.2 Analyses of molecular shape diversity 
have demonstrated that the limitations of the chemistry toolbox may have led 
to significant overpopulation of certain types of molecular shapes, hampering 
the structural diversity required to efficiently explore biologically relevant 
chemical space. 
 
5 
 
 
As such, it is essential that new approaches to discovering bioactive 
small molecules attempt to increase structural diversity by incorporating less 
commonly used synthetic methodology. This should consequently allow 
access to unexplored areas of chemical space that could lead to hits that 
would otherwise not be uncovered using chemistries currently employed in 
pharmaceutical discovery processes. 
 
1.1.2 High-Throughput Screening of Diverse Libraries 
 
Medicinal chemists have often initiated drug discovery programmes 
by screening large libraries of compounds using an in vitro biological assay, 
a process known as High-Throughput Screening (HTS).17 HTS is the 
automated screening of a large numbers of molecules, with active hit 
compounds providing an entry point for drug discovery projects.18 Each 
compound in the library is screened in a high-throughput assay, and the 
Figure 1.3 - Occurrence of reaction classes, plotted as the percentage of 
which it shows up in at least one manuscript (n = 125; representative data set 
taken from J. Med. Chem. in 2014 and 1984).8 Figure adapted from J. Med. 
Chem., 2016, 59, 4443–4458.  
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activity of each compound reported. Further validation of any active 
compounds can provide an entry point for medicinal chemists into the drug 
discovery process. The total number of small molecule drugs that have been 
found to have originated from HTS is thought to be roughly 50%.19 However, 
recent additions to the hit discovery toolbox may have decreased this 
reliance on HTS - a recent analysis of articles from the Journal of Medicinal 
Chemistry between 2016 and 2017 demonstrated that 31% of candidate 
starting points sampled were identified via a random HTS.7 
 
 One drug currently on the market that was the result of a successful 
HTS project is Sorafenib, a multi-kinase inhibitor used for the treatment of 
advanced renal cell carcinoma.20 Raf serine/threonine kinase isoforms 
cRaf1, MEK1, or ERK2 were identified as suitable targets due to their vital 
role in the MAPK cascade involved in cellular proliferation and survival.21 A 
scintillation proximity assay was used in the HTS campaign that allowed 
detection of inhibitors of the kinases cRaf1, MEK1, or ERK2.22 A HTS 
campaign was initiated, screening around 200,000 compounds, with one 
compound identified as a promising hit with an IC50 of 17 μM (Figure 1.4). 
Optimisation of the hit by evolving the compound with a range of synthetic 
transformations, notably generation of a library of bis-aryl analogues via 
parallel synthesis, increased the potency. Structure-Activity Relationship 
(SAR) studies informed the design and synthesis of more analogues until 
Sorafenib was identified as a nanomolar modulator of Raf1. 
 
The example shown in Figure 1.4 is an example of extensive 
optimisation of HTS hits using a reliable toolkit of synthetic methods, and this 
process has led to the discovery of many effective drugs.23 However, high 
clinical failure rates have led to escalating downstream costs and doubts as 
to the efficiency of this linear process. 
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The majority of compounds generated from HTS-initiated programs 
have also tended to be flat, aromatic and achiral; with high sp2 character.24 
This is speculated to be a result of the dependence upon the previously 
mentioned toolkit of reliable synthetic methods,2 in addition to pressure to 
abide explicitly with guidelines to make compounds with lead-like properties. 
Emphasis appears to have been placed upon synthetic accessibility of 
scaffolds screened in biochemical assays rather than the true diversity of 
compound libraries, limiting the proportion of three-dimensional chemical 
space that the can be explored.11 One approach to tackle this issue is Lead-
Oriented Synthesis which focuses on the synthesis of diverse compounds 
with lead-like molecular properties. 
 
Figure 1.4 – Overview of the discovery of Sorafenib utilising HTS and 
subsequent optimisation via SAR studies.20 
8 
HTS clearly has value in generating excellent starting points for drug 
discovery, and ongoing curation of the libraries utilised is essential for it to 
continue to be a productive source of hits. Development of higher quality 
screening libraries that explore novel chemical space is therefore prudent to 
prevent declining productivity.25 
 
 
1.1.3  Diversity- and Lead-Oriented Synthesis 
 
Diversity-Oriented Synthesis (DOS) is a strategy facilitating the 
generation of novel and diverse combinatorial libraries that can be screened 
against a variety of targets in order to support the discovery of bioactive 
molecules.26,27 In contrast to traditional target-oriented approaches that aim 
to access precise regions of chemical space with respect to a specified 
target, DOS utilises a range of synthetic strategies to obtain diverse novel 
scaffolds.28 By maximising diversity in the molecular scaffold and its 
appendage, functional groups and stereochemistry, small DOS libraries of 
compounds that vary in structure can be generated to efficiently explore 
chemical space. These libraries aim to generate compounds with novel 
frameworks that can be added to screening libraries, offering diversity that 
does not currently exist in many HTS compound collections. 
 
The strategies employed in DOS to achieve skeletal diversity utilise 
highly functionalised molecules, or molecules that contain functionality 
capable of forming numerous different scaffolds. When treated with 
reagents, functional groups pair within the molecule to form new scaffolds, or 
different reactions occur at the functionality dependent on the conditions 
employed (Figure 1.5).29 Efficient, high yielding, and stereoselective 
reactions are used over a number of steps to assemble a small library of 
diverse compounds. By using a divergent strategy in which forward synthetic 
analysis is utilised, complex and diverse areas of chemical space can be 
explored.30 
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Spring et al. synthesised a DOS compound library using rhodium-
carbenoid chemistry.31 Utilising a reagent-based approach, once a 
functionalised substrate had been generated, the group was able to 
synthesise 35 structurally diverse scaffolds by performing different 
transformations and couplings (Scheme 1.1). Screening of the compound 
collection revealed two compounds that displayed anti-mitotic activity in 
cells. Further modification of these compounds facilitated the identification of 
(S)-Dosabulin, a novel small molecule capable of arresting mitosis by 
depolymerising microtubules with sub-micromolar efficacy. This discovery 
validated DOS in tandem with phenotypic screening as an effective strategy 
for the identification of bioactive entities. 
 
DOS is a highly efficient strategy in obtaining libraries of diverse 
compounds for use in screening, but the strategy still requires the synthesis 
and rational design of molecules that may not display activity in a target-
driven approach. Additionally, synthetic and scaffold diversity is prioritised 
over the utility of the products made, with no consideration given to the 
molecular properties of the products formed. 
 
Figure 1.5 – The two principal approaches to scaffold diversity in DOS. (a) 
Reagent-based approach in which different reagents (x, y and z) cause 
diverse scaffolds to be formed from the same starting material. (b) Substrate-
based approach in which the same reaction conditions (x) are used, but 
different reactivity (𝜶, 𝜷 and 𝜸) is encoded within the substrate. 
10 
 
 
Lead-Oriented Synthesis (LOS) is a similar concept to DOS, that aims 
to deliver shape-diverse libraries of compounds. However, unlike DOS, 
compounds discovered via LOS must have specific lead-like molecular 
properties that give them higher utility in the drug discovery process.32 
Molecules should also be tolerant to a wide range of polar functional groups, 
be without residual reactive centres, and not be susceptible to LogP drift – a 
phenomenon whereby reactions tend to occur with higher efficiency with 
substrates that possess more non-polar functionality, making them more 
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Scheme 1.1 - Selection of products generated in a diversity-oriented 
synthesis that enabled identification of a modulator of mitosis. By using a 
reagent-based approach, numerous diverse scaffolds were synthesised from 
a common starting material containing multiple functional groups. a) 
cyclopentadiene, Rh2(OAc)4 (1 mol%), DCM; b) mCPBA, DCM; c) OsO4 (2.5 
mol%), NMO, acetone-H2O (9:1); d) 2,6-lutidine, NMO, OsO4 (2.5 mol%), 
PhI(OAc)2, acetone-H2O (10:1), then NH2R, NaBH(OAc)3, DCM; e) 2,6-
lutidine, NMO, OsO4 (2.5 mol%), PhI(OAc)2, acetone-H2O (10:1), then 
NaBH4, MeOH; f) alkene, Hoveyda-Grubbs (II) catalyst (10 mol%), ethylene, 
toluene, 100oC; g) Pd(OAc)2 (10 mol%), PPh3 (15 mol%), (HO)2B-
Heterocycle, 2N K2CO3, toluene, 90oC; 
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synthetically tractable.33  Additionally, synthetic routes to compounds must 
utilise cheap reagents and conditions, allowing easy translation of the 
chemistry into a drug discovery setting. 
 
 
 
Foley et. al. demonstrated an example of a ‘top-down’ LOS approach, 
in which compound libraries based on many diverse natural product-like 
scaffolds were synthesised (Scheme 1.2).34,35  The approach used a [5+2] 
cycloaddition to obtain a cycloadduct, that was subjected to synthetic 
strategies such as cleavage, addition of new functionality and ring 
expansion, to generate 26 diverse scaffolds from the same key intermediate.  
Four of these scaffolds were subsequently decorated, enabling the 
production of over 2900 medicinally relevant screening compounds. Notably, 
the scaffolds had broad natural product-like features, but were only distantly 
related to specific natural products themselves, hence providing attractive 
starting points for drug discovery. This approach is discussed further in 
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Scheme 1.2 – Overview of a ‘top-down’ approach to LOS to develop a 
number of libraries based upon lead-like scaffolds. 
Key Intermediate 
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Chapter 5, as my contributions to this project resulted in the delivery of a 
number of compounds that populated one of the synthesised libraries. 
 
 
1.1.4  Structure-Based Design 
 
Structure-Based Drug Design (SBDD) is a more rational approach to 
drug discovery than HTS, that uses the known structure of a biological target 
to direct the design of bioactive molecules (Figure 1.6). By determining the 
structure of the target protein, compounds or fragments can be docked into 
regions of the structure in silico and arbitrarily scored based on their 
predicted interactions with the target.36 Acquisition of these compounds and 
testing via a biochemical assay allows experimental efficacy values to be 
obtained, which can be compared to the scoring functions generated by 
computer algorithms. 
 
 
 
The scoring functions produced by algorithms serve to prioritise 
compounds for synthesis and assaying, by attempting to reduce the volume 
of synthesis required to obtain active compounds. Structural determination of 
a modulator in complex with the target reveals potential sites for optimisation 
on the ligand that can be altered to increase potency. After several rounds of 
Figure 1.6 - Flow chart demonstrating the a typical iterative process of a 
Structure-Based Drug Design campaign.36 
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this process, compounds with sufficiently high specificity and potency can be 
identified and taken forward in the drug discovery process as candidate 
molecules. 
 
Table 1.1 details an example of a clinical candidate discovered with 
the aid of SBDD, the HIV protease inhibitor L-735,524.37 Initial in silico 
modelling of the inhibitor L-685,434 in complex with HIV protease enabled 
structure guided optimisation of the hit compound, with the aim of designing 
 
  
Compound R cIC95 (nM) IC50 (nM) 
3 
 
400 7.8 
11 
 
1500 347 
12 
 
n.d. 80 
13 
 
>400 15 
14 
(L-732,747) 
 
100 0.35 
 
Table 1.1 – Compounds investigated during the structure-guided optimisation 
of L-685,434 to L-732,747, an inhibitor of HIV protease.37 cIC95 = 
computationally predicted concentration to observe a 95% inhibitory effect. 
OH
N
H
O
OH
Ph
BocHN
L-685,434
OH
N
H
O
OH
Ph
R
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a more potent competitive inhibitor of the enzyme. L-685,434 lacked 
appropriate solubility and pharmacokinetic properties, and it was 
hypothesised that incorporating a basic amine into the structure of the 
compound could improve bioavailability and aqueous solubility. Incorporation 
of the amine into a ring would also limit the conformational freedom. A 
selection of the molecules designed in silico, synthesised and tested during 
the optimisation process are shown in Table 1.1. The information generated 
from the in silico docking and scoring was evidently efficiently used to 
increase the potency of the hit compound, enabling discovery of L-732,747. 
 
The SBDD approach, when used in combination with hits provided 
from HTS screens, provides a powerful method of generating potent lead 
compounds, allowing faster access to a quantitative understanding of the 
interactions a ligand and the desired target.38 However, there are inherent 
errors of the algorithms used in the docking and scoring process. In silico 
docking do not always correlate to experimental in vitro activity, but indicate 
a higher probability of discovering an active ligand.39 This is in part due to 
failures to consider role of solvent in the binding site, desolvation of the 
inhibitor, and the conformational variability of the inhibitor and the target.40 In 
addition, in silico scoring of fragments can only be initiated in cases where 
the biological target is fully defined. As such, it remains only a technique 
useful for guiding chemists in making rational decisions in the optimisation of 
lead compounds, rather than a strategy for generating novel scaffolds that 
explore new areas of chemical space. 
 
1.1.5 Fragment-Based Discovery 
 
In 1996, Fesik et al. reported a new technique for identifying 
compounds with nanomolar affinities for their desired target, a method they 
described as “SAR by NMR”.41 Weakly binding small organic molecule 
fragments (with millimolar/high-micromolar activity) were identified by 
detecting chemical shift changes in 15N-labelled protein targets via 
heteronuclear single quantum coherence (HSQC) spectroscopy. Once 
several weakly binding fragments had been identified and optimised at 
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different, but proximal residues of the protein, X-ray crystallography was 
carried out to find the location and orientation of the fragments interacting 
with the target, and the weakly binding fragments linked together to obtain 
ligands with nanomolar affinities. 
 
 
 
This technique has evolved into what is now commonly known as 
Fragment-Based Drug Discovery (FBDD), and has rapidly developed over 
the last 20 years into a popular and viable alternative to methods such as 
HTS (Figure 1.7).42 By screening libraries of fragments, each with typically 
up to ~18 heavy atoms,43 rather than much larger libraries of drug-like 
compounds with up to 30 heavy atoms, both the speed and efficiency of 
screening are increased. This is due to the observation that for each heavy 
atom added to a molecule, there are roughly an order of magnitude more 
molecules in chemical space that are possible to explore, hence the 
fragments sample chemical space much more efficiently.44 Biological protein 
targets present complex surfaces for ligands to bind, and fragments are 
capable of exhibiting high-quality well-defined interactions with a target, 
despite demonstrating binding affinities in much higher millimolar ranges. 
For this reason, the concept of ligand efficiency (LE) was defined as the free 
energy of binding of a ligand divided by its heavy atom account, and is a 
common metric calculated to determine binding efficiency of a fragment.45  
 
Figure 1.7 – Overview of Fragment-Based Drug Discovery. 
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Numerous FBDD leads have now been progressed into clinical 
trials,42,46 showing the enthusiasm of academic groups and pharmaceutical 
companies in adopting the strategy. An example of a clinical candidate 
discovered via fragment-based drug discovery is the -site amyloid 
precursor protein cleaving enzyme 1 (BACE1) inhibitor Verubecestat (Figure 
1.8).47 Beginning from a selection of isothiourea fragment hits, further 
development aided by SBDD provided insights that enabled optimisation of 
the pharmacophore, resulting in an iminohydantoin lead compound. The 
lead displayed high ligand efficiency, and improved binding, in part to the 
projection of the phenyl group into a hydrophobic pocket of the protein. 
Further optimisation enabled improved potency and selectivity, eventually 
resulting in the discovery of Verubecestat, which eventually progressed to be 
a clinical candidate targeting mild to moderate prodromal Alzheimer’s 
disease. 
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Figure 1.8 – Overview of the discovery of Verubecestat, a BACE1 inhibitor, 
using a fragment-based approach. 
KD (NMR) 550 M KD (NMR) 15 M 
Ki 3.7 M (LE 0.37) Ki 696 nM 
Verubecestat (MK-8931) 
BACE1 Ki 2.2 nM 
Cell IC50 2.1 nM 
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1.1.6 Emerging High-Throughput Discovery Methods 
 
Miniaturisation and parallel processing have allowed acceleration of 
drug discovery workflow. Such approaches have already been implemented 
effectively for high-throughput discovery of chemical reactions and reaction 
optimisation, in which arrays of catalysts and ligands with diverse mixtures of 
substrates have been assembled, in addition to methods that allow bioactive 
molecule discovery. 
 
 
The processes of high-throughput chemical synthesis, reaction 
optimisation and screening on a biochemical assay have been integrated to 
good effect. Miniaturisation and parallel processing enabled the high-
throughput optimisation of a lead compound that inhibited diacylglycerol 
Figure 1.9 – An overview of microscale high-throughput optimisation applied 
to the discovery of spiropiperidine DGAT1 inhibitors. 
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acyltransferase (DGAT1) (Figure 1.9).48 The lead was a potent modulator of 
DGAT1, but exhibited poor selectivity and solubility. Miniaturised reaction 
arrays enabled optimisation of challenging SNAr reactions: variation of base, 
solvent and substrate class enabled the discovery of robust synthetic 
conditions. These conditions enabled the synthesis of a spiropiperidine 
compound that exhibited good potency but poor solubility. A series of 
analogues was made that led to the discovery of a more potent, selective 
and soluble lead compound. 
 
 
 
 
On-chip IC50 = 7  0 nM 
Plate-based IC50 = 17 nM 
On-chip IC50 = 59.5  19 nM 
Plate-based IC50 = 66 nM 
 
Technology that integrates both synthetic and biological evaluation in-
flow has also been established. A notable example explored the SAR of a 
series of inhibitors of the protease beta-secretase 1 (BACE1), in which 
N
O
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F
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F F
O
N
F
Figure 1.10 – Overview of a flow-reaction and screening based workflow 
utilised to generate SAR for a series of inhibitors of BACE1.49 
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aniline core fragments were coupled in flow to carboxylic acid building blocks 
(Figure 1.10).49 The workflow facilitated the integrated synthesis, 
purification, and screening of each product made using an on-chip flow-
based biochemical assay, altering the concentration gradient flowing through 
a capillary. The hit compounds demonstrated to be active using the flow 
system were screened individually using a plate-based assay, allowing 
validation of their activity.  This workflow allowed dose-dependency to be 
rapidly established for each compound in around one hour, enabling the 
definition of SAR for a series of inhibitors. 
 
Cernak et. al. described a method entitled NanoSAR, in which 
nanomole-scale Suzuki and C-N coupling reactions mixtures were screened 
on a label-free affinity-selection mass spectrometry bioassay to discover 
modulators for three kinase targets.50 A known fragment was derivatised via 
nanoscale reactions, utilising a range of building blocks, with reaction 
conditions optimised to match each specific building block. Crude reaction 
mixtures were then analysed by ultra HPLC-mass-spectrometry to assess 
conversion and reaction efficiency, before being screened on an affinity-
selection mass spectrometry bioassay. This allowed screening of a range of 
reaction conditions for each combination of building blocks used, and the 
affinities of the crude mixtures for the target were then ranked. Mixtures 
showing the highest affinity were then reproduced on a larger scale to 
identify products. Using this method, potent modulators of all three kinases 
were discovered using the nanoscale reactions that required minimal 
consumption of chemical matter. Figure 1.11 demonstrates this workflow for 
one of the kinase targets, Checkpoint kinase 1 (CHK1). 
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Figure 1.11 – Overview of the discovery of inhibitors for CHK1 kinase, 
utilising the NanoSAR technique. 
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1.2 Activity-Directed Synthesis (ADS) 
 
Activity-Directed Synthesis (ADS) is a novel bioactive molecule 
discovery approach in which molecule activity directs the emergence of an 
associated synthesis.51 By exploring chemistries where alteration of the 
catalyst or conditions results in a diverse range of outcomes, a range of 
complex products can be formed enabling the exploration of a wider area of 
biologically relevant chemical space. Taking inspiration from the evolution of 
natural products, the focus is placed on molecules that are biologically 
active. 
 
1.2.1 Natural Product Biosynthesis 
 
Natural products have emerged to provide functional benefit to the 
host organism that produces them. Diverse substances produced as 
products in biosynthetic pathways within bacteria, plants, fungi, and other 
lower organisms that lack an immune system, or tend to inhabit competitive 
ecosystems. The complex and varied structures of these substances are 
produced by similarly sophisticated biosynthetic pathways that are driven by 
functional benefit to the host organism.  It has been suggested that bioactive 
secondary metabolites are capable of boosting an organism’s fitness for 
survival by increasing their ability to compete within an ecosystem.52 The 
activity of a secondary metabolite is therefore a consequence of its structure, 
as natural selection results in the production of molecules whose activity has 
assisted their host organism’s survival.53 The evolution of biosynthetic 
pathways is therefore structure-blind and function-driven, which contrasts 
sharply with human-led ligand discovery approaches. 
 
Figure 1.12 outlines the biosynthetic pathway of terpenes, the largest 
class of natural products that are found in a variety of plants, animals and 
microorganisms.54 The enzyme terpene cyclase produces a range of 
different structures by catalysing the cyclisation of different isoprenoid 
pyrophosphate units that are produced via the mevalonate pathway. Five-
carbon building blocks such as isopentenyl pyrophosphate (IPP) and 
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dimethylallyl pyrophosphate (DMAPP) are precursors for primary 
metabolites like testosterone, the carotenoids and coenzyme Q. Other 
secondary metabolites are also produced: monoterpenes from geranyl 
pyrophosphate, sesquiterpenes from farnesyl pyrophosophate; and 
diterpenes from geranylgeranyl pyrophosphate. Terpene cyclases have very 
little primary sequence homology despite being structurally similar, 
suggesting the different classes have diverged rapidly from a common 
enzyme ancestor. 
 
Figure 1.12 – A schematic overview of terpene biosynthesis that yields 
a diverse range of functional natural products.54 
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1.2.2 Strategy Underpinning ADS 
 
ADS is a structure-blind, function-driven iterative process in which 
arrays of reactions are designed with the purpose of combining the synthesis 
and screening process to inform the design of bioactive molecules.55 By 
considering the reaction starting materials to be analogous to metabolites 
and the reagents and catalysts to be analogous to biosynthetic proteins, it is 
possible to mimic some aspects of the emergence of natural products in 
nature. 
 
Using a microwell plate, reactions are carried out on a small scale 
(e.g. 100 L) (see Figure 1.13). The substrates and catalyst in each well are 
varied in order to generate a range of products. Following the reaction, the 
catalysts and solvent are removed from each well, and the products 
dissolved in DMSO, then buffer, and screened using the selected assay. The 
data from screening are analysed and the results inform the design of a 
subsequent array of reactions. This subsequent reaction array can be 
screened at lower concentrations, incorporating selection pressures into the 
protocol. This process is repeated until a reaction yielding a sufficiently 
promising bioactive compound is found, at which point the reaction is scaled 
up, and the active product within the mixture of products isolated, 
characterised, and the biological activity verified and evaluated. Reactions 
with multiple possible outcomes are ideally used in ADS rather than 
optimised reactions with high yields and selectivity. This enables the 
screening of an array of diverse compounds against the desired biological 
target, allowing comparison of multiple chemotypes.  
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Figure 1.13 - Overview of Activity-Directed Synthesis. Arrays of reactions are 
performed with variable substrates, catalyst and solvents. The resulting 
product mixtures are scavenged, then assayed to identify reactions yielding 
bioactive products. Analysis of each round of screening can inform the design 
of a subsequent array of reactions. 
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1.2.3 ADS Case Study 
 
Initial work by Karageorgis et al. used metal-
carbenoid chemistry to validate the ADS approach with 
intramolecular reactions, employing the Androgen 
Receptor as a model target.51 -Diazo carbonyl 
compounds are able to participate in many 
intermolecular reactions56 (C-H, N-H and O-H insertions; cycloadditions, 
cyclopropanation) in addition to intramolecular reactions forming various new 
rings from the existing substrate scaffold.57 The designed diazo substrates 
contained aryl-amide motif 1, adapted from a trifluoromethyl aryl fragment 
that had been identified in a previous report as a good starting point for AR 
agonist discovery, and were designed to maximise the range of outcomes 
possible with the chemistry.58 The substrates were shown to have no activity 
under the conditions of the assay and catalyst scavenging methods were 
developed to prevent any effects of the metal catalysts on protein 
functionality or assay read-out. This ensured that any bioactivity observed 
was likely to stem from formation of a bioactive entity. 
 
Arrays of reactions were executed that harnessed intramolecular 
reactivity. In the first ADS round, 12 -diazo amides underwent reaction in 
the 96 well plate, with three different catalysts being varied. Screening of the 
array at a total product concentration of 10 𝜇M showed that four of the 
product mixtures yielded highly active products. The substrates and 
conditions used in these reactions informed the design of the next array, 
using variations of them to try to explore related chemical space. In addition, 
two substrates that had not yielded active product mixtures in the first round 
were included as a control. The second array of reactions varied the 
aforementioned six substrates, an expanded range of eight catalysts and 
four solvents, albeit screened at ten-fold lower concentration relative to 
products (1 𝜇M total product concentration) in the assay than the first array. 
The most active product mixtures arose when two of the active substrates 
from the first array (Table 1.2, starting material entries 1-6) were reacted 
with rhodium carboxylates in either DCM, toluene or EtOAc, and the 
NC
CF3
N
O
1
EC50 = 92 ± 13 mM
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conditions employed in these reactions were used to informed the design of 
the following round. The third array exploited the two active substrates plus 
four structurally related substrates varied in the reaction mixtures, along with 
six varieties of rhodium carboxylate catalyst in three different solvents, 
screened at ten-fold lower concentration than the previous array (100 nM). 
 
Starting 
Material 
Reaction 
Conditions 
Product 
Yield 
(%) 
EC50 
(nM) 
 
Rh2(esp)2 (1 mol%), 
EtOAc 
 
75 
340 
 30 
 
Rh2(oct)4 (1 mol%), 
DCM 
71 
Rh2(OAc)4 (1 mol%), 
DCM 
68 
 
Rh2(esp)2 (1 mol%), 
DCM 
 
90 
470 
 40 
 
Rh2(oct)4 (1 mol%), 
DCM 
88 
Rh2(OAc)4 (1 mol%), 
DCM 
55 
 
Rh2(esp)2 (1 mol%), 
EtOAc 
 
78 
440 
 60 
 Rh2(tpa)4 (1 mol%), 
Toluene 
70 
For the eight most bioactive product mixtures from the third array, the 
structures for the products were elucidated, enabling identification of three 
major bioactive compounds. The purified compounds were evaluated for 
agonism of the AR independently (syntheses, structures and activities 
shown in Table 1.2). Three sub-micromolar novel agonists of the AR 
receptor were discovered from just three arrays of intramolecular reactions, 
with only three products requiring purification through the whole process. 
Table 1.2 - Synthesis, yield and activity of the bioactive intramolecular ADS 
products found by Karageorgis et al. 51 
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Following the successful study of ADS using one substrate with 
intramolecular reactions, ADS using intermolecular reactions was 
investigated.59 Using a variety of substrates that were N-substituted with 
groups that would disfavour intramolecular reactions, the rhodium-catalysed 
carbenoid chemistry could be utilised with a co-substrate to form new 
scaffolds between two molecules. In round one, 192 out of a possible 480 
reactions were randomly chosen using four substrates, ten co-substrates, six 
catalysts and two solvents, screened at a 10 M total product concentration. 
The co-substrates were selected to ensure diversity when reacted with the 
substrates and catalysts. 192 reactions in round one yielded only two 
significantly active compounds, that informed design of the subsequent 
array. Round two focused on substrates 3 and 5, Rh2((S)-DOSP)4 and 
similar catalysts, and derivatives of co-substrates that yielded active 
products in round one: cyclohexene and indole, whilst also including other 
structurally related co-substrates and catalysts. 86 reactions were chosen 
from a possible 360 combinations of the two substrates, 18 co-substrates, 
five catalysts and DCM or toluene as solvents; screening at half the total 
product concentration of round one (5 M). Product mixtures utilising 
substrate 3 were identified as promising in combination with a selection of 
catalysts, with superior activities to both of the active product mixtures in 
round one. Round three combined substrate 3 with a range of 12 co-
substrates and four catalysts in DCM, screening at a concentration of 1 M 
to further increase selection pressure, yielding two bioactive product 
mixtures. A selection of the bioactive products formed in all three rounds of 
the intermolecular experiments can be seen in Table 1.3. 
 
SAR studies of the two bioactive compounds produced in the third 
round of intermolecular ADS permitted the identification of key structural 
features in each series, facilitating the discovery of novel chemotypes that 
acted as agonists of the AR. The activity of the original fragment 1 had been 
improved 125-fold in only three rounds of ADS, validating the strategy as an 
approach to explore chemical space efficiently and generate novel bioactive 
scaffolds suitable as starting points for drug discovery. 
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R Substrates Catalyst Product + Yield EC50 (M) 
1 
3 +  
Rh2((S)-DOSP)4 80% 8.8  0.7 
1 
3 +   
Rh2((S)-DOSP)4 71% 7.3  0.2 
2 
5 +   
Rh2(OAc)4 18% 0.79  0.06 
2 
3 +   
Rh2((S)-DOSP)4 82% 4.7  0.1 
2 
3 +  
Rh2((S)-DOSP)4 76% 4.9  0.1 
2 
3 +   
Rh2(esp)2 73% 3.8  0.2 
3 3 +  
 
Rh2((R)-DOSP)4 
73%; 56% ee 
1.1  0.1 
3 3 +   
 
Rh2(OAc)4 
 
75% 
0.73  0.03 
Table 1.3 – Intermolecular reactions yielding bioactive compounds from ADS 
with the respected activities of the products.59 R = round of ADS the 
combination was discovered in. 
2, R = Ac 
3, R=H 
 
4, R = Ac 
5, R=H 
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1.2.4 Other Function-Driven Approaches to Bioactive Molecule 
Discovery 
 
A similar function-drive approach, termed synthetic fermentation, 
emerged at around the same time as ADS, in which bioactive, unnatural 
peptides were developed from small building blocks using amide-forming 
ligations (Figure 1.14).60 Arrays of reactions harnessed six different -
ketoacid initiating monomers, eight elongating isoxazolidine monomers, and 
nine isoxazolidine monomers that had functionality rendering them as 
terminating groups. In each well, one initiator, three elongating monomers 
and one terminator were combined in order to generate oligomers, whose 
identity depended on the combination of monomers used. 
 
The oligomeric products in each well were assayed directly against 
NS3/4A HCV protease, and if activity in a well in the array was observed, the 
contents of the well were determined. This method incorporated the 
principles of evolutionary feedback and selection pressures were 
implemented, leading to the fermentation of around 6000 peptidomimetics 
Figure 1.14 - Overview of Synthetic Fermentation.60 Oligomerisation of 
building blocks in mild aqueous conditions without the aid of reagents, 
organisms or enzymes, to form mixtures of peptide products in each synthetic 
culture. Initiating (I), elongating (M) and terminating (T) monomers are utilised 
to form peptide products that can be screened directly for biological activity. 
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from the 23 different monomers. Despite the successful identification and 
characterisation of a NS3/4A HCV protease inhibitor with an IC50 of 1.0 M, 
there are constraints on the range of products possible, as the underpinning 
peptide chemistry used in the platform is only capable of producing β-
peptides. 
 
1.3 Androgen Receptor 
 
1.3.1 Biology of the Androgen Receptor 
 
 
 
 
The androgen receptor (AR) is a member of the steroid and nuclear 
receptor superfamily. Binding of androgenic hormones to the AR regulates 
Figure 1.15 – Overview of the transcriptional pathways activated/deactivated 
upon ligand binding to the AR receptor. NTD = N-terminal domain, DBD = 
DNA-binding domain, HR = hinge region, LBD = ligand binding domain, HSP 
= heat shock protein, AG = agonist, ANG = antagonist, P = phosphorylation. 
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its function, inducing conformational changes that affect receptor-DNA and 
receptor-protein interactions. Gene expression regulated by the AR is 
responsible for pubertal changes and sexual differentiation in males, in 
addition to organ tissue, muscle and bone production and maintenance 
throughout the body.61,62  
 
Figure 1.15 shows the transcriptional pathway induced when the AR 
is activated. When an agonist such as testosterone interacts with unbound 
AR in the cytoplasm, conformational changes in the ligand-binding domain 
form a surface that can interact with proteins that control transcription. The 
AR undergoes dimerisation, phosphorylation, and translocation into the 
nucleus. The resulting complex then binds to the promoter region of AR-
responsive genes, resulting in the recruitment of transcriptional activator 
proteins and activation of gene expression. Diseases directly linked to AR 
dysfunction include prostate cancer and androgen insensitivity syndrome.62  
 
1.3.2 Known Androgen Receptor Modulators 
 
 
Figure 1.16 – Crystal structure of the AR ligand-binding domain in complex 
with testosterone. (PDB: 2AM9). The 3-keto (H-bond to Arg752) and 17-OH 
(two H-bonds to Thr877 and Asn705) groups of testosterone and their 
interactions to the protein are indicated. 
T
877 
R
752 
N
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The AR is one of the oldest known and frequently studied anabolic 
targets in mammalian systems, with work dating back to 1889.63 Many 
different Selective Androgen Receptor Modulators (SARMs) have been 
identified, with a wide range of efficacies.64  The scaffold of endogenous 
steroidal agonists such as testosterone and 5𝛼-dihydrotestosterone provide 
the ideal positioning for two key anchors for AR binding: the 3-keto (H-bond 
to Arg752) and 17-OH (two H-bonds to Thr877 and Asn705) groups are 
essential for binding affinity (see Figure 1.16). SAR of the wider range of 
modulators outside of the steroid class shows general hydrophobicity of the 
ligands to be largely important. 
 
Despite their efficacy, the use of steroids as therapies for disease are 
associated with significant side effects, and identification of alternative AR 
modulators is desirable. Many small molecule SARM candidates have been 
advanced to clinical studies that are more selective for the androgen 
receptor than other tissues, reducing the side effects commonly observed 
with steroid use. SARMs would be useful for a wide array of indications 
where stimulation of tissue growth would be a beneficial clinical outcome, 
such as Cachexia (muscle wastage), Duchenne Muscular Dystrophy, 
Osteoporosis, specific cancers and Stress Urinary Incontinence (SUI).65 A 
number of SARM compounds are in the clinic for a range of indications, as 
shown in Figure 1.17. 
 
  
 
Enobosarm (GTX Inc.) 
Phase II 
SUI/ER+ Cancer/AR+ Cancer 
LGD-4033 (Viking) 
Phase II 
Cachexia 
RAD140 (Radius) 
Phase I 
ER+ Cancer 
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Figure 1.17 – A range of SARM clinical candidates. 
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Entry Modulator pEC50 Ref 
1 
 
7.09 49 
2 
 
7.29 49 
3 
 
7.94 49 
4 
 
7.80 51 
5 
 
8.40 51 
6 
 
8.90 51 
7 
 
9.80 51 
 
Table 1.4 shows a selection of modulators of the AR and their EC50 
values for the AR. Entries 1, 2 and 3 in Table 1.4 were identified in a review 
by Sheehan et al. of natural and synthetic ligands that bind to the AR.64 The 
efficacy values of the ligands were given as relative binding affinities in 
comparison to methyltrienolone in a competitive AR binding assay. 
Compounds featuring para- and meta- substituted aryl rings with some 
CN
CF3
OH
CN
CF3
CF3
HO
Table 1.4 – Selected AR modulators.  
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hydrophobic character such as entries 1 and 2 were identified as suitable 
non-steroidal binders. Para-substituted phenols such as entry 3 were also 
identified as modulators. Entries 4, 5, 6 and 7 were identified by Handlon et 
al. as selective nanomolar androgen receptor modulators, and the aryl motif 
featured within the compounds is the same as featured in previous work on 
ADS.66 These compounds do not feature a nitrogen atom adjacent to the 
aromatic ring, showing that amide functionality is not essential for 
compounds to be potent agonists. 
 
1.4 Overview of Covalent Organocatalysis 
 
Organocatalysis is a burgeoning domain of organic chemistry, 
studying the use of small molecules as catalysts in synthetic 
transformations.67 Organocatalysts can catalyse formation of diverse 
products, and the different classes of catalyst available have a range of 
reactivity capable of exploring many different ring systems. Organocatalysed 
reactions are generally insensitive to moisture and oxygen, with reactions 
that will generally run at room temperature, and are capable of forming 
products with high enantiomeric and diastereomeric ratios. Unlike the 
rhodium-catalysed chemistry used previously in ADS, the production of 
impurities related to toxic metal catalysts is avoided. These attributes may 
make organocatalysis a great selection for use in Activity Directed 
Synthesis. 
 
The origins of organocatalysis can be traced back to Emil 
Knoevenagel, who used secondary amines as catalysts in aldol 
condensations between -ketoesters with aldehydes or ketones (Scheme 
1.3).68 Following Knoevenagel’s discovery, a variety of reactions in which 
amines, including natural products (primarily cinchona alkaloids), were found 
to catalyse product formation were discovered,69,70 but the potential of 
Scheme 1.3 - The Knoevenagel Condensation (1898) 
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organocatalysis was not realised until the late 1990s when Macmillan, who 
discovered the organocatalysed Friedel-Crafts reaction,71 coined the term. 
Numerous activation modes and methodologies exist, many of which may be 
suitable for exploitation in ADS. 
 
Amines are the most common class of organocatalyst, utilising 
primary and secondary amines to catalyse reactions. The field has seen a 
renaissance following the initial work in asymmetric organocatalysis by the 
likes of Hajos and Parrish decades ago,70 with the simultaneous discovery of 
the proline-catalysed intermolecular aldol reaction and the Mannich 
reactions by List et al.,72,73 and the chiral imidazolidinone-catalysed Diels-
Alder reaction by Macmillan et al.74 
 
1.4.1 Enamine Catalysis 
 
Enamines are among the most reactive neutral carbon nucleophiles, 
displaying rates of reaction comparable to some charged nucleophiles such 
as enolates.75 Many enamines are sensitive to hydrolysis, making them hard 
to isolate, but this is advantageous in organocatalysis, where they are 
generated catalytically in situ. Brönsted acid-promoted condensation of an 
amine with a ketone or aldehyde initially affords an iminium ion, before 
deprotonation to form the enamine species.76 The nucleophilic enamine 
attacks the electrophile, generating another iminium ion. Hydrolysis of the 
iminium species gives the -substituted product and regenerates the 
catalyst that can re-enter the catalytic cycle. The Brönsted acid, HX, can 
either be a protic solvent, an external added acid, or a functional group 
present in the amine catalyst. Scheme 1.4 shows the catalytic cycle of 
enamine activation. 
 
Chiral amine catalysts are capable of inducing high enantioselectivity 
in enamine-catalysed reactions (Scheme 1.5). Type A catalysts, such as 
proline, include an integrated H-bond donor that can activate the electrophile 
and orient its approach, and tend to be used to direct enantioselectivity in 
aldol, Mannich and -amination/oxygenation reactions.77 Type B catalysts 
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include non-acidic bulky groups, and sterically block approach of 
electrophiles from one side, as in diarylprolinol silyl ether catalysts. They 
excel in reactions such as -halogenation and conjugate additions where H-
bond assistance is not required, although are versatile enough to work with 
most enamine and iminium catalysed reactions.78 
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Scheme 1.4 - The catalytic cycle of enamine catalysis, and examples of 
classic reactions where enamine catalysis is applied.  
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1.4.2 Iminium Catalysis 
 
Iminium catalysis is another prominent activation mode in 
organocatalysis. Initial work on iminium catalysis focused on 
cycloadditions,74,80 but the strategy was soon extended to Michael 
additions,71,81 with iminium catalysis now being a well-established strategy 
for conjugate addition of nucleophiles to the -position of ,-unsaturated 
aldehydes. Formation of the iminium ion has a similar activating effect of 
complexation of a carbonyl group to a Lewis acid, lowering the LUMO 
energy of the -system in an ,-unsaturated aldehyde, increasing its 
electrophilicity.82 
 
Following Brönsted acid-promoted condensation of the carbonyl and 
amine to form the iminium ion and a molecule of water, a nucleophile attacks 
at the -position. This forms an enamine in equilibrium with the equivalent 
iminium intermediate, which can be hydrolysed to form the product and 
regenerate the catalyst that can re-enter the cycle. The generation of a 
molecule of water is noteworthy: unlike Lewis acid catalysed reactions, 
iminium catalysed reactions tend to be tolerant of moisture and air, 
increasing their practicality. Scheme 1.6 shows the catalytic cycle of iminium 
catalysis. 
 
Although amines with H-bond directing groups such as proline can be 
used,83 better yields are generally obtained with bulky non-acidic groups, 
such as in the widely used imidazolidinone catalysts devised by 
O
N N
R
ON
XH
R
O
aldehyde enamine Type B
steric control
or
Type A
H-bond assistance
R2
R1
Scheme 1.5 - The influence of steric control vs. hydrogen bonding control in 
amine catalysis. 
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MacMillan.71,74 As with enamine catalysis, chiral amine catalysts are capable 
of forming chiral products, with the steric bulk of substituents on the amine 
catalyst determining the conformation of the electrophilic ,-unsaturated 
iminium ion formed, as well as the face of nucleophilic attack. 
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Scheme 1.6 - The catalytic cycle of iminium catalysis, and classic examples 
of Diels-Alder and Indole alkylations using iminium catalysis. 
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1.4.3 N-Heterocyclic Carbene Catalysis 
 
Benzoin 
Condensation85 
 
Stetter 
Reaction86 
 
 
Chiral N-heterocyclic carbenes (NHCs) are a class of Lewis basic 
catalysts capable of inverting the polarity of aldehyde substrates, generating 
nucleophiles via the premise of umpolung reactivity.87  Although widely 
known as modifying ligands for transition metals following isolation of stable 
imidazolylidene carbenes by Arduengo,88 their utility as organocatalysts was 
realised much later. Studies into NHC-catalysed reactions began with 
development of an asymmetric benzoin reaction by Sheehan et al.89 using 
chiral thiazolium salt-derived NHCs. However, enantiomeric excesses 
exceeding 90% were not achieved until work by Enders et al. decades later, 
using a chiral triazolium salt-derived NHC.85 Many NHC catalysts have been 
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Scheme 1.7 - The catalytic cycle of NHC-catalysis for ipso-functionalisation 
via formation of an acyl anion equivalent. 
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developed that are complex chiral structures, capable of giving products in 
high enantiomeric excess, although several achiral catalysts are still 
successfully used in order to generate racemic mixtures of products with 
good yields – useful for application within ADS to maximise the number of 
products formed. Although many activation modes are possible, two 
fundamental modes of reactivity are catalysed by NHCs. 
 
Pairing an NHC catalyst with an unconjugated aldehyde enables ipso-
functionalisation (Scheme 1.7). Following deprotonation of the NHC salt-
derived pre-catalyst, nucleophilic attack of the NHC on the aldehyde yields a 
zwitterionic intermediate that equilibrates via proton transfer to the Breslow 
intermediate, a nucleophilic enaminol species.90 Addition of an electrophile 
at the nucleophilic ipso-carbon of the newly formed acyl anion equivalent 
forms a cationic intermediate, which collapses to form the ipso-functionalised 
carbonyl and regenerates the carbene catalyst. 
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The second reaction type catalysed by NHCs is the formation of 
activated homoenolates from ,-unsaturated aldehydes (Scheme 1.8). 
Following in situ deprotonation to form the active NHC species, nucleophilic 
attack of the NHC on the -unsaturated aldehydes yields the Breslow 
intermediate. Rearrangement leads to the formation of the homoenolate 
species, which is nucleophilic at the -position. Nucleophilic attack on a 
suitable electrophile results in a -functionalised species, whilst also 
regenerating the pre-catalyst which can re-enter the catalytic cycle. 
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1.5 Project Outline 
 
The expansion of the synthetic toolkit that can be used with the 
approach is important to further validate ADS as a method for finding novel 
scaffolds. The robust nature of organocatalysis, and the structurally diverse 
products that the class of chemistry can mediate the formation of, appears to 
make it a feasible and potentially productive class of chemistry that can be 
applied to ADS. Consequently, this project had two major objectives: 
 
1.5.1 Objective 1: Configuration of Organocatalysis for ADS 
 
The first step towards the initial goal of configuring organocatalytic 
chemistry to be compatible with ADS is to identify exemplar organocatalytic 
reactions from the literature and replicate them in the laboratory. The 
reactions selected have to form products with a range of interesting 
scaffolds, with high sp3-centre content where possible. A desirable outcome 
would be successful translation of a range of organocatalytic reactions into 
the microscale plate format required for ADS, and demonstration of their 
operational efficiency on this scale using a set of general conditions for each 
class of organocatalyst. This objective is the focus of Section 2.3.3 of this 
thesis. 
 
Additionally, conditions for the treatment of product mixtures needed 
to be devised before carrying out the assay, that would allow removal of 
undesirable electrophilic functionality that may possibly interfere with assay 
readout. These conditions would ideally remove this functionality using 
simple and inexpensive reagents, or process them to add extra functionality 
into the products. A desirable outcome for this aim would be the 
identification of effective reductive conditions to remove undesirable 
electrophilic functionality, and quantifiable conversion upon a range of 
exemplar substrates. This objective is the focus of Section 2.4 of this thesis. 
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1.5.2 Objective 2: Exploring the Value of Organocatalysis in ADS 
 
Following configuration of organocatalysis in a micro-scale plate 
format, the value of using the chemistry with the ADS format could be 
explored. 
 
Approaches for the design of effective reaction arrays needed to be 
developed, that could explore diverse chemical space using a range of the 
organocatalytic reactivities outlined in Section 1.4. Ideally, the components 
used in these reactions would be selected using an efficient computational 
workflow, that would be developed to optimise the set of substrates selected 
for both reactivity and properties. Different strategies that balanced 
unpredictable reactivity that could create unexpected products, against 
conversion to products using literature precedent, would need to be explored 
in order to gain insight into best practices for execution of organocatalytic 
reaction arrays for future users. Additionally, once results were obtained 
from a reaction array, approaches for the design of subsequent reaction 
arrays would need to be developed. The development of these workflows 
would need to be supported by a robust high-throughput assay, that would 
have to be established so that activity within product mixtures could be 
identified. 
 
Feedback for both of these objectives could be obtained by executing 
the reaction arrays, followed by screening reaction mixtures for functional 
products, which is the subject of Chapter 3. This would enable assessment 
of the value of organocatalysis in the context of activity-directed biomolecule 
discovery and enable future users of the ADS platform to employ it 
effectively. 
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2 Configuration of Organocatalytic Chemistry for ADS 
 
2.1 Selection and Synthesis of Organocatalysts 
 
The catalysts used in ADS needed to be easily obtainable and had to 
possess a range of reactivities with diverse substrates and reaction types in 
order to create a varied range of products that can explore as much 
chemical space as possible. Racemic or achiral versions of the selected 
catalysts were desirable in order to explore activity of both enantiomeric 
series of products. 
 
As the field of organocatalysis has advanced, many researchers have 
made attempts to optimise organocatalyst classes so that reactions with high 
stereoselectivity can be carried out, making the catalysts more complex to 
synthesise, and therefore more expensive to obtain if commercially 
available. By selecting simpler catalysts with broader reactivity, it may be 
possible to explore activity of more isomers of the potential products. 
 
The Jörgensen-Hayashi class of catalyst is favoured in many amine-
catalysed organocatalytic reactions due to diverse reactivity with a range of 
substrates. Triethylsilyl-protected diphenylprolinol 6 and trimethylsilyl-
protected diphenylprolinol 7 (see Scheme 2.1), two of the variety of 
organocatalysts developed by Jörgensen and Hayashi, were selected as 
catalysts to explore enamine and iminium reactivity. The diarylprolinol silyl 
ethers that fall into this class are well established as efficient general 
organocatalysts, providing both HOMO activation (enamine), and LUMO 
activation (iminium), with good selectivity and reactivity.91 The bulky 
substituent at the 2-position on the amine catalyst provides steric control in 
reactions, directing the electrophile towards the opposite face to the 
sterically large substituent of the catalyst. By using a racemic mixture of both 
enantiomers of the catalyst, both possible enantiomers of product will be 
present in successful reactions. 
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Catalyst 6 was obtained in one step from diphenylprolinol, by 
treatment with triethylsilyl trifluoromethanesulfonate and triethylamine in 
dichloromethane, with a yield of 56%. The use of the more sterically 
demanding triethylsilyl group in catalyst 6 increases the stability of the 
compound when compared to the more commonly seen trimethylsilyl-
protected catalyst 7.92 7 and its enantiomer are both commercially available.  
 
 
 
Second generation Macmillan imidazolidinone catalysts are also 
widely exploited, often in combination with a trifluoroacetic acid co-
catalyst.71,80,84 The imidazolidinone catalyst (10) was produced in three 
steps, treating phenylalanine 8 with thionyl chloride in methanol, then adding 
methylamine to form the methyl amide 9. The methyl amide 9 was then 
refluxed in chloroform with ytterbium (III) triflate and pivaldehyde, mediating 
a cyclisation that resulted in the production of a  mixture of separable 
diastereomers in a yield of 85%, with the active catalytic cis-diastereomer 
obtained in an overall yield of 35%.93 
 
The N-heterocyclic carbene catalysts for the project were selected to 
exploit ‘umpolung’ modes of activity with carbonyl substrates. Both 11, 1,3-
bis(2,4,6-trimethylphenyl)imidazolium chloride (iMes), and 12, 2-mesityl-
Scheme 2.1 – Synthesis of amine catalysts chosen to initially test the scope 
of literature reactions. Both enantiomers of the Macmillan imidazolidinone 
catalyst 10 were prepared. 
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2,5,6,7-tetrahydropyrrolo[2,1-c][1,2,4]triazol-4-ium chloride, are widely used, 
achiral, cheap and commercially available. 
 
 
  
Figure 2.1 – N-Heterocyclic carbene catalysts selected for use in ADS 
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2.3 Identification of Exemplar Organocatalytic Chemistry 
 
Diverse examples of organocatalytic reactions from the literature 
needed to be identified that could be transferred into a micro-scale plate 
format suitable for ADS. The products of the reactions had to be 
representative of the kind of chemotypes that were to be explored with ADS. 
These reactions could then be reproduced, testing their viability in a 
miniaturised format essential for the platform to operate with the requisite 
throughput. Comparison of the outcomes of these micro-scale reactions with 
their full-scale counterparts could then allow comparison of their efficiency in 
producing the predicted products, enabling assessment of the success of the 
transfer to the micro-scale format. 
 
Using a range of the selected catalysts from 2.1, reactions were 
selected that could demonstrate the diversity of the chemistry possible with 
organocatalysis, and the ability of the chemistry to yield complex structures 
that could sufficiently explore diverse areas of chemical space. The 
reactions had to require minimal additional components (such as 
acids/bases, oxidants) other than substrates and catalysts to permit 
operational simplicity when executing ADS arrays. 
 
 A range of complex catalysts are utilised throughout the literature, 
that are intended optimise reactions to give products in high yields and 
enantioselectivity. As ADS requires operational simplicity, using the simpler 
catalysts detailed in 2.2 was important to gauge the efficiency of the selected 
reactions and to determine the diversity of the products that could be 
produced with the outlined palette of catalysts. 
 
2.3.1  Amine-Catalysed Reactions 
 
An organocatalytic Michael-aldol spiroannulation of an isatin-derived 
alkene with a linear dialdehyde was demonstrated by Huang et al. (Scheme 
2.2).94 This proceeded via an enamine catalysed Michael addition to the 
alkene, followed by cyclisation through an intramolecular aldol reaction. The 
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reaction reported in the literature used trimethylsilyl diarylprolinol catalyst 7 
rather than catalyst 6, which was used when recreating this reaction in the 
laboratory. Isatin-derived alkene 13 was stirred in DCM with diarylprolinol 
catalyst 6 (10 mol%), before adding 2.4 equivalents of a 50% aqueous 
solution of glutaraldehyde. Stirring for 14 hours and purification afforded the 
aldehyde 14 in a yield of 22%. 
 
 
A pair of organocatalytic reactions proceeding by double Michael-
Aldol cascade mechanisms was attempted (Scheme 2.3). Sequential double 
iminium-catalysed Michael-addition of the substrate to the ,-unsaturated 
aldehydes, followed by an enamine-catalysed intramolecular aldol reaction 
to close the ring generated spirocyclic products. Wang et al. used a 
thiazolidinedione substrate with a range of ,-unsaturated aldehydes to 
synthesise a range of spirocyclic thiazolidinedione derivatives. Melchiorre et 
al. generated spirocyclic benzofuranone derivatives using the same strategy, 
albeit under different conditions. To replicate these reactions,  
thiazolidineone 15 or benzofuranone 17 was added to a solution of 
diphenyprolinol catalyst 6 (20 mol% for 16, 5 mol% for 18) in 
dichloromethane, before adding 3 equivalents of cinnamaldehyde, and in the 
case of 18, a catalytic amount of benzoic acid. Following purification, the 
aldehydes 16 and 18 were both afforded in yields of 15%.  
 
Scheme 2.2 - Organocatalytic Michael-aldol spiroannulation of an isatin-
derived alkene with glutaraldehyde.94 
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Singh et al. developed a Michael-cyclisation approach to the 
synthesis of substituted -lactones from a range of pyrazoleamides and ,-
unsaturated aldehydes (Scheme 2.4). A large range of substituted phenyl 
substituents could in principle be used on either component, demonstrating 
good potential for the exploration of chemical space. Iminium-catalysed 
Michael addition of the pyrazoleamide to the ,-unsaturated aldehyde, 
hydrolysis of the pyrazole moiety, lactonisation, then nucleophilic addition of 
the pyrazole back into the compound leads to the formation of the highly 
substituted products. The pyrazoleamide 19 was added to a solution of 
catalyst 6 (10 mol%) in toluene, before addition of 1.5 equivalents of 
cinnamaldehyde. This mixture was stirred for 24 hours, and purification 
Scheme 2.3 - Organocatalytic double Michael-aldol cascade reaction of 
thiazolidinedione/benzofuranone with -unsaturated aldehydes to form 
spirocyclic aldehyde products. 95,96 
Scheme 2.4 - Organocatalytic Michael-cyclisation cascade between a 
pyrazoleamide and cinnamaldehyde forming substituted -lactones.97 
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afforded the lactone 20 in a yield of 29% (in comparison to a reported yield 
of 89% using the TMS catalyst 7). 
 
Ye et al. developed a reaction using chloroacetophenones and ,-
unsaturated aldehydes to form cyclopropyl aldehydes, with each atom in the 
ring being a stereocentre (Scheme 2.5). Michael addition of the -
chloroketone to the iminium ion derived from the enal results in an enamine 
species which can then form a three-membered ring by alkylating at the -
position. Cinnamaldehyde was stirred in DCM and an equivalent of 
triethylamine, before addition of 3 equivalents of -chloroketone 21, with 
catalyst 6 (10 mol%). After 24 hours of stirring at room temperature, 
purification afforded the cyclopropyl aldehyde 22 in a yield of 75% (in 
comparison to a literature yield of 93% using catalyst 7). 
 
 
 
An iminium-catalysed indole alkylation discovered by Austin et al. 
presented a good model reaction to test secondary amine catalysis using the 
Macmillan imidazolidinone catalyst (Scheme 2.6). Iminium-activation, with 
the imidazolidinone and a TFA co-catalyst, of the ,-unsaturated aldehyde 
facilitates attack of the indole nucleophile through the 3-position, generating 
a functionalised indole aldehyde. The literature reaction uses low 
temperature conditions (−87oC) and in a mixed solvent of dichloromethane 
and isopropanol, but the reaction was replicated at room temperature and 
using chloroform as the solvent. Three equivalents of N-methylindole were 
Scheme 2.5 - Organocatalytic Michael/𝛂-alkylation reaction between a 
chloroacetophenone and ,-unsaturated aldehyde to form a cyclopropyl 
aldehyde.98 
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added to a stirred solution of crotonaldehyde, imidazolidinone (10) and TFA 
(20 mol%) in chloroform. After stirring for 24 hours, purification afforded the 
substituted indole 23 in a yield of 40% (literature yield was 82%, in which a 
much lower temperature was used). 
 
 
 
2.3.2 N-Heterocyclic Carbene Catalysed Reactions 
 
Nair et al. discovered an NHC-catalysed annulation of 1,2-dicarbonyl 
compounds (including isatins) with ,-unsaturated aldehydes capable of 
forming spiro γ-butyrolactones (Scheme 2.7). The catalyst forms the 
homoenolate species with the aldehyde, attacking the dicarbonyl through the 
-position. The nucleophile formed can then attack back in to release the 
catalyst and form the spiro-products. In both reactions in Scheme 2.7, 1.5 
equivalents of the relevant cinnamaldehyde was added to a stirred solution 
of imidazolium NHC catalyst 11 (6 mol%) and DBU in THF. The relevant 1,2-
dicarbonyl compound was then added, and the reaction allowed to stir for 24 
hours. Purification afforded the relevant spirocycle in variable yields. Lactone 
24 was obtained in a 25% yield, comparable to the 92% yield demonstrated 
in the literature, while the spirocyclic oxindoles 25a and 25b were formed in 
yields of 22% and 26%. This reaction was of particular interest, as the isatin 
moiety is a constituent of a wide range of natural products, and is known to 
have a wide range of pharmacological activity against a range of biological 
targets.99  
Scheme 2.6 – Macmillan Imidazolidinone catalysed Michael-Addition of an 
indole to an ,-unsaturated aldehyde.84 
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A variation of the reaction mechanism utilised by Nair et al. is shown 
in Scheme 2.8, a reaction class found by Bode et al.. Homoenolate addition 
of the enal into the aldehyde and then ring closure by the alkoxide releases 
the catalyst and forms the γ-butyrolactone product. Two equivalents of 4-
bromobenzaldehyde was added to a stirred solution of 4-
methoxycinnamaldehyde in THF, with imidazolium NHC catalyst 11 (8 
mol%) and DBU. Following purification, the major diastereomer 26 was 
obtained in a 40% yield, with an isolated diastereomeric ratio of 89:11. In 
comparison to the literature procedure which reported a crude 80:20 d.r and 
76% yield.  Both substrates in this reaction could be varied to include various 
groups. 
Scheme 2.7 - Organocatalytic homoenolate addition involving an ,-
unsaturated aldehyde and a 1,2-dicarbonyl.100 
Scheme 2.8 - Organocatalytic synthesis of disubstituted γ-butyrolactones via 
the direct annulation of ,-unsaturated aldehydes and benzaldehydes.101 
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An iMes NHC-catalysed reaction forming substituted cyclopentene 
systems with two stereocentres was discovered by Nair et al. (Scheme 2.9). 
The homoenolate species adds into the -position of the enone, then 
intramolecular aldol attack of the newly reformed enolate into the carbonyl 
enone then permits -lactonisation to reform the catalyst and form the 
product. DBU was added to a suspension of the imidazolium NHC catalyst 
11 (6 mol%) in THF, before addition of chalcone and 1.5 equivalents of 4-
methoxycinnamaldehyde. Following purification, the cyclopentene 27 was 
obtained in a 77% yield, in comparison to 88% reported in the literature.  
 
Sudalai et al. reported the NHC-catalysed oxidative coupling reaction 
shown in Scheme 2.10, which is catalysed by thiamine hydrochloride, 
another NHC catalyst structurally related to vitamin B1. The catalyst reacts 
with the -bromoketone, eliminating hydrogen bromide to form the 
ketodeoxy Breslow intermediate. This Breslow intermediate can attack the 
aldehyde, with the resulting species ejecting the catalyst and forming the 
,-epoxyketone product. 4-Nitrobenzaldehyde and an excess of the 2-
bromoacetophenone were added to a flask, followed by the thiamine 
hydrochloride NHC catalyst 28. DMSO and DBU were added, and the 
mixture was stirred for 18 hours. Following purification, the epoxyketone 29 
was obtained in a yield of 22% (in comparison to the reported literature yield 
of 78%). 
Scheme 2.9 - Synthesis of 1,3,4-trisubstituted cyclopentenes using an NHC-
catalysed reaction between chalcones and ,-unsaturated aldehydes via a 
homoenolate species.102 
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Rommel et al. reported a triazolium NHC-catalysed homoenolate 
addition of ,-unsaturated aldehydes to saccharin derivatives. The catalyst 
reacts with the ,-unsaturated aldehyde to form an activated umpolung 
Breslow intermediate, that reacts with the ketimine via a six-membered ene-
like transition state. It is proposed that this transition state is stabilised by a 
hydrogen bond to the sulfonyl oxygen from the Breslow intermediate, 
allowing transfer of the acyl proton to the imine nitrogen atom, forming a new 
carbon-carbon bond. The reaction was reproduced by placing sulfonyl imine 
30 in a flask, followed by 1.2 equivalents of crotonaldehyde. The triazolium 
NHC catalyst 12 was then added, followed by DCM and DBU. After stirring 
for 24 hours, purification afforded the -lactam major cis-product 31 in a yield 
of 80%, in comparison to the literature yield of 78%. The diasteromeric ratio 
of 86:14 in favour of the cis-isomer was identified by crude NMR, in 
comparison to the literature diasteromeric ratio of 75:25.  
 
 
Scheme 2.10 - NHC-catalysed oxidative coupling of -bromoketones with 
aldehydes to form ,-epoxyketones.103 
Scheme 2.11 – Triazolium NHC-catalysed annulation of an ,-unsaturated 
aldehyde to saccharin derivatives.104 
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2.3.3 Transfer of Chemistry to Microwell Plate Format 
 
The exemplar reactions found and reproduced had all been carried 
out in a flask-based format on between 50-100 mg scale with regards to the 
limiting substrate. ADS is executed in a microwell plate format, where 
reactions are not stirred or agitated, are not under inert atmospheres, and 
the total reaction volumes are significantly reduced in order to fit inside low-
volume reaction vials. 
 
The viability of a selection of organocatalytic reactions compatible 
with this format had to be determined, and a set of general conditions that 
could be transferrable between reactions in the same organocatalytic class 
developed, so as to decrease the operational complexity of putting together 
complex reaction arrays. 
 
To transition the chemistry from the full-scale flask to the micro-scale 
array format, a selection of the reactions explored in 2.2 were carried out in 
capped 100 μL reaction vials in a 96-well plate, while maintaining the same 
overall concentration as the full-scale reactions (Scheme 2.12). The 
reactions selected captured the full range of organocatalysts described in 
2.1, exploring diverse reactivities that could generate a diverse range of 
scaffolds that were representative of the chemotypes that could be explored 
in organocatalytic ADS. 
 
As the mass of the components to be used in the reactions was very 
small, stock solutions of the substrates were made, and the appropriate 
amounts added to reaction wells before allowing evaporation. Following 
evaporation, 100 μL of a catalyst system containing the catalyst, solvent and 
any relevant additives was then added. The wells were then sealed with 
caps to prevent evaporation of solvents and left for 24 hours, before 
obtaining LC-MS analysis of the micro-scale crude reaction.  
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Alongside the micro-scale reaction, the procedure was also executed 
in a flask on a scale described in the literature. The LC-MS analysis of this 
mixture was also obtained, allowing comparison of the outcome to the micro-
scale reaction. The full-scale reaction was then worked up and the crude 
products purified as in the literature protocol for each reaction, affording the 
pure product in each case. This allowed full analysis and characterisation of 
the relevant product, including LC-MS data indicating the relevant peak for 
the pure product on the LC-MS spectra. Comparing this LC-MS data to that 
of the crude mixtures of both the full-scale and micro-scale reactions allowed 
identification of the correct product in the reaction, demonstrating successful 
translation of the reaction from the full-scale to the micro-scale reaction. 
 
Table 2.1 provides a comparison of the LC-MS traces for the reaction 
in which the spiro γ-butyrolactone products 25a and 25b are formed by an 
NHC-catalysed annulation between an ,-unsaturated aldehyde and an 
isatin, as previously shown in Scheme 2.7. The LC-MS trace for the full-
scale reaction shows a peak with mass corresponding to the anticipated 
product, and LC-MS of the isolated product, which was confirmed by NMR, 
demonstrated that to be correct. The same mass was found at the same 
Scheme 2.12 – the reactions selected to use to study compatibility with the 
plate format. 
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retention time in the microscale plate-based reaction, with the LC-MS trace 
appearing almost identical to that of the flask reaction. This confirmed that 
the reaction had been transferred successfully to the format required for 
ADS. Similar analyses for the other three reactions shown in Scheme 2.12 
can be found in the experimental, demonstrating successful transfer of the 
reactions to a plate format  
 
 
Format LC-MS Trace Retention 
Time 
(Mins) 
Mass 
Found 
Flask 
 
0.59 (1) 
 
294.14 
 
Isolated 
Product 
0.59 (1) 
 
293.93 
 
Plate 0.59 (1) 294.14 
 
 
Table 2.1 – Comparison of a reaction performed in a flask, and on a 100 𝛍𝐋 
scale in a vial. LC-MS data shows the expected product (calculated M-H+ 
294.11) isolated from the flask-based reaction is also present in the reaction 
vial used for the microscale reaction. 
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2.4 Development of Post-Reaction Protocols 
 
Electrophilic functional groups such as aldehydes and Michael 
acceptors are undesirable in molecules in the early stages of the drug 
discovery process where large numbers of compounds are tested.105 The 
unsuitability of these reactive groups stems from their potential to react with 
the protein of interest, thereby potentially interfering with the result of an in 
vitro assay.106  
 
Many of the substrates in the reactions demonstrated in Section 2.2 
feature such functionality. Both aldehydes and ,-unsaturated aldehydes 
are electrophilic, and can potentially react with nucleophiles. It would 
therefore be beneficial to convert the substances containing these moieties 
to more benign products before screening of the product mixtures on the 
assay. A range of model compounds were selected for these experiments, 
featuring functionality representative of the kind that were likely to be 
observed in both substrates and products (Figure 2.2). 
 
 
 
2.4.1 Reduction with Sodium Borohydride 
 
Addition of a solution of sodium borohydride in methanol directly into 
a mixture was selected as a protocol to reduce electrophilic functionality. 
The substrates (0.035 mmol) were dissolved into deuterated chloroform with 
a known equimolar amount of an unreactive standard, 1,2,4-trichloro-5-
Figure 2.2 – Range of model substrates selected for the development of 
post-reaction work-up protocols. 
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methoxybenzene. The solution was transferred into an NMR tube and an 
initial 400 MHz 1H NMR spectrum of the mixture was obtained. 40 μL 
(0.0525 mmol, 1.5 equiv.) of a solution of sodium borohydride (11.92 mg in 
240 μL) in methanol was added directly to the NMR tubes containing each of 
the six selected substrates and left for two hours before obtaining another 
400 MHz 1H NMR spectrum. Conversion of the substrate to products could 
be observed by comparison of a distinguishable peak of a proton 
environment that experienced an upfield shift upon reduction in the NMR 
spectra (~10.0 ppm for aldehydes, proton adjacent to carbonyl of ketone in 
testosterone) to the integral of the aromatic proton in the standard (see 
Appendices for an example). 
 
 
As can be observed in Figure 2.3, these conditions provided 
excellent levels of conversion, eliminating electrophilic functionality such as 
Figure 2.3 – Conversion of the model substrates by treatment with the 
sodium borohydride reduction conditions. 
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electrophilic aldehydes and Michael acceptors. NMR data for these 
transformations can be found in the experimental. 
 
However, a concern regarded the potential for degradation of the 
sodium borohydride solution in methanol. Making a solution and adding it to 
a reaction array takes time, and for maximum efficiency of reduction, it was 
essential the solution used for the reduction did not degrade over the 
timescale of the reaction. Methanol reacts with the sodium borohydride to 
form methoxyborates, resulting in effervescence due to the reaction evolving 
four equivalents of hydrogen gas per equivalent of sodium borohydride when 
in an excess of the solvent.107 
 
 
The reduction efficiency of sodium borohydride in a selection of 
suitable alcohols (methanol, ethanol and propan-2-ol) over a five hour 
timescale was investigated in order to gauge which solvent was best to use. 
Cinnamaldehyde (0.027 mmol) was used as a model substrate to test the 
reducing power of the solutions, and was added to a vial containing an 
approximately equimolar amount of standard 1,2,4-trichloro-5-
methoxybenzene (0.027mmol), followed by deuterated chloroform (400 μL). 
Solutions of sodium borohydride (15.32 mg in 400 μL of relevant alcohol) 
were made up, and 40 μL of each solution (0.0405 mmol, 1.5 equiv.) added 
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Figure 2.4 – Conversion of cinnamaldehyde in reduction reactions, using 
sodium borohydride solutions at varying timepoints after their assembly. 
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to the reaction to determine conversion at one hour intervals over a 5 hour 
period. The resulting product mixtures were then analysed by 400 MHz 1H 
NMR spectroscopy after one hour reaction time. Propan-2-ol was ruled out 
as an option immediately, as the sodium borohydride was insoluble, and was 
therefore not suitable to use in the ADS workflow as a reductive protocol. 
Figure 2.4 displays the results for remaining methanol and ethanol 
solutions. 
 
Degradation of the reducing solution occurs much more slowly with 
ethanol rather than methanol. Ethanol was able to dissolve the sodium 
borohydride and showed much slower effervescence in comparison to the 
methanol solution, due to the slower reaction between ethanol and sodium 
borohydride forming the sodium tetraethoxyborate species and evolving 
hydrogen as a result. The ethanol solution was able to maintain a good level 
of reducing ability for well over 4 hours, providing a large enough window to 
give good conversion in reaction arrays over a suitable time period. 
Consequently, sodium borohydride in ethanol was used as the post-reaction 
protocol for reduction. 
 
2.4.2 Reductive Amination 
 
An alternative reaction for processing of aldehyde products is 
reductive amination. Not only can the reactive groups be removed from 
potential bioactive products, but additional functionality can be added into 
the products by capping the carbonyl groups with amines, potentially 
increasing efficacy by adding another functional group into the molecule that 
can interact with the biological target.  A selection of methods for reductive 
amination with dimethylamine as the model amine component in the reaction 
were considered; including sodium borohydride in tandem with 
phosphotungstic acid,108 triethylsilane and TFA,109 and -picoline borane in 
methanol.110 However, a method using the desired secondary amine in 
addition to tetramethylammonium triacetoxyborohydride was selected. 
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The carbonyl substrates (0.027 mmol) and a known equimolar 
amount of 1,2,4-trichloro-5-methoxybenzene standard and were dissolved in 
deuterated chloroform before transferring the solution to an NMR tube. After 
a 300 MHz 1H NMR spectrum of the initial mixture had been obtained, the 
dimethylamine (0.030 mmol, 1.1 equiv.) was added to the NMR tube and 
allowed to potentially form an imine with a carbonyl species for 10 minutes. 
40 μL (0.0405 mmol, 1.5 eqv.) of a solution of tetramethylammonium 
triacetoxyborohydride (63.93 mg, 0.243 mmol) in acetic acid (240 μL) was 
then added. A 300 MHz 1H NMR spectrum of each mixture was obtained 
after 24 hours to monitor conversion, using the aldehyde proton signal (~10 
ppm) of the spectrum to measure conversion, while also observing new peak 
formation to identify products. Conversion to dimethylamine products was 
observed with all substrates, although reductive amination of testosterone, a 
Figure 2.5 – Conversion of the model substrates by treatment with 
dimethylamine, then tetramethylammoniumtriacetoxyborohydride 45 minutes 
later to reduce the imine. 
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compound featuring a cyclic α, β-unsaturated ketone, was unsuccessful 
(Figure 2.5). 
 
To quench reductant potentially left over from the workup conditions 
that had the capability to interfere with further steps in the protocol, 5 
equivalents of acetaldehyde were added to the product mixtures. The low 
boiling point of acetaldehyde (20.2oC) and its products from both work-up 
protocols, ethanol (78.4oC) and dimethylethylamine (36.5oC) meant that they 
would be evaporated before screening. 
 
The conditions established instilled confidence that any highly 
electrophilic functionality within compounds present in product mixtures 
during ADS could be removed to generate species with less potential for in 
vitro assay interference. 
 
2.5 Summary of Configuration of Organocatalysis for ADS 
 
A wide range of organocatalysed reactions were identified that 
yielded diverse scaffolds and their viability was demonstrated. Following this, 
conditions were developed that allowed successful translation of 
organocatalysed reactions from a flask to a micro-scale format suitable for 
ADS. A selection of reactions that utilised a number of different 
organocatalysts across both amine and NHC classes were chosen to 
demonstrate this, and the outcomes of the miniaturised reactions were 
proven to be comparable to the outcomes of the same reactions in a flask.  
Post-reaction work-up protocols were then developed. A reduction with 
sodium borohydride, and a reductive amination with dimethylamine and 
morpholine with tetramethylammonium triacetoxyborohydride were efficient 
in removing electrophilic functionality that could be present in both the 
substrates and products of organocatalysed reactions. 
 
With these methods in place, the focus could now move to exploring 
the value of organocatalysis in ADS, using alternative strategies to form 
intermolecular products with potential bioactivity. 
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3 Exploring the Value of Organocatalysis in ADS 
 
With conditions for the execution of an ADS array based around 
organocatalysis chemistry devised, arrays of reactions could now be carried 
out to synthesise and identify bioactive products. Setting up a suitable high-
throughput biochemical assay was essential to allow fast and efficient 
screening of products for any activity against the biological target. Following 
this, a number of different strategies for designing ADS reaction arrays 
utilising organocatalysis were explored. 
 
3.1 Configuration of TR-FRET Androgen Receptor Assay 
 
A commercially-available TR-FRET (Time Resolved Fluorescence 
Resonance Energy Transfer) Androgen Receptor assay was selected to 
screen product mixtures generated from the reaction arrays for agonism of 
the Androgen Receptor. A FRET assay operates on the basis that when two 
fluorophores, a donor and acceptor, are in close proximity (roughly 10 
nm)111, and their respective emission and excitation spectra overlap, the 
donor fluorophore can transfer energy to the acceptor fluorophore, leading to 
emission of fluorescence.112 Time-resolved FRET utilises lanthanide metal 
donors that have much longer fluorescence lifetimes than standard FRET 
donors. This decreases the likelihood of assay interference often caused by 
screened organic compounds that have short fluorescence lifetimes. 
 
In the context of the TR-FRET AR assay (see Figure 3.1), a terbium-
labelled anti-GST antibody binds to the GST-labelled ligand binding domain 
of the AR protein (AR-LBD). Upon binding of an agonist ligand, a 
conformational change occurs around helix 12 in the AR-LBD, increasing its 
affinity for the fluorescein-labelled coactivator peptide, resulting in 
recruitment of the peptide. The resulting binding event between the AR-LBD 
and the fluorescein-labelled peptide brings the two fluorophores into mutual 
proximity. 
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The terbium label of the antibody can be excited by irradiation at 340 
nm. The terbium label will emit this radiation at a wavelength of 495 nm if the 
energy in the absence of a proximal acceptor fluorophore. However, if the 
donor terbium is proximal to the fluorescein acceptor as a result of a binding 
event between the peptide and the AR-LBD, the terbium label can transfer 
the absorbed energy to the fluorescein-labelled peptide, which emits at a 
wavelength of 520 nm. The ratio between the intensities of the emissions at 
the two wavelengths (520 nm/495 nm) correlates with the efficiency of 
energy transfer between donor and acceptor fluorophores, which allow 
determination of the extent of agonism. The assay can be executed to 
determine dose-dependent effects of specific ligands and determine EC50 
values. Alternatively, ligands can be screened at a single concentration to 
determine activity in comparison to a positive control, such as testosterone, 
a known potent AR agonist. 
 
Figure 3.1 – An overview of the TR-FRET AR assay. The GST-tagged AR-
LBD binds to an anti-GST terbium-labelled antibody, the donor fluorophore. 
Upon binding of an agonist, a conformational change in the AR-LBD enables 
recruitment of the fluorescein-tagged peptide, the acceptor donor. Irradiation 
at 340 nm excites the terbium label, and the energy can be transferred to the 
fluorescein acceptor. The ratio between the emission intensities at 520 nm 
from the fluorescein, and 495 nm from the terbium label, can enable 
assessment of the bioactivity of the agonist. 
66 
To establish the assay, a 12-point three-fold serial dilution of 
testosterone was assayed, with concentrations of ligand ranging from 5 M 
down to 28.2 pM in pH 7.5 buffer, with a final concentration of 1% DMSO. 
Once the 12-point three-fold serial dilution of a 500 M DMSO solution of 
testosterone had been completed, each of the solutions was diluted 50-fold 
with buffer, and then added to the assay plate in triplicate. AR-LBD solution 
was then added at a concentration of 112 nM, followed by a solution of the 
terbium-labelled antibody at 20 nM and the fluorescein-labelled peptide at 2 
M. After 4 hours, the emission intensities at 520 nm and 495 nm of each 
well was measured on a Perkin-Elmer Envision 2103 Multilabel reader. This 
enabled an EC50 value of 17.4 nM to be obtained for testosterone that was 
concordant with previously reported values.113 
 
The concentration of the AR-LBD solution added to wells in the assay 
was variable, depending on which particular kit was being used during the 
project at the time, as there was significant batch-to-batch variation of the 
protein used. At a number of points in the project, consistency in obtaining a 
reasonable dynamic TR-FRET range was variable when using the assay, an 
observation that was likely due to batch-to-batch variation of the 
Figure 3.2 – Dose-response curve obtained for Testosterone. Calculated 
EC50 value of 17.4 nM was consistent with literature values. 
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commercially available assay kit. To address this, it was found that doubling 
the recommended final concentration of the terbium-labelled anti-GST 
antibody from 5 nM to 10 nM increased reliability, leading to a larger 
dynamic range. Assays in which higher concentrations of antibody were 
used are noted throughout the thesis. 
 
3.2 Design and Execution of an Exhaustive ADS Reaction Array 
 
3.2.1 Design of Round 1 ADS Reaction Array 
 
Initially, a reaction array was designed to harness a wide range of 
complementary organocatalytic reactivities. The design of the reaction 
arrays that were planned for the first round is outlined in Figure 3.3. Using 
four different catalyst systems (C1-C4) in combination with 24 commercially-
available diverse co-substrates (B1-B24) per plate; one ‘armed’ substrate 
(A1-A5) per plate could be utilised to simplify the set-up of an exhaustive 
array. There were two replicates of each plate of reactions, to enable the use 
of the two work-up procedures devised in the previous chapter: one plate 
using a sodium borohydride reductive work-up, and the other using a 
reductive amination work-up with dimethylamine. As five armed substrates 
were made for use in Round 1, this resulted in a total of 960 product 
mixtures to screen in Round 1. 
 
The first round array was designed to be exhaustive, using every 
possible combination of substrate, co-substrate, catalyst and work-up 
protocol. It was envisaged that this approach would maximise the amount of 
chemical space that could potentially be explored. This approach inevitably 
led to the exploration of many combinations for which there was no literature 
precedent. However, this may add a degree of unpredictability to the 
discovery of bioactive products, as unexpected outcomes could emerge from 
productive reaction mixtures. This would increase the diversity of potential 
products so that they are outside the scope of known literature and enable 
the potential discovery of novel chemotypes and reactions.  To maximise 
the probability of this occurring, functional groups known to exhibit reactivity 
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in organocatalytic reactions needed to be integrated into the substrates 
used.  
 
 
 
B1 B9 B17 B1 B9 B17 B1 B9 B17 B1 B9 B17 
B2 B10 B18 B2 B10 B18 B2 B10 B18 B2 B10 B18 
B3 B11 B19 B3 B11 B19 B3 B11 B19 B3 B11 B19 
B4 B12 B20 B4 B12 B20 B4 B12 B20 B4 B12 B20 
B5 B13 B21 B5 B13 B21 B5 B13 B21 B5 B13 B21 
B6 B14 B22 B6 B14 B22 B6 B14 B22 B6 B14 B22 
B7 B15 B23 B7 B15 B23 B7 B15 B23 B7 B15 B23 
B8 B16 B24 B8 B16 B24 B8 B16 B24 B8 B16 B24 
 
 
 
 
 
 
 
 
As in the previous AR project, it was decided that a set of substrates 
‘armed’ with warhead moieties known to modulate the AR (noted in Section 
1.3.2) would provide a good starting point for developing novel bioactive 
compounds, permitting a range of scaffolds to be built around these groups, 
providing functionality that could enable increased bioactivity. The structures 
of the armed substrates (A1-A5) are noted in Figure 3.3, and each feature a 
CN
CF3
H
O
CN
CF3
H O
CN
CF3
O
CN
CF3
O
Cl
Cl
Cl
H
O
A1 A2 A3 A4 A5
Figure 3.3 - Design of the reaction arrays for the first round of ADS. Each of 
the ten 96-well plates that were to be executed corresponded to one of the 
five armed substrates (A1–A5) with one of the two work-up procedures 
(sodium borohydride reduction, or dimethylamine reductive amination). There 
were to be 24 co-substrates (represented by B1-B24) and 4 catalyst systems 
C1-C4) in use on each plate, resulting in a total of 960 first round reactions. 
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functional group that was known to have reactivity with an organocatalyst, as 
well as a motif known to modulate the AR: either a 4-cyano-3-
trifluoromethylphenyl group, or a 4,3-dichlorophenyl group. 
 
The substrates capture all of the reactivity modes outlined in Section 
1.4 – the enal (,-unsaturated aldehyde) class of substrate (A1 and A2) 
can capture both iminium (Scheme 1.6) and homoenlolate (Scheme 1.8) 
reactivities with amine and NHC catalyst classes respectively. The 
benzaldehyde A3 was the precursor for the required ,-unsaturated 
aldehyde A1, and had the capability to be activated with an NHC catalyst to 
generate a potent nucleophile (Scheme 1.7), in addition to being a suitable 
electrophile in reactions due to the carbonyl group. The methyl ketone A4 
could potentially be activated by an amine catalyst to form a nucleophilic 
enamine species (Scheme 1.4) that could react with a suitable electrophile, 
or the ketone functionality could be an electrophile for a suitable nucleophilic 
partner. The -chloroketone A5 could be made in one simple step from the 
methyl ketone A4, and had potential utility as an electrophile capable of 
forming interesting small membered ring scaffolds, bringing extra diversity to 
the potential product set.98 
 
3.2.2 Synthesis of Armed Substrates 
 
Synthesis of the benzaldehyde A3 was executed by slow addition of 
isopropylmagnesium chloride lithium chloride complex in THF (the ‘turbo 
Grignard’ reagent) to relevant aryl iodide at 0 oC. Formyl-1-piperidine was 
then added to act as the formyl donor, and after purification by flash column 
chromatography, the benzaldehyde A3 was afforded in a yield of 50% 
(Scheme 3.1).66  
 
The methyl ketone A4 was also synthesised from the aryl iodide 32, 
but utilised palladium-catalysed Stille chemistry. The aryl iodide was refluxed 
for 24 hours with tributyl(1-ethoxyvinyl)tin (33) in the presence of palladium 
(II) acetate, potassium iodide and DABCO in dioxane. The solution was then 
cooled, filtered through celite and evaporated, before treating the resulting 
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residue with hydrochloric acid and THF. Following purification by flash 
column chromatography, this afforded methyl ketone A4 in a yield of 74%. 
Synthesis of the methyl ketone enabled the synthesis of 
chloroacetophenone A5.  The methyl ketone A4 was stirred overnight with 
benzyltrimethylammonium dichloroiodate (34) in THF. Purification of the 
crude product by flash column chromatography afforded the -chloroketone 
A5 in a yield of 72%. 
 
 
The ,-unsaturated aldehydes A1 and A2 were synthesised via a 
one-step Wittig procedure. A slight excess of 1.1 equivalents of 
(triphenylphosphoranylidene)acetaldehyde was added to a flask with the 
relevant benzaldehyde and refluxed in THF for 20 hours. Following 
purification by flash column chromatography, this afforded enal A1 in a yield 
of 58%, and A2 in a yield of 59%. 
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Scheme 3.1 – Synthesis of the armed substrates. 
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3.2.3 Selection of Co-Substrates 
 
A computational approach was used to aid selection of 24 co-
substrates for use in the first round of the exhaustive project. The 
cheminformatics platforms Pipeline Pilot and KNIME were used to, allowing 
filtering of large databases of over 250,000 compounds from commercial 
suppliers to smaller sets of compounds with reactive functional groups, 
optimised physiochemical properties and maximal diversity. 
 
The workflow began with filtering compounds in the database for 
functionality that had some precedent to react with at least one of the 
‘armed’ substrates when paired with an organocatalyst – the sub-structures 
that were used as the filters can be found in Section 6.7. Physical 
parameters for each compound were then calculated, and the set filtered to 
obtain compounds with desirable characteristics. Molecular weight and 
rotatable bonds were limited, and AlogP was set between -1 and 3 to 
prevent the synthesis of overly heavy, greasy or polar compounds. Financial 
expenditure was controlled for filtering using pricing and quantity information, 
available from both suppliers, allowing exclusion of compounds that were 
more expensive than £100 per gram of material. This resulted in a set of 
compounds with potential reactive functionality, that had appropriate 
molecular properties for drug-like compounds. 
 
The lists of different classes of compounds were then merged, and a 
native Pipeline Pilot module was used to select 35 diverse compounds from 
this combined set, using their structural fingerprints as the basis for diversity 
(Figure 3.4). This was a larger selection than the 24 co-substrates proposed 
in the initial design, as we anticipated some of the compounds may be 
unsuitable due to potential poor solubility, assay interference or lack of 
current commercial supply. These traits, if identified, led to their exclusion 
from the array, allowing trimming of the set down to 24 co-substrates. 
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Figure 3.4 – The 35 co-substrates selected using the cheminformatics 
workflow. 
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3.2.4 Execution of Mock Array 
 
With all of the components for Round 1 obtained, a mock array was 
executed to determine if any individual components to be included in the 
array would cause assay interference or have solubility issues. Stock 
solutions were made up at the exact specification that would be used in the 
reaction array, and each individual component taken through each of the 
work-up procedures (reduction and reductive amination) separately. Each of 
these crude products was then screened using a single-point assay to 
determine the relative activities of each component. By normalising the 
results relative to the testosterone positive control, activity data for the 
component could be obtained, and its likelihood of assay interference 
determined.106 The mock array was completed at a screening concentration 
of 10 M relative to the armed substrate; hence the co-substrates were 
being screened at 20 M due to their relative excess in the reaction mixtures 
(assay readout in experimental). 
 
A survey of the previously compiled reaction library found that most of 
the organocatalytic reactions in the literature tended to proceed at their 
highest reported efficiency at reaction concentrations ranging from 50 mM to 
300 mM relative to the limiting substrate. The reaction concentration was 
therefore set to 100 mM with respect to the limiting reagent, the armed 
substrate. The final co-substrate concentration in the reactions was set to 
200 mM, and the catalyst loading 10 mol% (10 mM). The order of these 
components was also of importance – by adding the smaller volumes of the 
substrate components and allowing the evaporation of the 30 L total 
volume of the solutions, 100 L of the catalyst system could then be added 
and the reaction wells sealed, resulting in minimal solvent loss during the 24 
hour reaction time during the execution of the ADS reaction arrays. 
 
An overview of the workflow for the execution of the mock array 
process is shown in Figure 3.5. Each component solution was made as it 
would be in a reaction array, at the identical concentration to be used, 
allowing easy identification of components with solubility issues or readout 
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interference. Each component was added to its own well in two separate 
plates (corresponding to the two different work-up conditions being 
implemented), then left to allow solvent evaporation, before subjecting the 
components to the work-up protocols. Additional controls were also carried 
out, performing the work-ups on empty wells to determine whether the 
conditions would cause interference. The plates were then evaporated in a 
GeneVac, and each well then diluted with DMSO to 100 mM concentration 
relative to Substrate A concentration, and further diluted with DMSO and 
buffer to 20 M solutions that were screened using a single-point assay 
procedure at a final concentration of 10 M relative to the limiting substrate. 
 
The single point assay procedure screened mixtures in triplicate, 
adding 5 L of the buffer solutions to the relevant wells of the assay plate. 
Once the relevant negative and positive (testosterone at a final 
concentration of 10 M) controls were added, this was followed by addition 
of 2.5 L of a solution of AR-LBD, and after 20 mins, 2.5 L of a 
Fluorescein-labelled peptide/Tb3+-labelled anti-GST antibody complex 
solution (concentration for both of these solutions specified on the individual 
assay kit). Incubation for four hours and reading of the plate using a Perkin-
Elmer Envision 2103 Multilabel reader allowed TR-FRET ratios to be 
obtained for each well, and thus bioactivity could be calculated for each 
single-point well relative to the testosterone positive control. The assay 
readout for the mock array executed can be seen in Figure 3.6. 
 
A number of components exhibited poor solubility or indicated 
interference; resulting in their exclusion from the first round (Table 3.1). Of 
those excluded, a number of them exhibited activity that highlighted assay 
interference, and a number also had solubility issues. From the remaining 
compounds, a number were eliminated due to similarity to other components 
in the set. The green highlighted compounds shown in Table 3.1 were 
selected for inclusion in the first round of ADS. The results of the mock array 
led to the finalised design of round 1 outlined in Figure 3.7. 
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Figure 3.5 – An overview of the workflow when used during the screening of 
the mock array. Each individual component solution was added to the same 
well in two different plates, at the concentration that was to be used in the 
first round reaction array. Evaporation was allowed, before subjecting to each 
plate to one of the two specified work-up conditions. Following quenching 
with acetaldehyde, the solutions were evaporated, before dissolving into 
DMSO, and then buffer to allow assay of the processed component. 
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Figure 3.6 – Assay readout for the control screen of components. This 
enabled the removal of co-substrates that could potentially interfere with 
results (highlighted in red). An empty column indicates the component was 
insufficiently soluble in chloroform. CIN = cinnamaldehyde. RW = work-up 
with cinnamaldehyde. RW/O = work-up without cinnamaldehyde. 
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Molecule % Molecule % Molecule % Molecule % 
 
B1 
14 
20 
 
B10 
5 
13 
 
B19 
1 
2 
 
B28 
13 
23 
 
B2 
20 
19 
 
B11 
7 
8 
 
B20 
-1 
4 
 
B29 
10 
20 
 
B3 
12 
20 
 
B12 
7 
6 
 
B21 
11 
18 
 
B30 
2 
7 
 
B4 
10 
13 
 
B13 
14 
25 
 
B22 
25 
29  
B31 
3 
-2 
 
B5 
18 
23 
 
B14 
13 
22  
B23 
8 
7  
B32 
3 
-2 
 
B6 
2 
19 
 
B15 
15 
20 
 
B24 
x 
 
B33 
16 
25 
 
B7 
0 
0 
 
B16 
12 
15 
 
B25 
15 
46 
 
B34 
14 
16 
 
B8 
-1 
2 
 
B17 
13 
13  
B26 
17 
33 
 
B35 
7 
10 
 
B9 
x 
 
B18 
6 
8 
 
B27 
x   
Table 3.1 – Activity data for co-substrates screened in the mock array.  Top = 
sodium borohydride reduction, bottom = reductive amination. x = insoluble 
and not tested. Components used highlighted in green. 
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Figure 3.7 – Components used in the Round 1 exhaustive array. Every 
combination of Substrate A, Substrate B, Catalyst and Work-Up was 
executed to generate a total of 960 reaction mixtures. 
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3.2.5 Execution of Exhaustive Reaction Array 
 
 
 
Figure 3.8 - Overview of the workflow used during the assembly and 
screening of the exhaustive arrays. Substrate A and B solutions were added 
to the relevant well on the assay plate, before allowing evaporation. The 
catalyst/additive/solvent solution was then added, before capping the wells 
for 24 hours of reaction time. Evaporation was allowed, before subjecting to 
each plate to one of the two specified work-up conditions. Following 
quenching with acetaldehyde, the solutions were evaporated, before 
dissolving into DMSO, and then buffer to allow assay of the crude reaction 
mixtures. 
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The round 1 reaction array was carried out as described in the 
protocol in Figure 3.8. Armed substrate component solutions were added to 
the relevant reaction well, followed by the co-substrate component solution. 
The solvent was then allowed to evaporate in each well, before adding the 
catalyst system solution. The wells were then capped, and 24 hours of 
reaction time allowed (Figure 3.9). After uncapping and allowing solvent 
evaporation, before subjecting the components to the work-up protocols, 
quenching with an acetaldehyde solution. The plates were then allowed to 
evaporate naturally, then evaporated to dryness in a GeneVac, and each 
well diluted with DMSO to 100 mM concentration relative to the substrate 
concentration. Wells were then diluted further initially with DMSO, and then 
with pH 7.5 buffer, to 20 M solutions relative to the limiting substrate. These 
solutions were added to the assay plate and screened at a concentration of 
10 M relative to the substrate concentration, using the single-point assay 
procedure described in Section 6.6.3, with a final concentration of 1% 
DMSO in each well. The TR-FRET ratio of emissions at 520 nm and 495 nm 
were measured for each well, allowing an indication as to the level of 
agonism for each mixture in relation to the testosterone positive control. 
 
 
Figure 3.9 – Experimental setup for the Round 1 reaction arrays. 96-well 
PTFE blocks were sealed with plastic caps. 
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Product mixtures with bioactivity at least two standard deviations (2) 
from the mean of the bioactivities of all product mixtures on a plate were 
considered as significant hits, corresponding to a 95% confidence interval 
(p=0.05). An example of this criteria being applied per assay can be seen in 
Figure 3.10, wherein the data for the plate utilising armed substrate A3 that 
was subjected to the reduction work-up protocol can be observed. From the 
ten 96-well plates that were initially screened, 47 of the 960 product mixtures 
showed activity that was statistically significant using our criteria, with 
respect to each plate. The assay readout for every plate from Round 1 can 
be observed in Section 6.8 of the experimental. 
 
As there were many crude mixtures to consider from this initial 
screen, hit validation was carried out on the 47 reactions that had exceeded 
the statistical criteria for each plate. The original reactions were repeated 
identically as they had been in the first round, including work-ups, and 
screened again at the same relative product concentration in order to 
validate the originally observed activity. This also helped to triage the initial 
results to a smaller set of productive combinations that could be used to 
design a second reaction array. 12 of the 47 mixtures retained comparable 
levels of activity observed in the original screen. The composition of the 12 
mixtures are summarised in Table 3.2, and the assay data for the Round 1 
Validation array observed in Section 6.8.1. 
 
Table 3.2 demonstrated that some of the combinations observed may 
have been related as they featured similar co-substrates. The majority of 
validated points utilised the reduction work-up, although two utilised the 
reductive amination procedure. All four of the catalysts were involved, 
suggesting diversity in the reactivity of the productive combinations, and 
potentially diversity in products being formed. 
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Figure 3.10 – Illustrative assay readout data for the reaction array involving 
A3 treated with sodium borohydride. Statistical criteria used to filter hits is 
indicated. 
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Mixture Substrate Co-Substrate Catalyst Work-Up %Activity 
A1B31C1R 
  
J-H 
C1 
NaBH4 
Reduction 
29 
A3B19C1R 
 
 
J-H 
C1 
NaBH4 
Reduction 
28 
A3B8C2R 
 
 
Macmillan 
C2 
NaBH4 
Reduction 
40 
A5B28C2R 
  
Macmillan 
C2 
NaBH4 
Reduction 
23 
A4B16C3R 
  
Triazolium 
C3 
NaBH4 
Reduction 
33 
A5B31C3R 
 
 
Triazolium 
C3 
NaBH4 
Reduction 
27 
A4B3C3R 
 
 
Triazolium 
C3 
NaBH4 
Reduction 
27 
A4B16C4R 
  
iMes 
C4 
NaBH4 
Reduction 
32 
A5B5C4R 
  
iMes 
C4 
NaBH4 
Reduction 
21 
A5B15C4R 
  
iMes 
C4 
NaBH4 
Reduction 
26 
A2B20C1RA 
 
 
J-H 
C1 
Me2NH 
RA 
70 
A4B20C3RA 
 
 
iMes 
C4 
Me2NH 
RA 
49 
Table 3.2 - Combinations from the validation array that displayed agonism of 
the AR at 10 M relative to the limiting substrate. % activity is the bioactivity 
of the combination in relation to testosterone (10 M). 
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3.3 Design and Execution of a Targeted ADS Reaction Array 
 
3.3.1 Design of Targeted Reaction Array 
 
As the aim of using the organocatalytic chemistry was to ultimately 
generate new scaffolds, limiting the variance from the literature with respect 
to the components used was likely to yield more reactions that formed 
intermolecular products. By electing to only use reactively compatible 
substrates pairings that had been shown to generate new scaffolds in 
previous literature, designing arrays of targeted reactions that were likely to 
proceed to form products in each well presented itself as an attractive 
approach. 
 
In previous work using metal-carbenoid chemistry, a diazo substrate 
could be activated via the catalyst to generate a species that is likely to react 
with many different substrates (Figure 3.11a). The chemistry used 
generates products cleanly and requires no work-up procedure that adds 
additional complexity to the mixture. Due to this, an exhaustive approach 
works well, producing diverse arrays of complex but clean mixtures of 
potential bioactive products from a relatively small palette of substrates. 
 
In contrast, organocatalysis may require very specific combinations of 
substrates and catalyst to convert to new scaffolds, and the design of the 
array therefore has to be adjusted accordingly (Figure 3.11b). Specific 
combinations of substrate, co-substrate and catalyst classes were used, 
based on literature precedent, with the vision that this would enable 
generation of new scaffolds and therefore products. For example, an NHC 
catalyst only has precedent to activate aldehyde species, and iminium 
activation will only occur with an  ,-unsaturated aldehyde. When 
compared to the exhaustive approach described in Section 3.2, the new 
proposed ‘targeted’ strategy offered increased probability of intermolecular 
product generation, but removed a large degree of the serendipitous 
discovery that had initially been expected from the exhaustively designed 
reaction arrays. 
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a) 
 
C-H insertion Cyclopropanation O-H insertion Other 
b)    
 
Specific combination of substrate, co-substrate and catalyst classes required 
 
With the aim of forming diverse new scaffolds using precedented 
chemistry in mind, an initial first array of 192 diverse reactions was devised, 
utilising 30 different scaffold forming reactions. In a similar format to that of 
the exhaustively designed array, armed ,-unsaturated aldehyde 
substrates featuring the 4-cyano-3-trifluoromethylphenyl (A1) and 3,4-
dichlorophenyl (A2) motifs provided the basis for each reaction. Pairing of 
the enals to both a compatible co-substrate class and organocatalytic 
system that had literature precedent would increase the probability of 
reactions proceeding to form products when compared to reactions in the 
exhaustively designed reaction array.  
Figure 3.11 – Comparison of the diazo chemical toolbox to the 
organocatalytic chemical toolbox. The diazo toolkit (a) was used to elaborate 
a fragment by pairing with a catalyst and co-substrate, with pairings where a 
reaction was very likely and probable to proceed to products via one of 
multiple possible outcomes, regardless of the combination. On the other 
hand, the organocatalytic toolkit (b) may require very specific pairings of 
components in order to generate intermolecular products. 
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Figure 3.12 – Overview of the design of the targeted array. Specific sets of co-
substrates were matched to each catalyst class. TB2 –16 were selected to pair with 
amine catalyst C1, TB18-32 were selected to pair with NHC catalysts C3 + C4. 
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It was elected to select two subsets of co-substrates: 15 that were 
compatible with the amine organocatalyst class, and 15 that were 
compatible with the NHC organocatalyst class. In both cases, these sets 
were selected using the cheminformatics workflow previously described in 
Figure 3.5. The co-substrates were commercially available, filtered for 
appropriate molecular properties, and contained functionality that had direct 
literature precedent to react with an ,-unsaturated aldehyde and either an 
amine or an NHC organocatalyst. 
 
Each of these 48 reactions were to be conducted in duplicate, with 
each of the duplicates being subjected to either the sodium borohydride 
work-up procedure, or the reductive amination work-up procedure with 
dimethylamine. Taking into account the two armed substrates, this resulted 
in 196 reactions in total. All reactions were to be quenched with 
acetaldehyde, before screening at 10 M concentration in a single-point 
assay for agonism of the AR. The design of the targeted array is 
summarised in Figure 3.12. 
 
3.3.2 Execution of Targeted Reaction Array 
 
In a similar fashion to the exhaustive array, reaction arrays began 
with the addition of 10 L of the armed substrate 1 M solution, followed by 
20 L of the 1 M co-substrate solution to each well. The wells were allowed 
to evaporate, then 100 L of the appropriate 100 mM catalyst/solvent 
solution was added to the wells before capping each vial and leaving the 
reactions for 24 hours. The wells were then uncapped to allow evaporation 
to dry crude mixtures, before employing the appropriate work-up conditions. 
The wells were then quenched with a 5 M acetaldehyde solution, and the 
plates allowed to evaporate naturally, before evaporating to dryness in a 
GeneVac. Each well was then diluted with DMSO to 100 mM concentration 
relative to Substrate A concentration, and further diluted with DMSO and 
buffer to 20 M solutions (2x) that were screened using the single-point 
assay procedure at 10 M described in Section 6.6.3. 
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Figure 3.13 – Assay readout for the targeted array of reactions featuring the 
armed substrate A1, that was subjected to the reduction work-up protocol. 
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Figure 3.14 – Assay readout for the targeted array of reactions featuring the 
armed substrate A1, that was subjected to the reductive amination work-up 
protocol. 
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Figure 3.15 - Assay readout for the targeted array of reactions featuring the 
armed substrate A2, that was subjected to the reduction work-up protocol. 
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Figure 3.16 - Assay readout for the targeted array of reactions featuring the 
armed substrate A2, that was subjected to the reductive amination work-up 
protocol. 
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Mixture Substrate Co-Substrate Catalyst Work-Up %Activity 
A1TB6C1R 
 
 
J-H 
C1 
NaBH4 
Reduction 
31 
A1TB8C1R 
 
 
J-H 
C1 
NaBH4 
Reduction 
33 
A1TB20C3R 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
33 
A1TB22C3R 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
41 
A1TB32C3R 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
34 
A2TB20C3R 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
30 
A2TB22C3R 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
34 
 
The assay readout for the targeted arrays can be seen in Figure 
Figure 3.13-Figure 3.16, and Table 3.3 shows a summary of the reaction 
mixtures that exhibited bioactivity exceeding the statistical criteria of lying at 
least two standard deviations (2) from the mean of the bioactivities of all 
product mixtures on each plate. None of the 192 product mixtures exhibited 
activity greater than 50% of the activity of testosterone (10 M) 
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Table 3.3 – Reaction combinations with bioactivity at least two standard 
deviations (2) from the mean of the bioactivities of all product mixtures on 
each of the two plate were considered significant, corresponding to a 95% 
confidence interval (p=0.05). 
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3.4 Design and Execution of Second Exhaustive ADS Reaction Array 
 
With a selection of productive combinations from two different first 
round design strategies in hand, the design of a second round of ADS was 
considered. The most promising product mixtures with respect to activity 
were identified in the exhaustive project (outlined in Table 3.2). For this 
reason, it was decided that a design approach for elaborating these hits 
would be developed, allowing further investigation of the chemical space that 
each combination of components explored. 
 
It was decided that for each combination found in Round 1, only the 
co-substrate and catalyst would be significantly varied for the combinations 
in Round 2. The armed substrate and work-up for each combination would 
be fixed and would not change, however catalyst would be varied within 
each class i.e. any hits with an amine organocatalyst would utilise both the 
Jorgensen-Hayashi and Macmillan catalysts, and any NHC catalysts hits 
would use both the iMes and triazolium catalysts. Each variation around a 
combination identified to be productive from round one can be thought of as 
a mini array – exploring the possibilities from the original combination, 
maintaining a level of commonality with it but utilising an expanded range of 
co-substrates to attempt to optimise the combination. 
 
Similarly to Round 1, a cheminformatics workflow was used, selecting 
for reactive functionality similar to the co-substrate in the Round 1 
combination, and physiochemical parameters. Using the databases and 
cheminformatics workflow denoted in Figure 3.4, appropriate co-substrates 
were found for most combinations. However, it was found that interesting 
variations of the important ,-unsaturated aldehyde class were not 
prevalent in commercial chemical catalogues. This class of compound were 
components in a number of the validated productive combinations from 
Round 1, so a selection of interesting derivatives that sought to improve the 
bioactivity of the resulting product were essential for the execution of an 
efficient second reaction array. To aid practical assembly, the reaction array 
was designed so that alongside the original combination that gave promising 
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reactivity, there would be up to 7 new co-substrates based around the 
productive Round 1 combination, allowing each combination variation to take 
up one column on the 96-well reaction plate. This would result in up to 14 
new variations of each reaction based upon the original Round 1 hit. 
 
  
  
 
 
 
 
 
 
 
 
 
3.4.1 Synthesis of Co-Substrates 
 
Synthesis of diverse heterocyclic analogues of ,-unsaturated 
aldehydes were carried out, using not only the Wittig method used 
previously when making A1 and A2 for Round 1, but also a Vilsmeier-Haack 
reaction to make the enals D6 and D7 (see Scheme 3.2). For the Wittig 
Figure 3.17 – Schematic showing the logic behind design of Round 2 
mixtures. Co-substrate was altered for each combination, as well as using 
the alternative catalyst in each organocatalyst class. 
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reactions, the respective aromatic aldehyde required was refluxed with either 
THF or toluene, with a slight excess of 
(triphenylphosphoranylidene)acetaldehyde for 24 hours. Conversion was 
observed in all cases, with the ,-unsaturated aldehydes (D1-D5) being 
synthesised with variable yields. 
 
a) 
 
 
b) 
 
 
Scheme 3.2 - Synthesis of a selection of ,-unsaturated aldehydes for use 
as co-substrates in Round 2 of ADS. a) The selection of ,-unsaturated 
aldehydes synthesised using the Witting chemistry. All reactions executed in 
either THF or toluene at reflux. b) The pair of ,-unsaturated aldehydes 
synthesised using the Vilsmeier-Haack reaction. 
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For the Vilsmeier-Haack reaction, 3-dimethylaminoacrolein was 
added to phosphoryl chloride, resulting in formation of a -chlorinated amine 
intermediate. Addition of a suitable heterocycle enabled electrophilic 
aromatic substitution, forming the desired ,-unsaturated aldehyde product 
following hydrolysis. 
 
3.4.2 Execution of Second Exhaustive ADS Reaction Array 
 
The final layout of the Round 2 reaction arrays consisted of 170 
reactions, using two 96-well reaction plates. Each pair of columns on the 
plate contained variations of reactions based around the same original 
productive Round 1 combination, with each column in a pair utilising a 
different catalyst. A mock array for the Round 2 components was executed, 
and no significant activity at the 1 M concentration was observed, with the 
exception of a few co-substrates exhibiting low TR-FRET ratios relative to 
the testosterone 10 M control. A full schematic for the layout of the Round 
2 reaction arrays can be observed in the experimental, in addition to a full 
specification of the components used across the 170 reactions explored. 
 
The Round 2 reaction array was conducted identically to the workflow 
denoted in Figure 3.8, except focusing on a more concentrated selection of 
combinations. The mixtures were initially screened at a concentration of 10 
M, but baseline activity for all of the mixtures was too high, resulting in a 
very large spread of activity. For this reason, the mixtures from Round 2 
were screened at 1 M relative to the concentration of the substrate. an 
order of magnitude lower than in Round 1, ensuring only the most productive 
bioactive combinations would be identified in Round 2. A number of 
combinations from Round 2 were prioritised, based on bioactivity shown in 
the assay. These combinations are highlighted on the assay readout which 
can be observed in the Figure 3.18 and Figure 3.19, and summarised in 
Table 3.4. 
97 
 
Figure 3.18 – Assay readout for Plate 1 of the second round of ADS, 
screened at a concentration of 1 M relative to the substrate, with activity 
assessed relative to a 10 M Testosterone control. All of these combinations 
utilised the sodium borohydride reduction workup. 
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Figure 3.19 - Assay readout for Plate 2 of the second round of ADS, screened 
at a relative concentration of 1 M relative to the substrate, with activity 
assessed relative to a 10 M Testosterone control. All combinations utilised the 
sodium borohydride reduction work-up, with the exception of the highlighted 
combinations that used the reductive amination work-up. 
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Mixture Substrate Co-Substrate Catalyst Work-Up %Activity 
A4D7C4 
  
iMes NHC 
C4 
NaBH4 
Reduction 
35 
A5G5C1 
 
 
Jorgensen-
Hayashi 
C1 
NaBH4 
Reduction 
55 
A4H4C3 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
44 
A5J4C3 
 
 
Triazolium 
NHC 
C3 
NaBH4 
Reduction 
47 
A2K1C1 
 
 
Jorgensen-
Hayashi 
C1 
Me2NH 
Reductive 
Amination 
52 
A4K1C3 
 
 
Triazolium 
NHC 
C3 
Me2NH 
Reductive 
Amination 
43 
Table 3.4 – A summary of mixtures from Round 2 that appeared to present 
bioactivity in a single point assay screen for agonism of the AR at 1 M 
concentration relative to the substrate in the reaction. % activity is the 
bioactivity of the combination in relation to testosterone (10 M). 
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3.5 Evaluation of Product Mixtures from Organocatalytic ADS 
 
3.5.1 Validation of Conversion and Bioactivity 
 
At this stage, it was decided that more in-depth analysis of a selection 
of the reactions identified throughout the project was necessary in order 
validate the hits discovered, and to gauge whether the chemistry had 
proceeded as anticipated. It was decided that two different approaches 
would be used to analyse the outcomes of these reactions: tracking the 
reactions by NMR and obtaining dose-response curves of the crude 
mixtures. This would allow confirmation of whether the reactions had 
generated intermolecular products, and whether the products were bioactive. 
 
NMR experiments were carried out, tracking the reactions over a 
period of 48 hours, allowing analysis of the conversion of each reaction. The 
reactions were assembled as had been previously done in the reaction 
array, at identical concentrations to the round 2 reaction arrays, albeit scaled 
up by a factor of 5. Appropriate concentration stock solutions for all 
components were assembled and screened independently before adding 
into a mixture. Substrate and co-substrate solutions were added to a 
reaction vial and allowed to evaporate, before addition of the 
catalyst/deuterated solvent mixture, and transfer to an NMR tube, using 13C 
NMR (125 MHz) spectroscopy to analyse at timepoints of 6, 24 and 48 
hours. This allowed a thorough assessment of reaction progress throughout 
the specified time period. Addition of the work-up at this point was 
unnecessary, as if the reaction did not produce intermolecular products pre-
work up, any products produced afterwards were unlikely to be the result of 
intermolecular reactions and were likely to be a product of reducing the 
reaction mixture. 
 
An example of the NMR analysis for the combination A5G5C1R 
(armed substrate A5, co-substrate G5, catalyst system C1 and the sodium 
borohydride reduction protocol – this nomenclature will be used to refer to 
reactions from ADS arrays hereon) identified in the second round of the 
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exhaustively designed array can be seen in Figure 3.20, and shows that 
despite apparent consumption of the armed substrate A5, no new peaks are 
formed in the NMR spectra over a 24 hour time period. The consumption of 
the substrate A5 may have been caused by it undergoing reaction with the 
amine catalyst C1 to form a species that was insoluble in the NMR solvent, 
precipitating out and therefore not being observed in the NMR spectra. This 
led to the belief that the bioactivity identified in the reaction A5G5C1R 
stemmed from sodium borohydride reduction of the substrate, rather than an 
intermolecular reaction. 
 
Armed Substrate (1 eqv.) Co-Substrate (2 eqv.) Catalyst (0.1 eqv.) 
 
 
 
in CDCl3 
 
Figure 3.20 – Analysis of the A5G5C1R combination via 500 MHz 13C-NMR 
demonstrated no formation of new intermolecular products. Despite 
conversion of the substrate, the co-substrate remains. 
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Armed Substrate (1 eqv.) Co-Substrate (2 eqv.) Catalyst (0.1 eqv.) 
 
  
in d8-THF 
 
 
 
Additionally, the NMR analysis of the two combinations from the 
targeted array, A1TB20C3R and A2TB20C3R (Table 6.2), demonstrated 
conversion of both substrate (A1 or A2) and co-substrate (TB20) in the 
reaction, along with formation of new peaks that indicated formation of a new 
CN
CF3
H
O
O
O
HO
Figure 3.21 - Analysis of the A1TB20C3R combination via 500 MHz 13C-
NMR demonstrated conversion of both substrate and co-substrates, and 
formation of new peaks prior to being subjected to the sodium borohydride 
reduction. This was also observed for the combination A2TB20C3R (Table 
6.2). Blue dots indicate new peaks in NMR spectra. 
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product, which was potentially the consequence of an intermolecular 
reaction (Figure 3.21). Other reaction mixtures analysed from using the 
NMR analysis either demonstrated no conversion of either substrate, or 
generated product mixtures that were deemed too complex to deconvolute. 
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Figure 3.22 – Dose-response curve for the crude mixture that was identified 
in the second round of ADS, for the combination between substrate A5, co-
substrate G5 and amine catalyst C1, followed by sodium borohydride 
reduction. The stated concentration is relative to the concentration of the 
substrate. 
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Alongside the NMR experiments, the crude mixtures were also 
screened for dose-dependency, obtaining dose-response curves. This 
allowed confirmation that the bioactivity in the mixture was being caused by 
a component with dose-dependent activity, rather than interference with the 
assay readout. A dose response curve was produced for each of them, as 
per the experimental in 6.6.2. The dose-response experiment revealed that 
half maximal effect was observed at low micromolar total product 
concentrations of the mixture A5G5C1R relative to the concentration of the 
limiting substrate (Figure 3.22). 
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Dose-response of the crude mixtures A1TB20C3R and A2TB20C3R 
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Figure 3.23 - Dose-response curve for the crude mixtures that were identified 
in the targeted ADS reaction array, for the combinations A1TB20C3R and 
A2TB20C3R. The stated concentration is relative to the concentration of the 
substrate. 
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3.23). Both of these combinations appeared to exhibit 50% of the maximal 
agonist activity in comparison to testosterone, suggesting they were partial 
agonists, in the region of 10 M activity. 
 
Fractionation was carried out for these prioritised reactions, but also 
the other reactions highlighted in Table 3.3 and Table 3.4. The reactions in 
these tables were replicated as they had been in the reaction arrays, but 
scaled up by a factor of 50. The crude mixtures were separated by 
fractionation via flash column chromatography. Screening of each of the 
isolated fractions individually at a concentration relative to the substrate of 
20 M using the single-point procedure highlighted any significant activity. 
This allowed for facile identification of any fractions that contained bioactive 
entities in all of the reactions highlighted, and these fractions could then be 
highlighted for further investigation. This experiment highlighted only three 
reactions that yielded fractions with greater than 25% bioactivity at 20 M 
relative to a testosterone (10 M) control – two fractions in A5G5C1R from 
the exhaustively designed reaction arrays, and A1TB20C3R and 
A2TB20C3R from the targeted arrays. These mixtures were the same as 
had been flagged by the NMR and dose-response validation approaches. 
The proposed compounds in each fraction were identified, and the reactions 
were scaled up to independently verify the identity of the component, and to 
validate the bioactivity. 
 
3.5.2   Scale-Up and Identification of Products 
 
In order to identify the active components within A5G5C1R, 500 MHz 
1H NMR spectra of the two fractions indicating bioactivity were obtained. By 
comparing to spectra from literature compounds, these initially appeared to 
be the two reduced diastereomers of the co-substrate (G5 - 4-(3,4-
dichlorophenyl)-1-tetralone). To verify that this was in fact the component 
responsible for causing bioactivity, an independent synthesis involving the 
direct sodium borohydride reduction of G5 in methanol was carried out, and 
the two diastereomers were isolated independently. The identities and 
configuration of each of the diastereomers (37% rac-35a; 41% rac-35b) was 
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determined via NMR analysis and compared to the literature data for the 
known compounds.114 Dose-response curves were obtained for both 
diastereomers, indicating that they both had low micromolar activity (Figure 
3.24). Even though the reduced G5 component was screened in the mock 
array for Round 2 at 1 M concentration, this co-substrate did not give a 
response that indicated that it was significantly active. 
 
 
  
 
Similar analysis was carried out for the reactions A1TB20C3R and 
A2TB20C3R. 500 MHz 1H NMR spectra of the fractions that were found to 
display bioactivity from the fractionation indicated that the components 
causing the bioactivity were aliphatic alcohol reduction products 36 and 37 of 
the ,-unsaturated aldehyde substrates A1 and A2. 
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Figure 3.24 – Dose-response for the racemic diastereomers for the reduced 
co-substrate in A5G5C1R. Both diastereomers exhibit low micromolar 
activity. 
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To verify that these compounds were bioactive, independent 
syntheses were carried out for the two materials. ,-unsaturated aldehyde  
A1 was reduced in a flask with palladium(II) acetate and methanol, using 
sodium borohydride in a flask sealed with a balloon. The molecular hydrogen 
produced in the reduction of the aldehyde group is trapped in the reaction, 
resulting in palladium-catalysed reduction of the double bond, producing the 
aliphatic alcohol 36, in a yield of 80%. In a separate method, 3-(3,4-
dichlorophenyl)propanoic acid was reduced to the aliphatic alcohol using 
borane-THF complex (1M) to form the aliphatic alcohol 37 in a yield of 73%. 
The aliphatic alcohols 36 and 37 were compared to known literature to help 
confirm their identity.115,116 Dose-response curves were obtained for both 
compounds, indicating that they both had micromolar activity as partial 
agonists (Figure 3.25). 
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Figure 3.25 - Dose-response for the aliphatic alcohol products of the 
reactions A1TB20C3R and A2TB20C3R. Both compounds display low 
micromolar level activity of the AR and appear to be partial agonists. 
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As the sodium borohydride induced reduction of ,-unsaturated 
aldehydes is known to produce the allyl alcohol, as was discovered in the 
development of the work-up protocols described in 2.4.1, it is proposed that 
activation of the ,-unsaturated aldehyde by the NHC resulted in a Breslow 
intermediate that had the ability to abstract a proton from the co-substrate. 
This results in the formation of the alkyl aldehyde once released from the 
catalyst, which can be subsequently reduced when the sodium borohydride 
work-up is applied to form the component which elicits agonism of the AR. 
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4 Conclusions and Future Work 
 
The primary objective of the project was to expand the chemical 
toolbox compatible with ADS. Organocatalytic reactions that used a broad 
range of catalysts to generate a diverse range of products were identified. A 
selection of these reactions was miniaturised, and their outcomes to their 
full-scale literature counterparts, demonstrating their successful translation 
to the micro-scale format required for ADS. Work-up conditions were then 
developed that were able to reduce electrophilic functionalities to more 
benign functional groups, or reductively aminate them to add extra 
functionality. This work enabled organocatalysis to be primed as a useful 
option in the chemical toolbox available for ADS. 
 
Following setup of a TR-FRET assay that screened for agonism of the 
androgen receptor, a number of strategies were then implemented to design 
ADS reaction arrays using the new chemical toolbox. A number of 
approaches were developed that allowed the design of reaction arrays that 
maximised diversity components, and therefore the products that could be 
generated. The exhaustively designed array promoted serendipitous 
discovery of bioactivity, only using the literature to loosely guide array 
design; whereas the targeted array focused more on conversion to new 
intermolecular products, using the literature to guide syntheses to known 
scaffolds. Workflows to follow up on any hits discovered from reaction arrays 
were developed, that included hit validation assays, fractionation of product 
mixtures, dose-response assays of crude mixtures and NMR analysis of 
reaction progression. 
 
A reliance on activity to direct the synthesis of bioactive compounds 
comes with the caveat that the approach has no preconceptions regarding 
the structure of the products generated, as demonstrated with the isolation 
of the compounds identified in Section 1.1. No bioactive intermolecular 
products were isolated using either strategy, but products with micromolar 
levels of agonism that stemmed from substrates were identified, 
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demonstrating that novel intermolecular agonists can be identified using the 
workflow if they are generated. 
 
4.1 Analysis of Value of Organocatalysis in ADS 
 
Organocatalysis appears to have useful attributes to be productive 
with ADS – robust and diverse reactions capable of forming a range of 
scaffolds with interesting stereochemistry. The setup of the chemistry in 
Section 2.3.3 demonstrated that a range of simple but varied 
organocatalytic reactions could function on the microscale format required 
for ADS, using small volumes, no stirring and reactions open to the air. 
However, the strategies that were used to design arrays necessitated 
variance from the known literature reactions, particularly with regards to 
substrate scope, which was necessary to arm substrates with motifs known 
to have affinity for AR binding. 
 
The lack of robustness when varying from the idealised conditions 
used in the seminal work that describes a new reaction is a problem for 
organic chemists, limiting synthetic utility of new reactions. It is well known 
that many organic reactions that are reported to work with relatively 
unfunctionalised substrates do not extend to work well in the synthesis of 
more complex functionalised target molecules.117 A ‘robustness screen’ has 
been proposed as a solution to this issue. The screen assesses the 
tolerance of a set of reaction conditions to a range of functional groups, 
while simultaneously assessing the stability of the functional groups to the 
reaction conditions.118–120 Parallel reaction processing using a small but 
efficiently selected range of functionalised additives and substrates can 
allow assessment as to the overall robustness of the reaction. Assessment 
of new synthetic methods with this screen and demonstrating their scope 
could potentially increase the speed at which new chemistries are adopted 
and allow for more complex synthetic problems to be solved. 
 
ADS with organocatalysis has been applied to another project within 
the group that targets the p53/MDM2 protein-protein interaction. The project 
111 
utilised a targeted design approach as outlined in Section 3.3, in which 576 
reactions were executed. No active intermolecular products were identified 
using this approach, but post-array analysis by LC-MS indicated that 
intermolecular products were formed in reactions that were inactive. 
 
4.2 Future Scope for Application of Organocatalysis in ADS 
 
A solution that could allow for successful demonstration of 
organocatalysis in ADS could be to attempt to generate compounds to 
screen using very simple substrates in reactions with strong literature 
precedent. These reaction arrays could then be screened against targets for 
which robust high-throughput assays are established but the selection of 
known small-molecule modulators is small. By starting with no 
preconceptions regarding target and not integrating affinity motifs into 
substrates, the approach would be truly target-agnostic, enabling the 
screening of a rapid number of chemotypes against targets for which there 
are little or no know modulating chemotypes, with a high probability of 
products being generated for every reaction in the array. This could provide 
valuable starting points for medicinal chemistry against difficult targets. 
 
Additionally, extra quantitative validation methods embedded into the 
ADS workflow could successfully show intermolecular product formation. 
Development of robust high-throughput HPLC or LC-MS methods could help 
identification of intermolecular products in reactions that show activity on a 
high-throughput assay, allowing prioritisation of reactions. 
 
In the early stage of its development, ADS has been demonstrated to 
have potential to be a fruitful method for developing bioactive molecules. 
Continuing to demonstrate its worth by using different varieties of chemistry 
against a range of biological targets could help to validate its position as an 
efficient bioactive hit molecule generation approach.  
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5 Appendix: Synthesis of Compounds Accessible using a 
Top-Down Lead-Oriented Synthesis Approach 
 
The work completed during an industrial placement contributed to a 
project that focused on the ‘top-down’ LOS approach to a large number of 
novel scaffolds (an overview of the project is described in 1.1.3). This work 
contributed to the realisation of four distinct compound libraries based upon 
two cycloadduct starting materials were synthesised, decorating a number of 
the scaffolds as part of a collaborative effort to generate a library. Work was 
undertaken to demonstrate the synthesis of the key cycloadduct on a 
multigram scale, before validating the chemistry by making fused-imidazole 
and fused-pyrazine derivatives using routes previously developed within the 
group (Figure 5.1). 
 
Figure 5.1 – Chemistry undertaken to enable production of large screening 
libraries based on complex molecular scaffolds. 
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Initially, the multigram scale synthesis of cycloadduct 41 was 
demonstrated. Starting from 10 g of kojic acid 38, the alcohol was treated in 
sequence with tert-butylchlorodimethylsilane and methanesulfonyl chloride 
to make 39, that was used in the next step of the synthesis without 
purification. Allylamine was used to substitute the activated mesylate leaving 
group to make the amine 40, which was once again used crude in the next 
step. The amine was then protected with a carboxybenzyl group to make 
carbamate 41 in an overall yield of 56% from the kojic acid starting material 
over 4 steps. The cycloadduct 41 was then refluxed in xylenes at 150 oC, 
initiating a [5+2] cycloaddition to form cycloadduct 42 in high yield, which 
was the key cycloadduct from which derivatives could be made. 
 
Several imidazole derivatives (47-51) were generated from 
cycloadduct 42 via one-pot Debus-Radziszewski reactions, resulting in 5 
novel analogues. Additionally, reaction of the cycloadduct 42 with ethylene 
diamine resulted in a fused pyrazine scaffold 43. The fused pyrazine 43 
could then be derivatised to substitute the nitrogen protecting group to 
generate novel analogues (44-46). This work demonstrated that the 
scaffolds could be readily functionalised to populate a library of screening 
compounds, and this was subsequently exploited by Edelris to generate a 
library of over 2900 compounds. 
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6 Experimental Procedures 
 
6.1 General Information 
 
Commercially available starting materials were obtained from Sigma-
Aldrich, Fluorochem, Alfa Aesar, Fisher Scientific, Acros, Apollo Scientific 
and Insight Biotechnology. All non-aqueous reactions were carried out under 
an atmosphere of nitrogen in oven-dried glassware unless stated. 
Anhydrous DCM, anhydrous THF, anhydrous toluene, anhydrous diethyl 
ether, anhydrous methanol and anhydrous acetonitrile were obtained from a 
PureSolv MD5 purification system. All other anhydrous solvents were 
obtained from sealed bottles from the aforementioned suppliers. All other 
solvents were of analytical grade and used as supplied. Ether refers to 
diethyl ether and petrol refers to petroleum spirit (b.p. 40–60 °C) unless 
stated. 
 
Solvents were removed under reduced pressure using a Büchi rotary 
evaporator and a Vacuubrand PC2001 Vario diaphragm pump. Reaction 
plated were evaporated where necessary with a GeneVac EZ-2 evaporator. 
Thin layer chromatography was carried out on pre-coated aluminium Merck 
SilicaGel 60 F254 plates, using ultraviolet light (λmax = 254 nm) and KMnO4 
for visualisation. Flash column chromatography was carried out using Merck 
Geduran SilicaGel (30–75 μM particles). 
 
Analytical LC-MS was performed using an Agilent 1200 series LC 
system consisting of a Bruker HCT Ultra ion trap mass spec, a high vacuum 
degasser, a binary pump, a high performance autosampler and micro well 
plate autosampler, an autosampler thermostat, a thermostated column 
compartment and diode array detector. The system used a Phenomenex 
Luna C18 50 x 2mm 5 micron column and two solvent systems: MeCN/H2O 
+ 0.1% Formic acid or MeCN/H2O. Accurate mass spectrometry was 
recorded using electrospray ionisation on a Bruker MaXis Impact 
spectrometer. Infrared spectroscopy was recorded on a Bruker Alpha-P ATR 
FT-IR spectrometer. 
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Proton (1H) and carbon (13C) NMR spectra were recorded on a Bruker 
300, Bruker Ascend 400 Bruker Avance 500 spectrophotometer using an 
internal deuterium lock at 300 K unless stated. Chemical shifts are quoted in 
parts per million downfield of tetramethylsilane and coupling constants (J) 
are reported in Hertz. Splitting patterns are abbreviated when reported: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet) app (apparent) and 
br (broad). DEPT 135, COSY, HMQC and HMBC pulse sequences were 
often used to aid spectral assignment. 
 
6.2 Chemistry Experimental Procedures 
 
6.2.1 Synthesis of Catalysts 
 
2-{Diphenyl[(triethylsilyl)oxy]methyl}pyrrolidine (6) 
 
 
 
TESOTf (5.80 mL, 25.7 mmol) was added drop-wise to a solution of 
(R)-(+)-diphenyprolinol (2.50 g, 9.85 mmol) and (S)-(-)-diphenyprolinol (2.50 
g, 9.85 mmol) and triethylamine (3.58 mL, 25.7 mmol) in DCM (35 mL) at 0 
oC. Following the addition, the reaction mixture was warmed to room 
temperature and allowed to stir for 72 hours. Conversion of the starting 
material was confirmed by TLC analysis, and the mixture quenched with 
water (10 mL). The product was extracted with DCM (2 x 10 mL), washed 
with brine (2 x 5 mL) and dried over anhydrous MgSO4 before evaporation 
under reduced pressure to give the crude product as a yellow oil. The crude 
product was purified by flash column chromatography, eluting with 10:1–5:1 
Hexane–EtOAc, to obtain the title compound121 as a straw coloured, 
transparent viscous oil (3.22 g, 8.70 mmol, 44%). H (500MHz, CDCl3): 7.52-
7.50 (2H, m, Ph), 7.40-7.38 (2H, m, Ph), 7.32-7.24 (6H, m, Ph), 4.05 (1H, t, J 
7.3, 2-H), 2.89-2.81 (1H, m, 5-Ha), 2.78-2.70 (1H, m, 5-Hb), 1.67-1.56 (3H, 
m, 4-H & 3-Ha/b), 1.29 (1H, m, 3-Ha/b), 0.89 (9H, t, J 7.9, CH2CH3), 0.39 (6H, 
1
2
N
H
3
4
5
Ph
OTES
Ph
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q, J 8.0, CH2CH3); C (125MHz, CDCl3): 146.7 (Ar), 145.5 (Ar), 128.8 (Ar), 
128.0 (Ar), 127.5 (Ar), 127.3 (Ar), 126.9 (Ar), 126.9 (Ar), 82.9 (COSi), 65.7 
(C-2), 47.3 (C-5), 27.7 (C-3), 25.1 (C-4), 7.3 (C-7), 6.5 (C-8); IR 𝝊max 
(neat)/cm-1: 3058.3, 3025.0, 2952.6, 2909.1, 2873.7, 1598.9;  Rf = 0.03 
(50:50 Hexane–EtOAc); HRMS (ESI): C23H33NOSi requires [M+H]+ 
368.2410, found 368.2415.  
 
(2S)-2-Amino-N-methyl-3-phenylpropanamide (9) 
 
 
 
Thionyl chloride (7.72 mL, 107 mmol) was added dropwise to a flask 
charged with L-phenylalanine (5.00 g, 30.3 mmol) in methanol (80 mL). After 
refluxing for 2 hours, the mixture was cooled to room temperature, and the 
reaction mixture was concentrated under reduced pressure. Methylamine 
(8M in ethanol, 7.8 mL, 60.6 mmol) was added along with additional ethanol 
(30 mL) and the mixture allowed to stir for 48 hours at room temperature. 
The reaction was then diluted with dichloromethane (50 mL) and water (25 
mL), and the pH adjusted to 12 with saturated K2CO3 solution. The layers 
were separated and the aqueous phase extracted with dichloromethane (2 x 
5 mL). The separated organic layers were combined, dried over Na2SO4, 
and concentrated under reduced pressure to obtain the title compound93 as 
a colourless amorphous solid (4.65 g, 26.1 mmol, 86%). H (500MHz, 
CDCl3): 7.35-7.23 (5H, m, Ar-H), 3.62 (1H, dd, J 9.4 and 4.0, 2-H), 3.30 (1H, 
dd, J 13.8 and 4.0, 3-Ha/b), 2.83 (3H, d, J 5.0, N-CH3), 2.69 (1H, dd, J 13.8 
and 9.4, 3-Ha/b); C (125MHz, CDCl3): 174.8, 138.0, 129.3, 128.7, 126.8, 
56.5, 41.1, 25.8; IR 𝝊max (neat)/cm-1: 3367.7, 3354.7, 3084.6, 3060.2, 
3030.7, 2959.6, 2943.0, 2919.4, 2866.7, 1673.1, 1603.6, 1581.5;  Rf = 0.07 
(75:25 EtOAc–Hexanes); HRMS (ESI):  C10H14N2O requires [M+H]+ 
179.1179, found 179.1176. 
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(2S,5S)-5-Benzyl-2-tert-butyl-3-methylimidazolidin-4-one (10) 
 
 
A solution of 2-amino-N-methyl-3-phenylpropanamide (500 mg, 2.80 
mmol), pivaldehyde (0.610 mL, 5.60 mmol) and ytterbium (III) triflate (18 mg, 
0.028 mmol, 1 mol%) in chloroform (30 mL) was refluxed for 16 hours to 
form a pale yellow solution. The reaction mixture was concentrated under 
reduced pressure, and the crude material purified by flash column 
chromatography, eluting with a gradient from 50:50 to 75:25 EtOAc–Petrol, 
to obtain the title compound93 as a pale yellow flakey solid (245 mg, 0.99 
mmol, 35%). H (500MHz, CDCl3): 7.31 – 7.07 (5H, m. Ar-H), 4.01 (1H, d, J 
1.5, 2-H), 3.66 (1H, ddd, J 7.6, 4.0, 1.4, 5-H), 3.10 (1H, dd, J 13.8, 4.0, 
Benzyl CHa/b), 2.90 (1H, dd, J 13.8, 7.5, Benzyl CHa/b), 2.87 (3H, s, NCH3), 
2.12 (1H, br s, NH ), 0.78 (9H, s, CCH3); C (125MHz, CDCl3): 175.4, 137.6, 
129.6, 128.7, 126.8, 83.6, 59.7, 38.7, 37.9, 31.4, 25.7; IR 𝝊max (neat)/cm-1: 
3367.7, 3354.7, 3084.6, 3060.2, 3030.7, 2959.6, 2943.0, 2919.4, 2866.7, 
1673.1; Rf = 0.36 (75:25 EtOAc–Petrol);  HRMS (ESI): C15H22N2O requires 
[M+H]+ 247.1810, found 247.1812. 
 
(2R)-2-Amino-N-methyl-3-phenylpropanamide (ent-9) 
 
 
 
Thionyl chloride (3.86 mL, 52.9 mmol) was added dropwise to a flask 
charged with D-phenylalanine (2.50 g, 15.1 mmol) in methanol (40.0 mL). 
After refluxing for 2 hours, the mixture was cooled to room temperature, and 
the reaction mixture concentrated under reduced pressure. Methylamine (8M 
in ethanol, 4.00 mL, 32.0 mmol) was added and the mixture allowed to stir 
for 48 hours at room temperature. The reaction was then diluted with 
dichloromethane (25 mL) and water (12.5 mL), and the pH adjusted to 12 
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with saturated K2CO3 solution. The layers were separated and the aqueous 
phase extracted with chloroform (2 x 5 mL). The separated organic layers 
were combined, dried over Na2SO4, and concentrated under reduced 
pressure to obtain the title compound93 as a colourless amorphous solid 
(2.40 g, 9.7 mmol, 61%). H (500MHz, CDCl3): 7.38 – 7.32 (2H, m, Ar 6’-H 
and 2’-H), 7.34 – 7.20 (3H, m, 3’-H, 4’-H and 5’-H), 3.64 (1H, dd, J 9.5, 3.9, 
2-H), 3.32 (1H, dd, J 13.8, 3.9, 3-Ha/b), 2.85 (3H, dd, J 5.0, 1.3, NCH3), 2.71 
(1H, dd, J 13.7, 9.4, 3-Ha/b); C (125MHz, CDCl3): 174.9, 138.1, 129.4, 
128.8, 126.9, 56.6, 41.2, 25.9; IR 𝝊max (neat)/cm-1: 3371.3, 3344.6, 3291.4, 
3085.6, 3061.8, 3031.3, 2939.2, 2914.5, 2875.7, 1644.2, 1523.0; Rf = 0.09 
(75:25 EtOAc–Hexanes); HRMS (ESI): C10H14N2O requires [M+H]+ 
179.1179, found 179.1175.  
 
(2R,5R)-5-Benzyl-2-tert-butyl-3-methylimidazolidin-4-one (ent-10) 
 
 
 
A solution of 2-amino-N-methyl-3-phenylpropanamide (2.00 g, 11.2 
mmol), pivaldehyde (2.44 mL, 22.4 mmol) and ytterbium (III) triflate (69 mg, 
0.11 mmol, 1 mol%) in chloroform (30 mL) was refluxed for 8 hours to form a 
pale yellow solution. The solvent was concentrated under reduced pressure, 
and the crude material purified by flash column chromatography, gradient 
eluting from 50:50 to 75:25 EtOAc–Petrol, to obtain the title compound93 as 
a white amorphous solid (832 mg, 3.38 mmol, 30%). H (500MHz, CDCl3): 
7.26 – 7.03 (5H, m, Ar-H), 3.99 (1H, d, J 1.6, 2-H), 3.64 (1H, ddd, J 7.7, 4.0, 
1.4, 5-H), 3.08 (1H, dd, J 13.7, 4.0, Benzyl CHa/b), 2.88 (1H, dd, J 13.7, 7.6, 
Benzyl CHa/b), 2.84 (3H, s, NCH3), 0.77 (9H, s, CCH3); C (125MHz, CDCl3): 
175.4, 138.0, 129.7, 128.7, 126.8, 82.6, 59.5, 38.4, 35.1, 30.8, 25.5; IR 𝝊max 
(neat)/cm-1: 3367.7, 3354.7, 3084.7, 3060.0, 3030.6, 2960.0, 2960.0, 
2919.4, 2867.0, 1672.8; Rf = 0.35 (75:25 EtOAc–Petrol); HRMS (ESI): 
C15H22N2O requires [M+Na]+ 269.1624, found 269.1622. 
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6.2.2 Synthesis of Exemplar Reactions from Literature 
 
1,3-Diethyl 2-(2-oxo-2,3-dihydro-1H-indol-3-ylidene)propanedioate (13)  
 
 
 
Diethyl malonate (325 mg, 2.03 mmol) and piperidine (0.22 mL, 2.24 
mmol) were added to a solution of isatin (300 mg, 2.03 mmol) in EtOH (10 
mL), and the mixture allowed to reflux for 24 hours. Following confirmation of 
conversion via TLC analysis, the resulting deep red mixture was evaporated 
to dryness under reduced pressure to obtain the title compound as a deep 
red powder (90 mg, 0.3 mmol, 15%). H (500MHz, CDCl3): 8.36 (1H, d, J 
7.8, 4-H), 8.04 (1H, br s, 1-H), 7.32 (1H, td, J 7.8 and 1.3, 6-H), 7.02 (1H, td, 
J 7.7 and 1.3, 5-H), 6.81 (1H, d, J 7.8, 7-H), 4.43 (2H, q, J 7.2, CH2CH3), 
4.38 (2H, q, J 7.2, CH2CH3), 1.38 (3H, t, J 7.2, CH2CH3), 1.37 (3H, t, J 7.2, 
CH2CH3); C (125MHz, CDCl3): 167.7 (C-2), 165.3 (COOEt), 162.9 (COOEt), 
143.5 (C-3), 134.6 (C-7a), 133.1 (C-3a), 129.6 (C-6), 129.0 (C-5), 122.8 (C-
4), 119.8 (C-3a), 110.2 (C-7), 62.3 (CH2CH3), 62.2 (CH2CH3), 14.0 
(CH2CH3), 13.9 (CH2CH3); Rf = 0.28 (75:25 Hexane–EtOAc); HRMS (ESI): 
C15H15NO5 requires [M+H]+ 290.1028, found 290.1023. 
 
2,2-Diethyl-(1R*,3S*,6S*)-3-formyl-6-hydroxy-2'-oxo-1',2'-dihydrospiro 
[cyclohexane-1,3'-indole]-2,2-dicarboxylate (14) 
 
 
 
1
2
3
4
N
H
5
6
7
O
EtO2C
CO2Et
5’
6’
7’
N 1’
2’
H
O
2
3 4
5
6
OH
EtO2C
OHC
EtO2C
120 
Gluteraldehyde solution (50% in H2O, 0.064 mL, 0.34 mmol) was 
added to a solution of diethyl 2-(2-oxoindolin-3-ylidene)malonate 13 (41 mg, 
0.14 mmol) and  2-{diphenyl[(triethylsilyl)oxy]methyl}pyrrolidine 6 (0.25 mL, 
5.0 mg, 0.014 mmol) in DCM (1 mL) at room temperature. The resulting 
mixture was stirred for 14 hours, and purified via flash column 
chromatography, eluting with 80:20-65:35 Petrol–EtOAc, to obtain the title 
compound94 as an amorphous colourless solid (12 mg, 0.0308 mmol, 22%). 
H (500MHz, CDCl3): 9.81 (1H, d, J 1.5, CHO), 8.05 (1H, br s, 1-H), 7.31 
(1H, d, J 7.7, 7’-H), 7.24 (1H, td, J 7.7 and 1.2, 6’-H), 7.02 (1H, td, J 7.7 and 
1.2, 5’-H), 6.84 (1H, d, J 7.7, 4’-H), 4.78 (1H, dd, J 11.7 and 4.8, 6-H), 4.23 
(2H, qd, J 7.2 and 1.6, ethyl CH2), 4.18 (1H, ddd, J 12.8, 3.8 and 1.5, 3-H), 
3.94 (2H, qd, J 7.1 and 1.5, ethyl CH2), 2.30 (1H, qd, J 13.2 and 4.6, 4-Ha/b), 
2.11 (1H, dd, J 13.4 and 2.7, 4-Ha/b), 2.01-1.90 (2H, m, 5-H), 1.23 (3H, t, J 
7.2, ethyl CH3), 0.90 (3H, t, J 7.2, ethyl CH3); C (125MHz, CDCl3): 200.7 (C-
CHO), 177.3 (C-2’), 168.5 (ester C=O), 168.2 (ester C=O), 142.5 (C-7’a), 
130.2 (C-3’a), 128.8 (C-6’), 124.4 (C-4’), 122.8 (C-5’), 109.5 (C-7’), 72.4 (C-
6), 62.2 (ethyl CH2), 62.1 (ethyl CH2) 61.6 (C-1), 57.3 (C-2), 49.1 (C-3), 26.6 
(C-5), 21.0 (C-4), 13.9 (ethyl CH3), 13.4 (ethyl CH3); Rf = 0.32 (50:50 Petrol–
EtOAc); HRMS (ESI): C20H23NO7 requires [M+H]+ 390.1553, found 
390.1551. 
 
(5R*,6S*,10R*)-2,4-Dioxo-6,10-diphenyl-1-thia-3-azaspiro[4.5]dec-7-ene-
7-carbaldehyde (16) 
 
 
 
Cinnamaldehyde (0.12 mL, 0.90 mmol) was added to a solution of 2-
{diphenyl[(triethylsilyl)oxy]methyl}pyrrolidine 6 (22 mg, 0.06 mmol) and 
thiazolidinedione 15 (35 mg, 0.3 mmol) in dichloromethane (1 mL) and 
stirred at room temperature for 36 hours. Following evaporation of the 
solvent under reduced pressure, the crude product was purified by flash 
column chromatography, eluting with 90:10 Hexane–EtOAc, to afford a 
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mixture of white solid and deep orange oil, which was further purified by 
mass directed prep-HPLC to obtain the title compound95 as a colourless 
amorphous solid (16 mg, 0.044 mmol, 15%). H (500MHz, CDCl3): 9.47 (1H, 
s, CHO), 7.22-7.37 (9H, m, 8-H; 2’-H, 3’-H, 4’-H, 6’-H), 7.14 (2H, dt, 4’-H), 
4.43 (1H, s, 6-H), 3.52 (1H, dd, J 11.2 and 5.9, 10-H), 3.39 (1H, dd, J 20.5 
and 11.2, 9-Ha/b), 3.03 (1H, dt, J 20.5 and 5.3, 9-Ha/b); C (125MHz, CDCl3): 
191.47 (CHO), 174.94 (C-2), 168.15 (C-4), 149.48 (C-8), 139.89 (Ph), 
137.83 (Ph), 137.23 (Ph), 130.52 (Ph), 129.35 (Ph), 128.61 (Ph), 128.52 
(Ph), 128.41 (Ph), 128.35 (Ph), 67.63 (C-5), 46.62 (C-6), 44.39 (C-10), 32.19 
(C-9); Rf = 0.07 (50:50 Hexane–Ethyl Acetate); HRMS (ESI): C21H17NO3S 
requires [M-H]- 362.0856, found 362.0875. 
 
(2'R*,3R*,6'S*)-2-Oxo-2',6'-diphenyl-2H-spiro[1-benzofuran-3,1'-
cyclohexan]-3'-ene-3'-carbaldehyde  (18) 
 
 
 
Cinnamaldehyde (0.17 mL, 1.35 mmol) was added to a solution of the 
catalyst 2-{diphenyl[(triethylsilyl)oxy]methyl}pyrrolidine 6 (9 mg, 0.0225 
mmol) and coumaran-2-one 17 (60 mg, 0.45 mmol) stirring in toluene (1 mL) 
at room temperature. Benzoic acid (0.002 mL, 0.0225 mmol) was added, 
and the mixture allowed to stir for 24 hours at room temperature. The 
mixture was flushed through a plug of silica, and the solvent evaporated 
under reduced pressure, before purification by flash column 
chromatography, eluting with 84:16 Hexane–Diethyl Ether, to obtain the title 
compound96 as a colourless amorphous solid (26 mg, 0.068 mmol, 15%). H 
(500MHz, CDCl3): 9.55 (1H, s, 3’-CHO), 7.46-7.19 (5H, m, Ar-H), 7.09-6.90 
(6H, m, Ar-H), 6.79-6.70 (2H, m, Ar-H), 6.62 (1H, td, J 8.0 and 0.8, Ar-H), 
5.47 (1H, dd, J 7.7 and 0.8, 4’-H) 4.12 (1H, s, 2’-H), 3.67 (1H, dd, J 11.3 and 
5.8, 6’-H), 3.47 (1H, m, 5’-Ha/b), 3.05 (1H, dt, J 20.7 and 5.1, 5’-Ha/b); C 
(125MHz, CDCl3): 192.2 (CHO), 177.1 (C-2), 152.5 (C-7a), 150.6 (C-3’), 
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139.3 (Ar), 138.8 (Ar), 137.7 (C-4’), 128.7 (Ar), 128.5 (Ar), 128.2 (Ar), 128.1 
(Ar), 127.5 (Ar), 127.3 (Ar), 126.8 (Ar), 122.6 (Ar), 110.0 (Ar), 53.5 (C-3), 
46.0 (C-2’), 42.5 (C-6’), 31.3 (C-5’); Rf = 0.17 (50:50 Hexane–Diethyl Ether);  
HRMS (ESI): C26H20O3 requires [M+H]+ 381.1491, found 381.1488. 
 
2-(4-Bromophenyl)-1-(1H-pyrazol-1-yl)ethan-1-one (19) 
 
 
 
Thionyl chloride (0.28 mL, 3.80 mmol) was added dropwise to a 
solution of pyrazole (200 mg, 2.90 mmol), 4-bromophenylacetic acid (821 
mg, 3.8 mmol) and triethylamine (1.64 mL, 11.8 mmol) in toluene (10 mL) at 
0 oC. The reaction was stirred at room temperature for 24 hours before 
quenching with water (10 mL). The organic layer was washed sequentially 
with HCl (1M, 10 mL), NaOH (2M, 10 mL) and brine (10 mL), before drying 
over MgSO4 and evaporating under reduced pressure to obtain the title 
compound122 as a pale pink amorphous solid (605 mg, 2.30 mmol, 79%). H 
(500MHz, CDCl3): 8.26 (1H, d, J 2.8, Pyrazole 3-H), 7.76 (1H, d, J 1.4, 
Pyrazole 5-H), 7.52 – 7.47 (m, 2H, Ar-H), 7.28 – 7.25 (m, 2H, Ar-H), 6.48 
(1H, dd, J 2.9 and 1.5, Pyrazole 4-H), 4.43 (2H, s, 2-H); C (125MHz, 
CDCl3): 169.5 (C-1), 144.4 (Pyrazole C-3), 132.4 (Ar), 131.9 (Ar), 131.6 (Ar), 
128.7 (Pyrazole C-5), 121.6 (Ar), 110.3 (Pyrazole C-4), 40.0 (C-2); IR 
𝝊max/cm-1 (film) 3146, 2979, 1977, 1765, 1736, 1587, 1526, 1487; HRMS 
(ESI): C11H9N2OBr requires [M+Na]+ 286.9790, found 286.9785. 
 
(3R*,4R*,6R*)-3-(4-Bromophenyl)-4-phenyl-6-(1H-pyrazol-1-yl)oxan-2-
one (20) 
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Cinnamaldehyde (0.07 mL, 0.56 mmol) was added to a flask 
containing 2-(4-bromophenyl)-1-(1H-pyrazol-1-yl)ethanone 19 (100 mg, 0.37 
mmol), 2-{diphenyl[(triethylsilyl)oxy]methyl}pyrrolidine 6 (14 mg, 0.037 mmol) 
and toluene (1 mL). The mixture was stirred for 24 hours at room 
temperature. Dichloromethane (10 mL) was added and the organic layer  
washed with saturated NaHCO3 (2 x 10 mL) before drying over Na2SO4 and 
evaporating under reduced pressure to give the crude product as a brown 
oil. The product was purified by flash column chromatography, eluting with 
80:20 Hexane–EtOAc, to give the title compound97 as an amorphous 
colourless solid (43 mg, 0.10 mmol, 29%). H (500MHz, CDCl3): 7.46 (2H, m, 
Ar-H), 7.14 – 7.11 (m, 2H, Ar-H), 7.06 – 6.97 (m, 3H, Ar-H), 6.86 – 6.83 (m, 
2H, Ar-H), 6.68 - 6.65 (2H, m, Ar-H), 6.29 (1H, dd, J 10.7 and 3.9, 6’-H), 6.17 
(1H, t, J  2.1, 4’-H), 3.74 (1H, d, J 12.0, 1H, 3-H), 3.19 (1H, td, J 12.0 and 
3.1, 4-H), 3.01 (1H, m, 5-Ha/b), 2.43 (1H, dt, J  14.1 and 3.5, 5-Ha/b); C 
(125MHz, CDCl3): 170.0 (C-2), 141.4 (C-3’), 139.8 (Ar), 136.2 (Ar), 131.9 
(Ar), 130.7 (Ar), 129.8 (Ar), 129.1 (Ar), 127.8 (Ar), 127.3 (Ar), 121.7 (Ar), 
107.4 (C-4’), 87.4 (C-6), 55.0 (C-3), 45.0 (C-4), 35.3 (C-5); Rf =  0.47 (40:60 
EtOAc–Hexane); HRMS (ESI): C20H17BrN2O2 requires [M+H]+ 397.0552, 
found 397.0548. 
 
(1R*, 2R*, 3R*)-2-(4-Methoxybenzoyl)-3-phenylcyclopropane-1-
carbaldehyde (22) 
 
 
4-Methoxyphenacylchloride 21 (110 mg, 0.60 mmol), cinnamaldehyde 
(25 L, 0.20 mmol), 2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine 6 (12 
mg, 0.04 mmol, 20 mol%) were dissolved in a flask of CH2Cl2 (2 mL), 
followed by addition of triethylamine (30 L, 0.20 mmol). The reaction 
mixture was stirred at room temperature for 24 hours, then the solvent 
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removed under reduced pressure. Hydrochloric acid (5 mL, 1M) was added 
to the residue, and the reaction mixture extracted with CH2Cl2 (5 mL x 3). 
The combined organic phases were dried over anhydrous sodium sulphate, 
filtered and evaporated under reduced pressure. The residue was purified by 
flash column chromatography, eluting with 95:5 Hexane–EtOAc, to yield the 
title compound98 as a yellow oil (42 mg, 0.14 mmol, 75%). H (400MHz, 
CDCl3): 9.87 (1H, d, J 2.8, CHO), 7.96-7.91 (2H, m, Ar-H), 7.23-7.12 (5H, m, 
Ar-H), 6.94-6.88 (2H, m, Ar-H), 3.85 (3H, s, H3CO), 3.63 (1H, dd, J 10.1 and 
4.9, 3-H), 3.57-3.51 (1H, td, J 5.5, 4.9 and 2.8, 1-H), 3.38 (1H, dd, J 10.1 
and 6.0, 2-H); C (101MHz, CDCl3): 199.1 (CHO), 191.0 (R2CO), 163.9 (Ar), 
133.7 (Ar), 130.7 (Ar), 129.1 (Ar), 128.8 (Ar), 128.4 (Ar), 127.5 (Ar), 114.0 
(Ar), 55.6 (H3CO), 36.3 (C-2), 35.6 (C-3), 33.9 (C-1); IR 𝝊max/cm-1 (film) 
3063.1, 3027.4, 3016.6, 2935.4, 2840.8, 2250.3, 1708.6, 1661.3, 1596.2, 
1573.7, 1510.2; Rf = 0.62 (50:50 Hexane–EtOAc); HRMS (ESI): C18H16O3 
requires [M+H]+ 281.1172, found 281.1169. 
 
3-(1-Methyl-1H-indol-3-yl)butanal (23) 
 
 
To a flask equipped with a magnetic stir bar containing rac-Macmillan 
catalyst (10 and ent-10, 24 mg, 0.1 mmol) was added chloroform (1 mL) and 
TFA (8 L, 0.1 mmol). After stirring for 5 minutes, crotonaldehyde (124 L, 
1.5 mmol) was added, before addition of methyl indole (63 L, 0.5 mmol) 
after another 10 minutes. The resulting suspension was stirred at ambient 
temperature for 24 hours. The reaction mixture was then passed through a 
silica gel plug with diethyl ether, before evaporation under reduced pressure. 
The resulting residue was purified by flash column chromatography (toluene) 
to afford the title compound84 as a brown amorphous solid (38 mg, 0.19 
mmol, 40%). H (500MHz, CDCl3): 9.76 (1H, td, J 2.3 and 0.5, 1-H), 7.65 
(1H, dq, J 7.9 and 0.9, Ar-H), 7.32 (1H, dq, J 8.2 and 0.9, Ar-H), 7.29-7.23 
(1H, m, Ar-H), 7.14 (1H, ddt, J 7.9, 6.9 and 0.9, Ar-H), 6.85 (1H, s, 2’-H), 
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3.76 (3H, s, NCH3), 3.73 – 3.66 (1H, m, 3-H), 2.89 (1H, dddd, J 16.3, 6.9, 
2.4 and 0.6, 2-Ha), 2.72 (1H, dddd, J 16.3, 7.0, 2.3 and 0.6, 2-Hb), 1.45 (3H, 
dd, J 7.0 and 0.7, 4-H); C (125MHz, CDCl3): 203.0 (C-1), 137.4 (Ar), 126.7 
(Ar), 125.3 (C-2’), 121.9 (Ar), 119.2 (Ar), 119.0 (Ar), 118.9 (Ar), 109.5 (Ar), 
51.1 (C-2), 32.8 (NCH3), 26.0 (C-3), 21.8 (C-4); IR 𝝊max/cm-1 (film): 3051.9, 
2958.7, 2926.0, 2877.1, 2823.5, 2722.4, 1718.1, 1612.1, 1549.1; Rf = 0.35 
(Toluene); HRMS (ESI): C13H15NO requires [M+Na]+ 224.1046, found 
224.1041. 
 
(4R*, 5R*)-4-(4-methoxyphenyl)-1-oxaspiro[4.5]decane-2,6-dione (24) 
 
 
 
1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride 11 (27 mg, 0.08 
mmol, 6 mol%) in THF (1 mL) was added to a flask, followed by DBU (0.024 
mL, 0.16 mmol). 4-methoxycinnamaldehyde (325 mg, 2.0 mmol) in THF (1 
mL) added followed by 1,2-cyclohexanediol (150 mg, 1.3 mmol) in THF (3 
mL). The reaction mixture was left at room temperature for 24 hours. 
Following TLC and LC-MS analysis, the reaction was filtered through celite 
and purified by column chromatography, eluting with 80:20 Hexane–EtOAc, 
to give the title compound100 as an off-white amorphous solid (87 mg, 0.32 
mmol, 25%). H (400MHz, CDCl3): 7.11 (2H, d, J 8.7, Ar), 6.85 (2H, d, J 8.7, 
Ar), 3.79 (3H, s, H3CO), 3.67 (1H, t, J 9.0, 4-H), 2.92 (2H, qd, J 17.8 and 9.0, 
3-H), 2.42-2.23 (2H, m, 10-Ha, 7-Ha), 2.17 (1H, td, J 12.8 and 4.3, 10-Hb), 
1.87-1.49 (5H, m, 7-Hb, 8-H, 9-H); C (100MHz, CDCl3): 206.3 (C-6), 174.8 
(C-2), 159.7 (p-Ar), 129.5 (Ar-H), 128.2 (i-Ar), 114.6 (Ar-H), 91.4 (C-5), 55.4 
(CH3), 50.7 (C-4), 41.4 (C-7), 39.0 (C-10), 36.2 (C-3), 25.4 (C-8), 22.2 (C-9); 
Rf = 0.46 (50:50 Hexane–EtOAc); HRMS (ESI): C16H18O4 requires [M+H]+ 
275.1278, found 275.1275. 
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1-Methyl-3'-phenyl-1,2-dihydrospiro[indole-3,2'-oxolane]-2,5'-dione 
 
DBU (9.0 L, 0.060 mmol) was added to a suspension of the iMes 
catalyst 11 (10 mg, 0.030 mmol) and methyl isatin (161 mg, 1.0 mmol) in 
THF. Cinnamaldehyde (66 mg, 0.50 mmol) was then added, and the 
reaction stirred at ambient temperature for 24 hours. The crude reaction 
mixture (d.r. 50:50 via NMR) was then passed through a short pad of Celite. 
After removal of the solvent, the residue was subjected to flash column 
chromatography (5:1, Hexane–EtOAc), resulting in the isolation of two 
separate diastereomers of the product.100 
 
 
 
(3R*,3'S*)-1-Methyl-3'-phenyl-1,2-dihydrospiro[indole-3,2'-oxolane]-2,5'-
dione (25a) (33 mg, 0.11 mmol, 22%) - H (500MHz, CDCl3): 7.54 (1H, ddd, 
J 7.4, 1.3 and 0.6, Ar-H), 7.38 (1H, td, J 7.8 and 1.3, Ar-H), 7.22 – 7.13 (4H, 
m, Ar-H), 6.94 – 6.90 (2H, m, Ar-H), 6.66 (1H, dt, J 7.9 and 0.7, Ar-H), 4.07 
(1H, dd, J 13.7 and 8.0, 3’-H), 3.81 (1H, dd, J 16.8 and 13.7, 4’-Ha), 2.91 
(1H, dd, J 16.8 and 8.0, 4’-Hb), 2.81 (3H, s, NCH3); C (125MHz, CDCl3): 
175.0 (C-5’), 172.7 (C-2), 144.4 (Ar), 132.2 (Ar), 131.4 (Ar), 128.6 (Ar), 128.5 
(Ar), 128.4 (Ar), 127.6 (Ar), 127.5 (Ar), 124.8 (Ar), 124.3 (Ar), 123.6 (Ar), 
108.7 (Ar), 86.6 (C-3), 51.1 (C-3’), 32.3 (C-4’), 25.9 (NCH3); IR 𝝊max/cm-1 
(film): 3067.2, 2982.3, 2918.7, 2888.3, 2849.8, 1784.3, 1744.5, 1694.6, 
1611.7, 1599.9;  Rf = 0.39 (65:35 Hexane–EtOAc); HRMS (ESI): C18H15NO3 
requires [M+H]+ 294.1125, found 294.1124. 
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(3R*,3'R*)-1-Methyl-3'-phenyl-1,2-dihydrospiro[indole-3,2'-oxolane]-2,5'-
dione (25b) (37 mg, 0.13 mmol, 26%) - H (500MHz, CDCl3): 7.27 – 7.19 
(4H, m, Ar-H), 7.04 – 6.95 (2H, m, Ar-H), 6.78  – 6.67 (2H, m, Ar-H), 6.27 
(1H, ddd, J 7.6, 1.3 and 0.6, Ar-H), 3.97 (1H, dd, J 8.7 and 4.5, 3’-H), 3.71 
(1H, ddd, J 17.6 and 8.7, 4’-Hb), 3.21 (3H, s, NCH3), 3.07 (1H, dd, J 17.6 
and 4.5, 4’-Ha); C (125MHz, CDCl3): 176.16 (C-5’), 174.38 (C-2), 143.92 
(Ar), 137.14 (Ar), 130.93 (Ar), 128.81 (Ar), 128.33 (Ar), 128.04 (Ar), 126.20 
(Ar), 123.37 (Ar), 122.85 (Ar), 108.64 (Ar), 86.12 (C-3), 48.03 (C-3’), 34.33 
(C-4’), 26.60 (NCH3); IR 𝝊max/cm-1 (film): 2982.4, 2918.2, 2888.4, 1784.7, 
1744.7, 1694.5, 1612.6, 1599.9;   Rf = 0.29 (65:35 Hexane–EtOAc);  HRMS 
(ESI): C18H15NO3 requires [M+H]+ 294.1125, found 294.1120. 
 
cis-5-(4-Bromophenyl)-4-(4-methoxyphenyl)oxolan-2-one (26) 
 
 
 
4-Bromobenzaldehyde (229 mg, 1.24 mmol), 4-
methoxycinnamaldehyde (100 mg, 0.62 mmol) and 1,3-bis(2,4,6-
trimethylphenyl)imidazolium chloride 11 (17.0 mg, 0.05 mmol, 8 mol%) 
added to flask, and THF (2 mL) added. DBU (10.0 L, 0.05 mmol, 7 mol%) 
added and solution left to stir for 24 hours at room temperature. The reaction 
mixture was concentrated under reduced pressure to give a crude oil (89:11 
dr in favour of the syn product). The crude material was purified by flash 
column chromatography, eluting with 92:8 Hexane–EtOAc, to afford the title 
compound101 (85 mg, 0.246 mmol). H (400MHz, CDCl3): 7.27 (2H, d, J 8.5, 
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5-Ph 3-H and 5-H), 6.77 (2H, d, J 8.4, 5-Ph 2-H and 6-H), 6.72 (2H, d, J 8.7, 
4-Ph 2-H and 6-H), 6.66 (2H, d, J 8.8, 6.72 (2H, d, J 8.7, 4-Ph 3-H and 5-H), 
5.72 (1H, d, J 6.7, 5-H), 3.98 (1H, q, J 6.2, 4-H), 3.72 (3H, s, OCH3), 3.02 
(1H, dd, J 17.4 and 8.2, 3-Ha), 2.85 (1H, dd, J 17.5 and 6.0, 3-Hb); C 
(125MHz, CDCl3): 176.6 (C-2), 159.0 (Ar), 134.9 (Ar), 131.2 (Ar-H), 129.0 
(Ar-H), 128.4 (Ar), 127.5 (Ar-H), 122.0 (Ar), 114.0 (Ar-H), 84.2 (C-5), 55.3 
(H3CO), 46.1 (C-4), 35.3 (C-3); Rf = 0.11 (80:20 Hexane–EtOAc); HRMS 
(ESI): C17H15BrO3 requires [M+H]+ 347.0277, found 347.0275. 
 
1-[(1R*, 5R*)-3,5-Diphenylcyclopent-2-en-1-yl]-4-methoxybenzene (27) 
 
 
 
DBU (8.0 L, 0.04 mmol, 12 mol%) was added to a suspension of 
1,3-bis(2,4,6-trimethylphenyl) imidazolium chloride 11 (11 mg, 0.02 mmol, 6 
mol%) in THF (2 mL). This was followed by addition of 4-
methoxycinnamaldehyde (79 mg, 0.48 mmol) and chalcone (100 mg, 0.34 
mmol). The resulting solution was stirred for 8 hours at room temperature, 
with an initial green colour of the reaction changing to dark blue upon 
completion. The reaction mixture was passed through a short pad of Celite, 
the solvent removed, and the residue purified by column chromatography, 
eluting with 98:2 Hexane–EtOAc, to afford the title compound102 as a viscous 
yellow oil (86 mg, 0.26 mmol, 77 %). H (400MHz, CDCl3): 7.48 (2H, dd, J 
7.0 and 1.6, Ar-H), 7.31 (2H, td, J 7.6 and 1.7, Ar-H), 7.29-7.10 (6H, m, Ar-
H), 7.02 (2H, dd, J 8.6 and 1.9, Ar-H), 6.77 (2H, dd, J 8.7 and 2.1, Ar-H), 
6.19 (1H, t, J 2.0, 2-H), 4.03 (1H, m, 1-H) 3.71 (3H, s, H3CO), 3.41-3.22 (2H, 
m, 4-Ha/b and 5-H), 2.98-2.92 (1H, m, 4-Ha/b); C (100MHz, CDCl3): 158.4 
(Ar), 145.6 (Ar), 142.0 (Ar), 137.1 (Ar), 136.1 (Ar), 128.6 (Ar), 128.5 (Ar), 
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127.6 (Ar), 127.4 (C-2), 126.3 (Ar), 125.9 (Ar), 114.0 (Ar), 60.1 (C-1), 55.3 
(H3CO), 54.8 (C-5), 42.0 (C-4); Rf = 0.73 (50:50 Hexane–EtOAc); HRMS 
(ESI): C24H22O requires [M+H]+ 327.1743, found 327.1744. 
 
(2R*, 3S*)-2-benzoyl-3-(4-nitrophenyl)oxirane (29) 
 
 
 
-bromoacetophenone (100 mg, 0.50 mmol), 4-nitrobenzaldehyde 
(83 mg, 0.55 mmol) and thiamine hydrochloride 28 (17 mg, 0.05 mmol) 
placed in a flask and flushed with nitrogen. DMSO-d6 (2 mL) and DBU 
(0.015 mL, 0.10 mmol) added and left to stir at room temperature for 18 
hours. Reaction quenched with water (10 mL) at 0 oC, then extracted with 
EtOAc (3 x 20 mL). Organic extracts washed with brine (3 x 20 mL), dried 
over sodium sulphate and evaporated to dryness, before purification by flash 
column chromatography, eluting with 75:25 Petrol–EtOAc, to give the title 
compound103 as an amorphous off-white solid (36 mg, 0.11 mmol, 22%). H 
(500MHz, CDCl3): 8.27 (2H, d, J 8.8, Ar-H), 8.04 – 7.98 (2H, m, Ar-H), 7.67 
– 7.63 (1H, m, Ar-H), 7.58 – 7.54 (2H, m, Ar-H), 7.53 – 7.49 (2H, m, Ar-H), 
4.28 (1H, d, J 1.8, 2-H), 4.21 (1H, d, J 1.8, 3-H); C (125MHz, CDCl3): 192.1 
(C-1), 149.8 (Ar), 142.9 (Ar), 135.4 (Ar), 134.50 (Ar), 129.18 (Ar), 128.57 
(Ar), 126.8 (Ar), 124.2 (Ar), 61.0 (C-2), 58.2 (C-3); Rf = 0.79 (34:66 EtOAc–
Petrol); HRMS (ESI): C15H11NO4 requires [M+Na]+ 292.0580, found 
292.0583. 
 
 
 
 
 
1
O
2
3
O
O2N
130 
(2R*,3S*)-3-methyl-2-phenyl-7λ⁶-thia-6-azatricyclo [6.4.0.0²,⁶] dodeca-
1(12),8,10-triene-5,7,7-trione (31) 
 
 
 
To a flask with a magnetic stirrer bar was added 3-phenyl-1λ⁶,2-
benzothiazole-1,1-dione 30 (98 mg, 0.40 mmol). Crotonaldehyde (36 µL, 
0.44 mmol), DCM (1 mL) and a solution of the triazolium catalyst 12 (2.63 
mg, 0.01 mmol) in DCM (1 mL) were added. Finally, DBU (12 µL, 0.080 
mmol) was added, and the flask stirred at ambient temperature for 24 hours. 
The reaction mixture was then purified by flash column chromatography 
(25:50:1, Hexane–DCM–Acetone) to obtain the title compound104 as an off 
white amorphous solid (96 mg, 0.32 mmol, 80%). H (500MHz, CDCl3): 7.87 
(1H, dd, J 8.3 and 1.0, Ar-H), 7.78 – 7.74 (2H, m, Ar-H), 7.60 (1H, td, J 7.6 
and 1.0, Ar-H), 7.51 – 7.47 (2H, m, Ar-H), 7.43 – 7.38 (2H, m, Ar-H), 7.37 – 
7.32 (1H, m, Ar-H), 2.99 (1H, ddd, J 12.9, 7.5 and 6.7, 3-H), 2.69 (1H, dd, J 
17.0 and 7.5, 4-Ha), 2.50 (1H, dd, J 17.0 and 12.9, 4-Hb), 1.11 (3H, d, J 6.7, 
CH3); C (125MHz, CDCl3): 170.4 (C-5), 141.9 (Ar), 136.4 (Ar), 135.3 (Ar), 
133.8 (Ar), 130.1 (Ar), 129.0 (2 x Ar), 128.7 (Ar), 126.6 (2 x Ar), 123.9 (Ar), 
122.4 (Ar), 75.1 (C-2), 42.3 (C-3), 40.4 (C-4), 16.5 (CH3); IR 𝝊max/cm-1 
(film): 3066.7, 2981.8, 2922.2, 2887.7, 1744.3, 1694.0, 1598.8; Rf = 0.41 
(25:50:1 Hexane–DCM–Acetone); HRMS (ESI): C17H15NO3S requires 
[M+H]+ 314.0845, found 314.0847. 
 
6.2.3 Synthesis of Round 1 Substrates 
 
4-Formyl-2-(trifluoromethyl)benzonitrile (A3) 
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To a solution of 4-iodo-2-(trifluoromethyl)benzonitrile (2.35 g, 5.05 
mmol) in THF (31.6 mL) at 0 oC, isopropylmagnesium chloride lithium 
chloride (1.3 M solution in THF, 7.30 mL, 9.48 mmol) was added dropwise 
and the mixture stirred for 45 minutes. Piperidine-1-carbaldehyde (1.05 mL, 
9.48 mmol) was added and stirring continued at 0 oC for 90 minutes. TLC 
analysis showed conversion to products. Saturated ammonium chloride 
solution (30 mL) was added to quench, and the mixture extracted with 
EtOAc (2 x 30 mL). The organic extracts were dried with magnesium 
sulphate, filtered and concentrated under reduced pressure, then purified by 
flash column chromatography (50:50, DCM-toluene) to give the title 
compound66 as a brown amorphous solid (790 mg, 3.97 mmol, 50%). H 
(500MHz, CDCl3): 10.15 (1H, s, CHO), 8.30 (1H, d, J 1.6, 3-H), 8.20 (1H, 
dd, J 7.9 and 1.6, 5-H), 8.06 (1H, d, J 7.9, 6-H); C (125MHz, CDCl3): 189.2 
(C=O), 138.8 (C-4), 135.8 (C-6), 134.1 (q, J 33.6, C-2), 132.9 (C-5), 127.2 
(q, J 4.6, C-3), 122.0 (q, J 274.3, CF3), 115.0 (q, J 2.1, C-1), 114.6 (CN); IR 
𝝊max (neat)/cm-1: 3084.7, 3050.3, 2920.5, 2869.2, 2235.1, 1703.5, 1614.1; 
Rf = 0.33 (50:50 DCM–toluene).  
 
4-Acetyl-2-(trifluoromethyl)benzonitrile (A4) 
 
 
 
4-Iodo-2-trifluoromethylbenzonitrile (1.29 g, 4.34 mmol), tri-n-butyl-(1-
ethoxyvinyl)tin (1.62 mL, 1.1 mmol), palladium(II) acetate (29 mg, 0.13 
mmol, 3 mol%), DABCO (29 mg, 0.26 mmol), potassium fluoride (755 mg, 
13.0 mmol) were stirred in 1,4-dioxane (16 mL) at 99 oC for 16 hours. The 
mixture was then cooled and filtered through celite, washing with ethyl 
acetate. The filtrate was then washed with water (25 mL) and brine (25 mL) 
before drying with magnesium sulphate, filtering and evaporating. 
Hydrochloric acid (2 M, 9 mL) and THF (25 mL) were added to the residue in 
the flask, and the solution stirred at room temperature overnight. Saturated 
6
5
4
3
2
1
CN
CF3
O
132 
sodium hydrogen carbonate solution (25 mL) was added slowly, and the 
mixture extracted with ethyl acetate (2 x 20 mL). The organic extracts were 
dried with magnesium sulphate, filtered and evaporated, and the crude 
product purified by flash column chromatography, eluting with 70:28:2 
Hexane–Ethyl Acetate–Triethylamine to obtain the title compound as pale 
orange amorphous solid (686 mg, 3.22 mmol, 74%). H (500MHz, CDCl3): 
8.34 (1H, d, J 1.6, 2-H), 8.22 (1H, dd, J 8.1 and 1.6, 5-H), 7.98 (1H, d, J 8.1, 
6-H), 2.69 (3H, s, CH3); C (125MHz, CDCl3): 195.1 (C=O), 140.1 (C-4), 
135.5 (C-6), 133.6 (q, J 33.4, C-2), 131.7 (C-5), 126.3 (q, J 4.7, C-3), 122.1 
(q, J 274.3, CF3), 114.8 (CN), 113.9 (m, C-1), 26.9 (CH3); IR 𝝊max (neat)/cm-
1: 3117.1, 3089.8, 3053.5, 2924.8, 2233.1, 1693.7,1611.4, 1572.5; Rf = 0.25 
(75:25 Hexanes–Ethyl Acetate); HRMS (ESI): C10H6F3NO requires [M+H]+ 
214.0474, found 214.0471. 
 
1-(Chloroacetyl)-2-(trifluoromethyl)benzonitrile (A5) 
 
 
 
4-Acetyl-2-(trifluoromethyl)benzonitrile (345 mg, 1.62 mmol) and 
benzyltrimethylammonium dichloroiodate (1.13 mg, 3.24 mmol) were 
dissolved in THF (8 mL) and stirred for 24 hours at room temperature. The 
reaction mixture was then evaporated, and ethyl acetate (20 mL) and 
sodium thiosuphate solution (5% w/v, 20 mL) were added to the residue. 
The layers were separated, and the organic layer dried over magnesium 
sulphate, filtered and concentrated under reduced pressure. The crude 
product was then purified by flash column chromatography, eluting with 
84:16 Hexane–Ethyl Acetate to give the title compound as a straw coloured 
amorphous solid (290 mg, 1.17 mmol, 72%). H (500MHz, CDCl3): 8.35 (1H, 
d, J 1.8, 3-H), 8.26 (1H, dd, J 8.1 and 1.8, 5-H), 8.02 (1H, d, J 8.1, 6-H), 4.68 
(2H, s, CH2); C (125MHz, CDCl3): 189.0 (C=O), 137.2 (C-4), 135.5 (C-6), 
133.9 (C-2), 132.0 (C-5), 126.6 (q, J 4.8, C-3), 121.8 (q, J 274.0, CF3), 114.7 
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(m, C-1), 114.4 (CN), 45.0 (CH2Cl); IR 𝝊max (neat)/cm-1: 3112.0, 3077.5, 
3048.4, 2939.2, 2233.8, 1715.9, 1611.8, 1569.4; Rf = 0.39 (75:25 Hexane–
Ethyl Acetate); HRMS (ESI): C10H5ClF3NO requires [M+H]+ 248.0085, found 
248.0081. 
 
4-[(1E)-3-Oxoprop-1-en-1-yl]-2-(trifluoromethyl)benzonitrile ( A1) 
 
 
 
4-Formyl-2-(trifluoromethyl)benzonitrile (290 mg, 1.46 mmol) and 
triphenylphosphoranylidene acetaldehyde (444 mg, 1.46 mmol) were 
dissolved in toluene (5 mL) and stirred at 70 oC for 20 hours. Conversion to 
products was confirmed by TLC and the mixture concentrated under 
reduced pressure, then purified by flash column chromatography (50:50, 
Toluene–DCM) to obtain the title compound as an amorphous pale orange 
solid (192 mg, 0.85 mmol, 58%). H (500MHz, CDCl3): 9.79 (1H, d, J 7.3, 3’-
H), 7.95 (1H, s, 3-H), 7.92 (1H, d, J 8.1, 5-H), 7.86 (1H, d, J 8.1, 6-H), 7.51 
(1H, d, J 16.1, 1’-H), 6.83 (1H, dd, J 16.1, 7.3, 2’-H); C (125MHz, CDCl3): 
192.4 (C-3’), 147.4 (C-1’), 138.8 (C-4), 135.6 (C-2’), 134.0 (q, J 33.0, C-2), 
132.6 (C-5), 131.3 (C-6), 126.3 (q, J 4.6, C-3), 122.1 (q, J 274.0, CF3), 115.0 
(CN), 111.7 (m, C-1); IR 𝝊max (neat)/cm-1: 3059.7, 2918.3, 2823.5, 2750.1, 
2232.2, 1673.0, 1627.1,1561.2, 1497.7;  Rf = 0.27 (50:50 Toluene–DCM); 
HRMS (ESI): C11H6F3NO requires [M+H]+ 226.0474, found 226.0471.  
 
(2E)-3-(3,4-Dichlorophenyl)prop-2-enal (A2) 
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3,4-Dichlorobenzaldehyde (1.00 g, 5.72 mmol) and 
triphenylphosphoranylidene acetaldehyde (1.74 g, 5.72 mmol) were 
dissolved in toluene (15 mL) and stirred at 70 oC for 24 hours. Conversion to 
products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (90:10 Hexanes–EtOAc) to 
obtain the title compound123 as an amorphous white solid (670 mg, 3.35 
mmol, 59%). H (500MHz, CDCl3): 9.70 (1H, d, J 7.5, 1’-H), 7.64 (1H, d, J 
2.1, 2-H), 7.50 (1H, d, J 8.3, 5-H), 7.40 (1H, dd, J 8.3 and 2.1, 6-H), 7.37 
(1H, d, J 16.0, 3’-H), 6.68 (1H, dd, J 16.0 and 7.5, 2’-H); C (125MHz, 
CDCl3): 193.1 (C-1), 149.5 (C-3), 135.3 (C-1’), 134.1 (C-4), 133.7 (C-3), 
131.2 (C-5), 130.1 (C-2), 130.0 (C-2’), 127.3 (C-6); IR 𝝊max (neat)/cm-1: 
3312.0, 3090.1, 3070.5, 2849.7, 2760.1, 1682.2, 1667.1, 1626.5, 1586.8, 
1554.0; Rf = 0.27 (90:10 Hexanes–EtOAc); HRMS (ESI): C9H6Cl2O requires 
[M+H]+ 200.9874, found 200.9868. 
 
6.2.4 Synthesis of Round 2 co-substrates 
 
(2E)-3-(Pyridin-2-yl)prop-2-enal (D1) 
 
 
Pyridine-2-carboxaldehyde (238 μL, 2.50 mmol) and 
triphenylphosphoranylidene acetaldehyde (761 mg, 2.50 mmol) were 
dissolved in THF (7.5 mL) and stirred at 70 oC for 24 hours. Conversion to 
products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (50:50 Pentane–Diethyl Ether) 
to obtain the title compound124 as an amorphous brown solid (75 mg, 0.56 
mmol, 22%). H (400MHz, CDCl3): 9.79 (1H, d, J 7.7, 1-H), 8.69 (1H, dd, J 
4.8 and 1.7, 6’-H), 7.76 (1H, td, J 7.8 and 1.7, 4’-H), 7.54 (1H, d, J 7.8, 3’-H), 
7.52 (1H, d, J 15.8, 3-H),  7.31 (1H, dd, J 7.8 and 4.8, 5’-H), 7.08 (1H, dd, J 
15.8 and 7.8, 2-H); C (100MHz, CDCl3): 193.7 (C-1), 152.9 (C-2’), 151.3 (C-
135 
3), 150.5 (C-6’), 137.0 (C-4’), 131.8 (C-2), 124.9 (C-5’), 124.3 (C-3’); IR 𝝊max 
(neat)/cm-1: 3045.8, 3006.3, 2920.1, 2846.0, 2756.6, 1668.9, 1629.3, 
1579.5, 1565.4; Rf = 0.22 (50:50 Hexanes–Diethyl Ether); HRMS (ESI): 
C8H7NO requires [2M+H]+ 267.1128, found 267.1126. 
 
(2E)-3-(4,5-Dimethylfuran-2-yl)prop-2-enal (D2) 
 
 
 
4,5-Dimethylfuran-2-carbaldehyde (305 μL, 2.5 mmol) and 
triphenylphosphoranylidene acetaldehyde (761 mg, 2.5 mmol) were 
dissolved in THF (7.5 mL) and stirred at 70 oC for 24 hours. Conversion to 
products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (80:20 Hexane–Diethyl Ether) 
to obtain the title compound as a deep red oil (148 mg, 0.99 mmol, 40%). H 
(400MHz, CDCl3): 9.55 (1H, d, J 7.9, 1-H), 7.08 (1H, d, J 15.5, 3-H), 6.57 
(1H, s, 3’-H), 6.47 (1H, dd, J 15.5 and 7.9, 2-H), 2.28 (3H, s, 4’-CH3), 1.97 
(3H, s, 5’-CH3); C (100MHz, CDCl3): 193.0 (C-1), 153.1 (C-2’), 148.12 (C-
5’), 138.1 (C-3), 124.2 (C-2), 121.0 (3’-H), 118.5 (C-4’), 12.0 (C-5 Methyl), 
9.8 (C-4 Methyl); IR 𝝊max (neat)/cm-1: 3087.6, 2953.5, 2922.7, 2848.2, 
1652.9, 1630.8, 1591.9, 1514.6; Rf = 0.62 (50:50 Hexanes–Diethyl Ether); 
HRMS (ESI): C9H10O2 requires [M+H]+ 151.0754, found 151.0749. 
 
(2E)-3-(Furan-3-yl)prop-2-enal (D3) 
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Furan-3-carbaldehyde (216 μL, 2.5 mmol) and 
triphenylphosphoranylidene acetaldehyde (761 mg, 2.5 mmol) were 
dissolved in THF (7.5 mL) and stirred at 70 oC for 24 hours. Conversion to 
products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (80:20 Hexane–Diethyl Ether) 
to obtain the title compound125 as a brown oil (72 mg, 0.59 mmol, 24%). H 
(400MHz, CDCl3): 9.61 (1H, d, J 7.8, 1-H), 7.75 (1H, s, 2’-H), 7.47 (1H, d, J 
1.9, 5’-H), 7.39 (1H, d, J 15.7, 3-H), 6.61 (1H, d, J 1.9, 4’-H), 6.43 (1H, dd, J 
15.7 and 7.8, 2-H); C (100MHz, CDCl3): 193.4 (C-1), 145.4 (C-2’), 145.0 (C-
5’), 142.5 (C-3), 128.8 (C-2), 122.9 (C-3’), 107.6 (C-4’); IR 𝝊max (neat)/cm-1: 
3123.5, 3048.4, 2820.4, 2732.6, 1760.1, 1668.5, 1626.3, 1565.8, 1553.7; Rf 
= 0.54 (50:50 Hexanes–Diethyl Ether). 
 
(2E)-3-(Thiophen-2-yl)prop-2-enal (D4) 
 
 
 
Thiophene-2-carbaldehyde (256 mg, 2.0 mmol) and 
triphenylphosphoranylidene acetaldehyde (761 mg, 2.1 mmol) were 
dissolved in chloroform (7 mL) and stirred at 70 oC for 24 hours. Conversion 
to products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (85:15 Pentane–Diethyl Ether) 
to obtain the title compound126 as a brown oil (128 mg, 0.93 mmol, 47%). H 
(400MHz, CDCl3): 9.62 (1H, d, J 7.7, 1-H), 7.58 (1H, d, J 15.6, 3-H), 7.50 
(1H, d, J 5.0, 5’-H), 7.36 (1H, dd, J 3.7 and 1.0, 3’-H), 7.11 (1H, dd, J 5.1 
and 3.7, 4’-H), 6.51 (1H, dd, J 15.6 and 7.7, 2-H); C (100MHz, CDCl3): 
193.0 (C-1), 144.5 (C-3), 139.4 (C-2’), 132.2 (C-3’), 130.5 (C-5’), 128.6 (C-
4’), 127.5 (C-2); IR 𝝊max (neat)/cm-1: 3324.98, 3104.0, 2814.6, 2721.6, 
1662.9, 1606.4, 1513.1; Rf = 0.64 (50:50 Pentane–Diethyl Ether); HRMS 
(ESI): C7H6O2S requires [M-H]- 153.0016, found 153.0011. 
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(2E)-3-(5-Methyl-1,2-oxazol-3-yl)prop-2-enal (D5) 
 
 
 
5-Methylisoxazole-3-carbaldehyde (444 mg, 4.0 mmol) and 
triphenylphosphoranylidene acetaldehyde (1.278 g, 4.2 mmol) were 
dissolved in THF (12.5 mL) and stirred at 70 oC for 24 hours. Conversion to 
products was confirmed by TLC, and the mixture evaporated before 
purification by flash column chromatography (85:15 Hexane–Diethyl Ether) 
to obtain the title compound124 as an amorphous white solid (420 mg, 3.06 
mmol, 77%). H (400MHz, CDCl3): 9.72 (1H, d, J 7.7, 1-H), 7.47 (1H, d, J 
16.2, 3-H), 6.62 (1H, dd, J 16.2 and 7.7, 2-H), 6.23 (1H, s, 4’-H), 2.45 (3H, s, 
5’-CH3); C (100MHz, CDCl3): 192.9 (C-1), 171.0 (C-5’), 159.8 (C-3’), 138.9 
(C-3), 134.1 (C-2), 99.5 (C-4’), 12.3 (5’-CH3); IR 𝝊max (neat)/cm-1: 3338.8, 
3128.6, 3040.1, 2854.3, 2836.4, 2752.0, 1681.0, 1597.1; Rf = 0.40 (75:25 
Hexanes–iethyl Ether); HRMS (ESI): C7H7NO2 requires [M+H]+ 138.0555, 
found 138.0544. 
 
(2E)-3-(1-Methyl-1H-pyrrol-2-yl)prop-2-enal (D6) 
 
 
 
N-Methylpyrrole (500 mg, 6.2 mmol) and 3-dimethylacrolein (561 μL, 
5.6 mmol) were dissolved in chloroform (2 mL), before dropwise addition of a 
solution of phosphoryl chloride (517 μL, 5.6 mmol) in chloroform (1 mL) at 
−10 oC. After 1 hour, a 30% solution of sodium perchlorate (3 mL) was 
added, and the mixture filtered and evaporated under reduced pressure. The 
residue was then stirred vigorously with an aqueous solution of potassium 
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hydroxide (1 mL, 5 M) and chloroform (6 mL). After 2 hours, the mixture was 
filtered, the phases separated, and the organic layer washed twice with 
water (2 x 5 mL). The organic layer was then evaporated and purified by 
flash column chromatography (DCM) to obtain the title compound127 as an 
amorphous off-white solid (234 mg, 1.73 mmol, 28%). H (400MHz, CDCl3): 
9.54 (1H, d, J 7.7, 1-H), 7.31 (1H, d, J 15.5, 3-H), 6.87 – 6.83 (1H, m, 5’-H), 
6.74 (1H, d, J 4.1, 3’-H), 6.43 (1H, dd, J 15.5 and 7.7, 2-H), 6.25 – 6.17 (1H, 
m, 4’-H), 3.74 (3H, s, NCH3); C (100MHz, CDCl3): 193.1 (C-1), 139.9 (C-3), 
129.3 (C-2’), 129.1 (C-5’), 123.6 (C-2), 114.7 (C-3’), 110.2 (C-4’), 34.7 
(NCH3); IR 𝝊max (neat)/cm-1: 3072.8, 2916.8, 2847.1, 1653.1, 1607.8, 
1521.2; Rf = 0.39 (DCM); HRMS (ESI): C8H9NO requires [M+Na]+ 158.0573, 
found 158.0576. 
 
(2E)-3-(1-Methyl-1H-indol-3-yl)prop-2-enal (D7) 
 
 
 
N-Methylindole (420 μL, 3.29 mmol) and 3-dimethylacrolein (300 μL, 
2.99 mmol) were dissolved in chloroform (1.5 mL), before dropwise addition 
of a solution of phosphoryl chloride (277 μL, 5.60 mmol) in chloroform (0.5 
mL) at −10 oC. After 1 hour, a 30% solution of sodium perchlorate (2 mL) 
was added, and the mixture filtered and evaporated under reduced pressure. 
The residue was then stirred vigorously with an aqueous solution of 
potassium hydroxide (1 mL, 5M) and chloroform (4 mL). After 2 hours, the 
mixture was filtered, the phases separated, and the organic layer washed 
twice with water (5 mL). The organic layer was then evaporated and purified 
by flash column chromatography (DCM) to obtain the title compound128 as 
an amorphous off-white solid (173 mg, 0.93 mmol, 28%). H (500MHz, 
CDCl3): 9.60 (1H, d, J 7.8, 1-H), 7.89 (1H, dt, J 7.8 and 1.0, Ar-H), 7.64 (1H, 
d, J 15.7, 3-H), 7.44 (1H, s, 2’-H), 7.40 – 7.28 (3H, m, Ar-H), 6.74 (1H, dd, J 
15.7 and 7.8, 2-H), 3.84 (3H, s, NCH3); C (125MHz, CDCl3): 194.2 (C-1), 
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146.4 (C-3), 138.4 (Ar), 134.2 (Ar), 126.0 (Ar), 124.3 (C-2), 123.6 (Ar), 122.1 
(Ar), 120.6 (Ar-H), 112.5 (C-3’), 110.3 (C-2’), 33.5 (NCH3); IR 𝝊max (neat)/cm-
1: 3090.2, 3053.6, 2910.0, 2817.2, 2725.6 1649.1, 1605.0, 1570.9, 1520. 2; 
Rf = 0.46 (DCM); HRMS (ESI): C12H11NO requires [M+H]+ 186.0913, found 
186.0911. 
 
6.2.5 Syntheses for Compounds Isolated from ADS 
 
4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
 
To a stirring mixture of 4-(3,4-dichlorophenyl)-1-tetralone (200 mg, 
0.68 mmol) in methanol (1.5 mL) was added sodium borohydride (39 mg, 
1.02 mmol) in portions. The mixture was stirred at ambient temperature for 3 
hours. Water was added and the mixture evaporated under reduced 
pressure to remove the volatile components. The remaining aqueous portion 
was extracted with ethyl acetate. The organic phase was then washed with 
water, dried with sodium sulfate and evaporated to dryness under reduced 
pressure to obtain the crude alcohol (50:50 mixture of diastereomers 
determined via 1H NMR). Purification by flash column chromatography 
(75:25 Hexane–EtOAc) gave the diastereomers114, rac-35a (73 mg, 0.25 
mmol, 37%) and rac-35b (82 mg, 0.28 mmol, 41%) as colourless oils.  
 
 
 
(1R*,4R*)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
(rac-35a) - H (500MHz, CDCl3): 7.46 (1H, dd, J 7.8 and 1.4, 8-H), 7.36 (1H, 
d, J 8.2, 5’-H), 7.28 (2H, m, 2’-H and 7-H), 7.18 (1H, td, J 7.6 and 1.4, 6-H ), 
6.98 (1H, dd, J 8.2 and 2.1, 6’-H), 6.82 (1H, app dt, J 7.6 and 1.4, 5-H), 4.87 
(1H, br q, J 4.7, 1-H), 3.99 (1H, dd, J 9.0 and 5.6, 4-H), 2.23 – 1.95 (4H, m, 
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2-H and 3-H), 1.90 (1H, br d, J 4.7, OH); C (125MHz, CDCl3): 147.1 (C-1’), 
139.1 (C-8a), 138.6 (C-4a), 132.5 (C-4’), 130.8 (Ar), 130.5 (Ar), 130.4 (C-3’), 
129.9 (Ar), 129.2 (Ar), 128.4 (Ar), 128.3 (Ar), 127.2 (Ar), 68.0 (C-1), 45.2 (C-
4), 30.2 (C-2), 28.3 (C-3); IR 𝝊max (neat)/cm-1: 3311.7, 3023.2, 2939.3, 
2865.1, 2830.4, 1588.6, 1560.6; Rf = 0.50 (75:25 Hexanes–EtOAc); HRMS 
(ESI): C16H14Cl2O requires [M+Na]+ 315.0314, found 315.0312. 
 
 
 
(1S*,4R*)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
(rac-35b) - H (500MHz, CDCl3): 7.64 – 7.48 (1H, d, J 7.8, 8-H), 7.33 (1H, d, 
J 8.3, 5’-H), 7.28 (1H, td, J 7.5 and 1.4, 7-H), 7.18 (1H, td, J 7.5 and 1.4, 6-
H), 7.12 (1H, d, J 2.1, 2’-H), 6.88 – 6.82 (2H, m, 6’-H and 5-H), 4.89 (1H, br 
q, J 6.0, 1-H), 4.14 (1H, t, J 6.3, 4-H), 2.43 – 2.27 (1H, m, 2-Ha), 2.16 – 2.08 
(1H, m 3-Ha), 1.86 (1H, br d, J 6.4, OH), 1.84 – 1.76 (2H, m, 2-Hb and 3-Hb); 
C (125MHz, CDCl3): 147.0 (C-1’), 139.8 (C-8a), 137.9 (C-4a), 132.5 (C-4’), 
130.7 (Ar), 130.4 (Ar), 130.3 (C-3’), 130.1 (Ar), 128.3 (Ar), 128.2 (Ar), 128.1 
(Ar), 127.3 (Ar), 68.3 (C-1), 44.6 (C-4), 30.1 (C-3), 29.1 (C-2); IR 𝝊max 
(neat)/cm-1: 3319.5, 2940.6, 2862.2, 2831.3; Rf = 0.31 (75:25 Hexanes–
EtOAc); HRMS (ESI): C16H14Cl2O requires [M+Na]+ 315.0314, found 
315.0308. 
 
3-(4-Cyano-3-trifluoromethylphenyl)propan-1-ol (36) 
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4-[(1E)-3-Oxoprop-1-en-1-yl]-2-(trifluoromethyl)benzonitrile (100 mg, 
0.45 mmol), sodium borohydride (17 mg, 0.45 mmol) and palladium (II) 
acetate (4.98 mg, 0.023 mmol) were added to a flask with a magnetic stirrer, 
with a deflated balloon attached to the neck. Methanol (5 mL) was slowly 
added into the flask via a syringe. The mixture was stirred at room 
temperature until the reaction was observed to be completed by TLC. The 
mixture was filtered, and the organic phase evaporated under reduced 
pressure. Brine was added, and the product extracted with chloroform. The 
organic layer was dried over magnesium sulfate, filtered and concentrated 
using a rotary evaporator. The crude mixture was purified by flash column 
chromatography (75:25 Hexane–EtOAc) to obtain the title compound115 as 
an amorphous white solid (83 mg, 0.36 mmol, 80%). H (500MHz, CDCl3): 
7.76 (1H, d, J 7.9, 5’-H), 7.67 – 7.61 (1H, m, 2’-H), 7.52 (1H, dd, J 7.9 and 
1.6, 6’-H), 3.70 (2H, td, J 6.0 and 4.0, 1-H), 2.92 – 2.82 (2H, m, 3-H), 1.99 – 
1.85 (2H, m, 2-H), 1.40 (1H, br s, O-H); (125MHz, CDCl3): 148.5 (C-1’), 
134.9 (C-5’), 133.0 (q, J 32.5, C-3’), 132.3 (C-6’), 127.0 (d, J 4.6, C-2’), 
122.6 (q, J 273.8, CF3), 115.8 (CN), 107.6 (d, J 2.2, C-4’), 61.6 (C-1), 33.5 
(C-2), 32.3 (C-3); IR 𝝊max (neat)/cm-1: 3289.7,2939.4, 2867.1, 2231.6, 
1614.8, 1578.1, 1502.3; Rf = 0.27 (75:25 Hexanes–EtOAc); HRMS (ESI): 
C11H10F3NO requires [M+H]+ 230.0787, found 230.0789. 
 
3-(3,4-Dichlorophenyl)propan-1-ol (37) 
 
 
 
3-(3,4-Dichlorophenyl)propanoic acid (500 mg, 2.25 mmol) was 
stirred in THF (10 mL), and borane-THF (1M in THF, 4.60 mL, 4.50 mmol) 
added at room temperature. After stirring for 12 hours, the mixture was 
cooled to 0 oC and quenched by addition of 1M NaOH. The mixture was 
diluted with ether and washed with water twice followed by brine. The 
organic phase was separated and dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. The residue was purified by flash 
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column chromatography (75:25 Hexane–EtOAc) to obtain the title 
compound116 as an amorphous white solid (360 mg, 1.65 mmol, 73%). H 
(500MHz, CDCl3): 7.34 (1H, d, J 8.2, 5’-H), 7.29 (1H, d, J 2.0, 2’-H), 7.03 
(1H, dd, J 8.2 and 2.0, 6’-H), 3.71 – 3.59 (2H, m, 1-H), 2.71 – 2.63 (2H, m, 3-
H), 1.93 – 1.81 (2H, m, 2-H), 1.33 (1H, br s, O-H); C (125MHz, CDCl3): 
142.2 (C-1’), 132.4 (C-3’), 130.5 (5’-H), 130.4 (C-2’), 129.9 (C-4’), 128.1 (6’-
H), 61.9 (C-1), 33.9 (C-2), 31.3 (C-3); IR 𝝊max (neat)/cm-1: 3318.3, 2939.8, 
2865.4, 1593.4, 1561.3; Rf = 0.39 (75:25 Hexanes–EtOAc). HRMS (ESI): 
C9H8Cl2O2 requires [M-H]- 216.9829, found 216.9824. 
 
6.2.6 Synthesis of Exemplar Screening Compounds 
 
Benzyl N-({5-[(tert-butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl)-
N-(prop-2-en-1-yl)carbamate (41) 
 
 
 
To a suspension of 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 38 
(9.99 g, 70.3 mmol) in dichloromethane (150 mL) at 0 oC was added 
triethylamine (10.8 mL, 77.3 mmol), tert-butylchlorodimethylsilane (10.7 g, 
71.0 mmol) and N,N-dimethylpyridin-4-amine (0.258 g, 2.11 mmol). 
Following addition, the ice bath was removed and the reaction warmed to 
room temperature and stirred for 90 minutes. The reaction was quenched 
with saturated NH4Cl solution (100 mL) and water (100 mL). Following 
separation, the aqueous phase was extracted using CH2Cl2 (2 x 150 mL). 
The organic extracts were combined, filtered through a phase separation 
funnel and concentrated in vacuo. The crude residue was used as substrate 
for the second part of the experiment. To the crude starting material (70.3 
mmol) diluted in dichloromethane (150 mL) at 0 oC was added triethylamine 
(12.1 mL, 86.45 mmol) then methanesulfonyl chloride (5.98 mL, 77.3 mmol) 
dropwise. The ice bath was then removed, and the reaction mixture warmed 
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to room temperature and left to stir for 45 mins. The reaction was then 
quenched with water (150 mL), then the phases separated before extracting 
the aqueous phase with dichloromethane (2 x 150 mL). The organic extracts 
were combined, filtered through a phase separation funnel and concentrated 
in vacuo. The crude residue of 39 was used in next step without purification. 
{5-[(tert-Butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl 
methanesulfonate (39) - H (400MHz, CDCl3): 7.69 (1H, s, 6-H), 6.48 (1H, 
s, 3-H), 4.97 (1H, s, CH2), 3.10 (3H, s, SO2CH3), 0.96 (9H, s, SiC(CH3)3), 
0.23 (6H, s, 2 x SiCH3); LC-MS (ES+): C13H22O6SSi requires [M+H]+ 335.09, 
found 335.09. 
 
To a crude residue of (5-((tert-butyldimethylsilyl)oxy)-4-oxo-4H-pyran-2-
yl)methyl methanesulfonate 39 (23.5 g, 70.3 mmol) diluted in 
dichloromethane (150 mL) at 0 oC was added triethylamine (9.80 mL, 70.3 
mmol) and slow addition of prop-2-en-1-amine (20 mL, 267 mmol). Following 
addition, the ice bath was removed, and the mixture stirred at room 
temperature overnight (17 hours). The reaction was quenched with water 
(150 mL), and following separation of the phases, the aqueous phase 
extracted with dichloromethane (2 x 150 mL). The organic extracts were 
then combined and filtered through a phase separation funnel before 
concentrating in vacuo. The crude residue of 40 was used in next step 
without purification. 5-[(tert-Butyldimethylsilyl)oxy]-2-{[(prop-2-en-1-
yl)amino]methyl}-4H-pyran-4-one (40) - H (400MHz, CDCl3): 7.64 (1H, s, 
6-H), 6.35 (1H, s, 3-H), 5.86 (1H, ddt, J 17.1, 10.3 and 6.0, CH=CH2), 5.24 – 
5.08 (2H, m, CH=CH2), 3.62 (2H, s, CqCH2NH), 3.27 (2H, dt, J 6.0 and 1.3, 
NHCH2CH=CH2), 0.96 (9H, s, SiC(CH3)3), 0.23 (6H, s, 2 x SiCH3); LC-MS 
(ES+): C15H25NO3Si requires [M+H]+ 296.16, found 296.16. 
 
To the crude residue 2-((allylamino)methyl)-5-((tert-
butyldimethylsilyl)oxy)-4H-pyran-4-one 40 (20.8 g, 70.3 mmol) diluted in 
dichloromethane (150 mL) at 0 oC was slowly added triethylamine (16.9 mL, 
121 mmol) followed by dropwise addition of benzyl carbonochloridate (15.1 
mL, 105 mmol). The ice bath was then removed, and the reaction mixture 
warmed to room temperature, stirring for 3 hours. The reaction was 
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quenched with saturated NH4Cl solution (150 mL) and water (150 mL), then 
the phases separated, and the aqueous phase extracted with 
dichloromethane (2 x 150 mL). The organic extracts were combined, filtered 
through a phase separation funnel and concentrated in vacuo to give the title 
product34 as a pale yellow amorphous solid (16.8 g, 39.1 mmol, 56% over 3 
steps from kojic acid).  H (400MHz, CDCl3, 330 K): 7.56 (1H, s, 6-H), 7.39-
7.27 (5H, m, Cbz Ar-H), 6.23 (1H, s, 3-H), 5.81-5.70 (1H, m, CH=CH2), 5.21-
5.10 (4H, m, CH=CH2 and OCH2Ph), 4.26 (2H, s, CqCH2N), 3.96 (2H, s, 
NCH2CH=CH2), 0.97 (9H, s, SiC(CH3)3), 0.24 (6H, s, 2 × SiCH3); C 
(100MHz, CDCl3, 330 K): 175.3 (C-4), 163.3 (C-2), 156.1 (N(CO)O), 145.8 
(C-5), 144.0 (C-6), 136.5 (CH=CH2), 132.9 (Ar-Cq), 128.7 (Ar-C), 128.4 (Ar-
C), 128.2 (Ar-C), 118.2 (CH=CH2), 113.7 (C-3), 65.6 (OCH2Ph), 50.3 
(CH2CH=CH2), 47.6 (CqCH2NH), 25.8 (SiC(CH3)3), 18.7 (SiCq), −4.3 (2 × 
SiCH3); LC-MS (ES+): C23H31NO5Si requires [M+H]+ 430.20, found 430.20.  
 
Benzyl (1R*, 5S*, 7S*)-9-[(tert-butyldimethylsilyl)oxy]-8-oxo-11-oxa-3-
azatricyclo [5.3.1.0¹,⁵]undec-9-ene-3-carboxylate (42) 
 
 
 
A stirred solution of benzyl N-({5-[(tert-butyldimethylsilyl)oxy]-4-oxo-
4H-pyran-2-yl}methyl)-N-(prop-2-en-1-yl)carbamate 41 (9.50g, 22.1 mmol) in 
xylenes (24 mL) was heated to reflux and stirred for 14 hours. The crude 
reaction mixture was then concentrated in vacuo and the residue purified by 
flash column chromatography (gradient to 40% EtOAc in Heptane over 35 
mins) to give the title compound34 as a colourless amorphous solid (8.98 g, 
20.9 mmol, 95%). H (400MHz, CDCl3, 50:50 mixture of rotamers): 7.39 – 
7.28 (5H, m, Cbz Ar-H), 6.29 (0.5H, s, 10-H), 6.26 (0.5H, s, 10-H), 5.14 (1H, 
s, OCHaHbPh), 5.13 (1H, s, OCHaHbPh), 4.78 (1H, d, J 8.1, 7-H), 4.07 – 3.88 
(2H, m, 2-Hb and 4-Ha), 3.68 (0.5H, d, J 13.1, 2-Ha), 3.64 (0.5H, d, J 12.8, 2-
Ha), 3.17 (1H, q, J 11.0, 4-Hb), 2.87 – 2.72 (1H, m, 5-H), 2.36 – 2.18 (1H, m, 
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6-Hb), 1.89 (1H, dt, J 13.7 and 9.4, 6-Ha), 0.93 (9H, s, SiC(CH3)3), 0.17 (6H, 
s, 2 x SiCH3); C (100MHz, CDCl3, 50:50 mixture of rotamers): 193.7 (C-8), 
154.5 (N(CO)O), 154.3 (N(CO)O), 148.1 (C-9), 136.8 (Ar-Cq), 138.7 (Ar C-q), 
128.7 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 127.3 (C-10), 127.2 
(C-10), 90.6 (C-1), 89.8 (C-1), 83.4 (C-7), 67.2 (OCH2Ph), 53.9 (C-2 or C-4), 
53.5 (C-2 or C-4), 53.1 (C-2 or C-4), 52.7 (C-2 or C-4), 47.1 (C-5), 46.2 (C-
5), 31.6 (C-6), 31.5 (C-6), 25.7 (SiC(CH3)3), 18.6 (SiCq), −4.5 (2 × SiCH3) (28 
of 36 expected peaks observed); LC-MS (ES+): C23H31NO5Si requires 
[M+H]+ 430.20, found 430.20. 
 
Benzyl (1R*, 9R*, 11R*)-15-oxa-4,7,13-triazatetracyclo[7.5.1.0¹,¹¹.0³,⁸] 
pentadeca-3(8),4,6-triene-13-carboxylate (43) 
 
 
 
In two equally sized batches, ethane-1,2-diamine (2.18 ml, 32.6 
mmol) was added to a suspension of benzyl (1R*, 5S*, 7S*)-9-[(tert-
butyldimethylsilyl)oxy]-8-oxo-11-oxa-3-azatricyclo[5.3.1.0¹,⁵]undec-9-ene-3-
carboxylate 42 (7.00 g, 16.3 mmol) in acetic acid (7.5 mL). Following stirring 
at room temperature for 10 minutes, the reaction mixture was then heated at 
160 oC under microwave irradiation for 30 minutes. The two batches were 
then combined and concentrated in vacuo. The residue was diluted in DCM 
(70 mL) and washed with saturated NaHCO3 solution (70 mL). The aqueous 
layer was extracted further with dichloromethane (4 x 30 mL), then the 
organic extracts combined, washed with water (2 x 30 mL) and brine (30 mL) 
before filtering through a phase separation funnel and concentrating in 
vacuo. The product was then purified by chromatography, eluting with DCM–
10% NH3/MeOH in DCM (0% to 30%), to give the title compound34 as a 
viscous orange oil (2.02 g, 5.99 mmol, 37%). H (400MHz, CDCl3): 8.39 (1H, 
d, J 2.6, 5/6-H), 8.28 (1H, d, J 2.5, 5/6-H), 7.39 – 7.28 (5H, m, Cbz Ar-H), 
5.29 (1H, d, J 6.9, 9-H), 5.14 (2H, d, J 3.0, OCH2Ph), 4.08 (1H, d, J 12.7, 14-
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Ha), 3.88 (1H, dd, J 11.4 and 9.3, 12-Hb), 3.47 (3H, m, 2-Ha, 12-Ha and 14-
Hb), 2.92 (1H, d, J 17.6, 2-Hb), 2.69 (1H, s, 11-H), 2.39 (1H, d, J 7.2, 10-Ha), 
2.26 (1H, s, 10-Hb); C (100MHz, CDCl3, mixture of two rotamers): 155.4 
(C-8), 154.6 (N(CO)O), 149.3 (C-3), 143.6 (C-5 or C-6), 141.7 (C-5 or C-6), 
136.8 (Ar-Cq), 128.6 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 91.2 (C-1), 90.3 (C-
1), 80.6 (C-9), 67.2 (OCH2Ph), 66.9 (OCH2Ph), 55.1 (C-14), 54.7 (C-14), 
54.4 (C-12), 54.1 (C-12), 46.7 (C-11), 45.7 (C-11), 43.4 (C-10), 43.2 (C-10), 
39.5 (C-2) (23 of 34 expected peaks observed);  IR 𝝊max (neat)/cm-1: 2953.4, 
2880.2, 1703.0; LC-MS (ES+): C19H19N3O3 requires [M+H]+ 338.14, found 
338.14.  
 
(1R*, 9R*, 11R*)-15-Oxa-4,7,13-triazatetracyclo[7.5.1.0¹,¹¹.0³,⁸]pentadeca-
3(8),4,6-triene (44) 
 
 
 
Sodium hydroxide (1.79 g, 44.8 mmol) was added to a stirred solution 
of benzyl (1R*, 9R*, 11R*)-15-oxa-4,7,13-
triazatetracyclo[7.5.1.0¹,¹¹.0³,⁸]pentadeca-3(8),4,6-triene-13-carboxylate 43 
(0.72 g, 2.13 mmol) in methanol (25 mL). The reaction mixture was heated 
at reflux for 15 hours, then acidified to pH 7 with concentrated hydrochloric 
acid, before reverse phase purification (10 to 30% MeCN in H2O(1% 
NH4OH)) to obtain the title compound34 as a brown oil (0.261 g, 1.28 mmol, 
60%). H (400MHz, MeOD): 8.50 (1H, d, J 2.7, 5/6-H), 8.41 (1H, d, J 2.6, 
5/6-H), 5.22 (1H, d, J 6.5, 9-H), 3.46 (1H, d, J 17.3, 2-Ha), 3.32 (1H, d, J 
12.6, 14-Ha), 3.13 (1H, dd, J 12.0 and 7.6, 12-Ha), 3.01 (1H, d, J 17.4, 2-Hb), 
2.90 (1H, d, J 12.1, 12-Hb), 2.81 (1H, d, J 12.7, 14-Hb), 2.65 – 2.50 (2H, m, 
10-Ha and 11-H), 2.17 (1H, m, 10-Hb); C (100MHz, MeOD):  157.0 (C-8), 
151.9 (C-3), 144.3 (C-5 or C-6), 142.6 (C-5 or C-6), 94.1 (C-1), 81.2 (C-9), 
56.4 (C-12), 54.9 (C-14), 48.1 (C-11), 44.6 (C-10), 39.5 (C-2); IR 𝝊max 
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(neat)/cm-1: 3324.5, 2977.4, 2901.4; LC-MS (ES+): C11H13N3O requires 
[M+H]+ 204.11, found 204.11. 
 
Methyl (1R*,9R*,11R*)-15-oxa-4,7,13-triazatetracyclo[7.5.1.01,11.03,8] 
pentadeca-3(8),4,6-triene-13-carboxylate (45) 
 
 
 
Methyl carbonochloridate (0.171 mL, 2.21 mmol) was added dropwise 
to a solution of (1R*, 9R*, 11R*)-15-oxa-4,7,13-
triazatetracyclo[7.5.1.0¹,¹¹.0³,⁸]pentadeca-3(8),4,6-triene 44 (300 mg, 1.48 
mmol) and N-ethyl-N-isopropylpropan-2-amine (0.514 mL, 2.95 mmol) in 
acetonitrile (5 mL) at 0 oC. Following the addition, the reaction was stirred at 
room temperature for 17 hours. The mixture was then diluted with brine (5 
mL) and extracted with DCM (3 x 5 mL). Purified by reverse phase 
purification (10% to 30% MeCN in H2O (1% NH4OH)) to obtain the title 
compound34 as a colourless viscous oil (0.248 g, 0.949 mmol, 64.3 %). H 
(400MHz, CDCl3): 8.40 (1H, d, J 2.6, 5/6-H), 8.28 (1H, d, J 2.6, 5/6-H), 5.28 
(1H, d, J 6.9, 9-H), 4.03 (1H, d, J 10.3, 12-Ha), 3.88 – 3.80 (1H, m, 14-Ha), 
3.71 (3H, s, CO2CH3), 3.46 (3H, m, 2-Ha, 12-Hb and 14-Hb), 2.92 (1H, d, J 
17.8, 2-Hb), 2.73 – 2.63 (1H, m, 11-H), 2.46 – 2.36 (1H, m, 10-Ha), 2.25 (1H, 
m, 10-Hb); c (100MHz, CDCl3, mixture of two rotamers): 155.3 (C-8), 
155.2 (N(CO)O), 149.2 (C-3), 143.5 (C-5 or C-6), 141.6 (C-5 or C-6), 91.0 
(C-1), 90.1 (C-1), 80.4 (C-9), 54.9 (C-12), 54.6 (C-12), 54.1 (C-14), 54.0 (C-
14), 52.6 (NCO2CH3), 46.6 (C-11), 45.6 (C-11), 43.2 (C-10), 39.4 (C-2) (17 
of 26 expected peaks observed); IR 𝝊max (neat)/cm-1: 3047.7, 2974.1, 
2879.3, 1693.6, 1541.4; HRMS (ESI): C13H15N3O3 requires [M+H]+ 
262.1191, found 262.1187. 
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Ethyl (1R*,9R*,11R*)-15-oxa-4,7,13-triazatetracyclo[7.5.1.01,11.03,8] 
pentadeca-3(8),4,6-triene-13-carboxylate (46) 
 
 
 
Ethyl carbonochloridate (0.073 mL, 0.77 mmol) was added dropwise 
to a solution of (1R*, 9R*, 11R*)-15-oxa-4,7,13-
triazatetracyclo[7.5.1.0¹,¹¹.0³,⁸]pentadeca-3(8),4,6-triene 44 (130 mg, 0.64 
mmol) and triethylamine (0.178 mL, 1.28 mmol) in DMF (2 mL) at 0 oC. 
Following the addition, the reaction was stirred at room temperature for 17 
hours. The mixture was then diluted with water (5 mL) and extracted with 
EtOAc (3 x 5 mL). Purified by reverse phase purification (15% to 35% MeCN 
in H2O (1% NH4OH)) to obtain the title product as a pale yellow viscous oil 
(85 mg, 0.309 mmol, 48%). H (500MHz, CDCl3): 8.40 (1H, d, J 2.6, 5/6-H), 
8.29 (1H, d, J 2.6, 5/6-H), 5.29 (1H, d, J 6.8, 9-H), 4.15 (2H, q, J 7.1, 
OCH2CH3), 4.04 (1H, d, J 12.7, 12-Ha), 3.85 (1H, m, 14-Ha), 3.52 – 3.32 (3H, 
m, 2-Ha, 12-Hb and 14-Hb), 2.93 (1H, d, J 17.6, 2-Hb), 2.69 (1H, m, 11-H), 
2.41 (1H, m, 10-Ha), 2.31–2.20 (1H, m, 10-Hb), 1.26 (3H, t, J 7.1, OCH2CH3); 
C(125MHz, CDCl3): 155.4 (C-8), 154.9 (N(CO)O), 149.4 (C-3), 143.6 (C-5 
or C-6), 141.7 (C-5 or C-6), 91.2 (C-1), 90.3 (C-1), 80.6 (C-9), 61.4 
(OCH2CH3), 55.0 (C-12), 54.7 (C-12), 54.1 (C-14), 46.7 (C-11), 45.7 (C-11), 
43.4 (C-10), 43.2 (C-10), 39.6 (C-2), 14.9 (OCH2CH3) (18 of 28 expected 
peaks observed); IR 𝝊max (neat)/cm-1: 3049.1, 2975.3, 2877.2, 1691.0, 
1539.8; HRMS (ESI): C14H17N3O3 requires [M+H]+ 276.1343, found 
276.1339. 
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General Procedures for Synthesis of Imidazole Analogues: 
 
A 
Ammonium acetate (10.0 equiv.) was added to a stirred suspension 
of the silyl enol ketone 42 (1.0 mmol, 1.0 equiv.) and the appropriate 
aldehyde (1.0 equiv.) in acetic acid (70 mM reaction concentration). The 
resulting mixture was heated to 60 oC and stirred for 17 hours. The reaction 
was allowed to cool to room temperature, then added to a saturated 
aqueous solution of sodium hydrogen carbonate (20 mL). The mixture was 
extracted with ethyl acetate (4 x 20 mL) and the combined organic layers 
dried over magnesium sulphate, before filtering and concentrating under 
reduced pressure. 
 
B 
Ammonium acetate (5.0 equiv.) was added to a stirred suspension of 
the silyl enol ketone 42 (1.0 mmol, 1.0 equiv.), the appropriate aldehyde (1.0 
equiv.) and the appropriate aniline (5.0 equiv.) in acetic acid (70 mM reaction 
concentration). The resulting mixture was heated to 60oC and stirred for 17 
hours. The reaction was allowed to cool to room temperature, then added to 
a saturated aqueous solution of sodium hydrogen carbonate (20 mL). The 
mixture was extracted with ethyl acetate (4 x 20 mL) and the combined 
organic layers dried over magnesium sulphate, before filtering and 
concentrating under reduced pressure. 
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Benzyl (1R*, 8R*, 10S*)-5-(furan-2-yl)-14-oxa-4,6,12-
triazatetracyclo[6.5.1.0¹,¹⁰.0³,⁷]tetradeca-3(7),4-diene-12-carboxylate (47) 
 
 
 
 
 
By general procedure A, using furfural, eluting with 50% to 100% 
EtOAc in Hexane, afforded the title compound (76 mg, 0.194 mmol, 65%) as 
a brown amorphous solid. H (400MHz, CDCl3): 7.40-7.28 (6H, m, Ar-H and 
furan 5-H), 6.82 (1H, d, J 3.4, furan 3-H), 6.48 (1H, dd, J 3.5 and 1.8, furan 
4-H), 5.26 (1H, d, J 5.9, 8-H), 5.21-5.07 (2H, m, OCH2Ph), 4.07 (1H, d, J 
12.6, 13-Ha), 3.83-3.72 (1H, m, 11-Ha), 3.55-3.36 (2H, m, 11-Hb and 13-Hb), 
3.27-3.14 (1H, m, 2-Ha), 2.71-2.64 (1H, m, 10-H), 2.61 (1H, d, J 15.5, 2-Hb), 
2.56-2.45 (1H, m, 9-Ha), 2.16- 2.05 (1H, m, 9-Hb); C (100MHz, CDCl3, 
mixture of two rotamers): 154.9 (N(CO)O), 146.1 (Ar-Cq), 142.1 (furan C-
5), 138.2 (Ar-Cq), 136.7 (Ar-Cq), 128.6 (Ph-C), 128.1 (Ph-C), 128.0 (Ph-C), 
112.0 (furan C-4), 106.7 (furan C-3), 91.1 (C-1), 90.2 (C-1), 67.1 (OCH2Ph), 
55.0 (C-13), 53.3 (C-11), 53.5 (C-11), 47.1 (C-10), 46.1 (C-10), 45.7 (C-9), 
45.6 (C-9), 32.8 (C-2) (21 of 40 expected peaks observed); IR 𝝊max 
(neat)/cm-1: 3117.7, 3031.2, 2952.7, 2874.3, 1694.2, 1589.6; HRMS (ESI): 
C22H21N3O4 requires [M+H]+ 392.1605, found 392.1608. 
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Benzyl (1R*, 8R*, 10S*)-5-cyclohexyl-14-oxa-4,6,12-
triazatetracyclo[6.5.1.0¹,¹⁰.0³,⁷]tetradeca-3(7),4-diene-12-carboxylate (48) 
 
 
 
By general procedure A, using cyclohexane carboxaldehyde, eluting 
with 50% to 100% EtOAc in Hexane, afforded the title compound (143 mg, 
0.351 mmol, 38%) as a brown amorphous solid. H (400MHz, CDCl3): 7.36-
7.28 (5H, m, Ar-H), 5.18-5.09 (3H, m, OCH2Ph and 8-H), 4.01 (1H, dd, J 
12.6 and 2.4, 13-Ha), 3.80-3.70 (1H, m, 11-Ha), 3.48-3.31 (2H, m, 11-Hb and 
13-Hb), 3.14-3.03 (1H, m, 2-Ha), 2.68-2.59 (2H, m, Cy 1-H and 10-H), 2.48-
2.35 (2H, m, 9-Ha and 2-Hb), 2.04-1.88 (3H, m, 9-Hb and Cy 2-Ha), 1.78-1.59 
(3H, m, Cy-H), 1.47-1.08 (5H, m, Cy 2-Hb and Cy-H); C (100MHz, CDCl3, 
mixture of two rotamers): 154.7 (N(CO)O), 151.6 (Ar-Cq), 136.7 (Ar-Cq), 
128.5 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 91.1 (C-1), 90.0 (C-1), 67.0 
(OCH2Ph), 55.0 (C-13), 53.5 (C-11), 47.0 (C-10), 46.0 (C-10), 45.7 (C-9), 
45.5 (C-9), 37.9 (Cy C-1), 32.7 (C-2), 32.2 (Cy C-2), 32.1 (Cy C-2), 26.0 (Cy 
C-3 or Cy C-4), 25.8 (Cy C-3 or Cy C-4) (21 of 40 expected peaks 
observed); IR 𝝊max (neat)/cm-1: 3064.6, 2925.2, 2850.7, 1684.4, 1611.5, 
1521.8; HRMS (ESI): C24H29N3O3 requires [M+H]+ 408.2282, found 
408.2283. 
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Benzyl (1R*, 8R*, 10S*)-6-(4-methoxyphenyl)-5-phenyl-14-oxa-4,6,12-
triazatetracyclo[6.5.1.0¹,¹⁰.0³,⁷]tetradeca-3(7),4-diene-12-carboxylate (49) 
 
 
 
By general procedure B, using benzaldehyde and p-anisidine, eluting 
with 50% to 100% EtOAc in Hexane, afforded the title compound (125 mg, 
0.246 mmol, 58%) as a dark brown amorphous solid. H (400MHz, 
CDCl3): 7.39-7.28 (7H, m, Ar-H), 7.25-7.17 (3H, m, Ar-H), 7.08 (2H, d, J 8.8, 
PMP 2-H), 6.92 (2H, d, J 8.8, PMP 3-H), 5.35 (1H, d, J 5.9, 8-H), 5.18-5.08 
(2H, m, OCH2Ph), 4.10-3.99 (1H, m, 13-Ha), 3.84 (3H, s, OCH3), 3.77 (1H, 
dd, J 11.6 and 8.9, 11-Ha), 3.55-3.42 (1H, m, 13-Hb), 3.41-3.30 (1H, m, 11-
Hb), 3.10-2.97 (1H, m, 2-Ha), 2.79-2.56 (2H, m, 9-Ha and 10-H), 2.38 (1H, d, 
J 15.6, 2-Hb), 2.21-2.09 (1H, m, 9-Hb). C (100MHz, CDCl3, mixture of two 
rotamers): 159.7 (PMP C-4), 154.8 (N(CO)O), 145.9 (Ar-Cq), 141.4 (Ar-Cq), 
136.9 (Ar-Cq), 130.6 (Ar-Cq), 129.8 (Ar-Cq), 128.6 (Ar-C), 128.3 (2 peaks, Ar-
C), 128.2 (Ar-C), 128.1 (2 peaks, Ar-C), 128.0 (Ar-C), 125.1 (Ar-C), 115.0 
(PMP C-3), 90.9 (C-1), 90.0 (C-1), 77.5 (C-8), 67.1 (OCH2Ph), 55.7 (OCH3), 
55.4 (C-13), 55.1 (C-11), 53.5 (C-11), 47.4 (C-10), 46.4 (C-10), 45.5 (C-9), 
32.5 (C-2) (28 of 50 expected peaks observed).; IR 𝝊max (neat)/cm-1: 3060.0, 
2952.9, 2837.0, 1697.7, 1608.1, 1583.7, 1511.3; HRMS (ESI): C31H29N3O4 
requires [M+H]+ 508.2231, found 508.2226. 
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Benzyl (1R*, 8R*, 10S*)-6-(3,5-dimethylphenyl)-5-phenyl-14-oxa-4,6,12-
triazatetracyclo[6.5.1.0¹,¹⁰.0³,⁷]tetradeca-3(7),4-diene-12-carboxylate (50) 
 
 
 
By general procedure B, using benzaldehyde and 3,5-dimethyl 
aniline, eluting with 50% to 100% EtOAc in Hexane, afforded the title 
compound (74 mg, 0.146 mmol, 42%) as a light yellow amorphous solid. H 
(400MHz, CDCl3): 7.45-7.27 (7H, m, Ar-H), 7.25-7.16 (3H, m, Ar-H), 7.10-
7.00 (1H, m, Ar-H), 6.77 (2H, s, Ar-H), 5.34 (1H, d, J 5.9, 8-H), 5.20-5.05 
(2H, m, OCH2Ph), 4.15-3.99 (1H, m, 13-Ha), 3.77 (1H, dd, J 11.5 and 8.8, 
11-Ha), 3.55- 3.31 (2H, m, 11-Hb and 13-Hb), 3.13-2.95 (1H, m, 2-Ha), 2.76-
2.60 (2H, m, 10-H and 9-Ha), 2.38 (1H, d, J 15.8, 2-Hb), 2.30 (6H, s, CH3), 
2.20-2.09 (9-Hb); C (100MHz, CDCl3, mixture of two rotamers): 154.7 
(N(CO)O), 145.6 (Ar-C), 141.3 (Ar-C), 139.7 (Ar-C), 139.6 (Ar-C), 136.9 (Ar-
C), 136.8 (Ar-C), 130.2 (Ar-C), 130.3 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 
128.1 (2 peaks, Ar-C), 128.0 (2 peaks, Ar-C), 124.8 (Ar-C), 124.4 (Ar-C), 
90.8 (C-1), 89.9 (C-1), 73.8 (C-8), 67.0 (OCH2Ph), 55.3 (C-13), 55.0 (C-13), 
53.5 (C-11), 47.3 (C-10), 46.3 (C-10), 45.4 (C-9), 32.4 (C-2), 21.2 (CH3) (29 
of 50 expected peaks observed); IR 𝝊max (neat)/cm-1: 3057.7, 3018.4, 
2973.4, 2944.3, 2877.4, 1700.6, 1611.7, 1596.7, 1510.1; HRMS (ESI): 
C32H31N3O3 requires [M+H]+ 506.2438, found 506.2432. 
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Benzyl (1R*, 8R*, 10S*)- 5,6-diphenyl-14-oxa-4,6,12-
triazatetracyclo[6.5.1.0¹,¹⁰.0³,⁷]tetradeca-3(7),4-diene-12-carboxylate (51) 
 
 
 
By general procedure B, using benzaldehyde and aniline, eluting with 
EtOAc, afforded the title compound (127 mg, 0.266 mmol, 62%) as a light 
yellow amorphous solid. H (400 MHz, CDCl3): 7.46-7.40 (3H, m, Ar-H), 
7.38-7.29 (7H, m, Ar-H), 7.24-7.19 (3H, m, Ar-H), 7.19-7.14 (2H, m, Ar-H), 
5.36 (1H, d, J 5.9, 8-H), 5.19-5.07 (2H, m, OCH2Ph), 4.06 (1H, d, J 12.0, 13-
Ha), 3.77 (1H, dd, J 11.5 and 8.9, 11-Ha), 3.56-3.43 (1H, m, 13-Hb), 3.41-
3.30 (1H, m, 11-Hb), 3.16-2.99 (1H, m, 9-Ha), 2.78-2.60 (2H, m, 2-Ha and 10-
H), 2.39 (1H, d, J 15.7, 2-Hb), 2.20- 2.10 (1H, m, 9-Hb); C (400 MHz, CDCl3, 
mixture of two rotamers): 154.8 (N(CO)O), 145.8 (Ar-C), 141.4 (Ar-C), 
136.9 (Ar-C), 136.8 (Ar-C), 130.2 (Ar-C), 130.0 (Ar-C), 129.9 (Ar-C), 128.8 
(Ar-C), 128.6 (Ar-C), 128.4 (2 peaks, Ar-C), 128.3 (Ar-C), 128.1 (Ar-C), 
128.0 (Ar-C), 126.9 (Ar-C), 124.9 (Ar-C), 90.9 (C-1), 89.9 (C-1), 73.8 (C-8), 
67.1 (OCH2Ph), 55.3 (C-13), 55.0 (C-13), 53.5 (2 × peaks, C-11), 47.3 (C-
10), 46.4 (C-10), 45.4 (C-9), 32.5 (C-2) (29 of 48 expected peaks observed); 
IR 𝝊max (neat)/cm-1: 3061.6, 2952.8, 2873.5, 1696.2, 1596.8; HRMS (ESI): 
C30H27N3O3 requires [M+H]+ 478.2125, found 478.2123. 
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6.3 Procedures for Transfer to Plate Format 
 
Plate Based Synthesis of Compound 22 
 
Cinnamaldehyde (1 M solution in CHCl3, 10 µL) and 4-
methoxyphenacyl chloride (1 M solution in CHCl3, 20 µL) were added to a 
300 µL reaction vial, and the solutions were allowed to evaporate. A solution 
of rac-2-{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (0.002 mM) and 
triethylamine (0.01 mM) in chloroform was added (100 µL), and the reaction 
vial sealed for 24 hours. LC-MS analysis was obtained, and compared to 
that of the same reaction performed in a flask on a 50 fold higher scale. 
NMR analysis of the purified product of the flask-based reaction was 
obtained, and the crude LC-MS analyses compared. 
 
 
Format LC-MS Trace Retention 
Time 
(Mins) 
Mass 
Found 
Flask 
 
0.60 (1) 
0.67 (2) 
 
474.26 
474.19 
 
 
Isolated 
Product 
0.60 (1) 
 
281.21 
Plate 0.59 (1) 
0.62 (2) 
474.25 
474.27 
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Plate Based Synthesis of Compound 23 
 
 
Crotonaldehyde (1 M solution in CHCl3, 10 µL) and N-methylindole (1 
M solution in CHCl3, 20 µL) were added to a 300 µL reaction vial, and the 
solutions were allowed to evaporate. A solution of (2R*,5R*)-5-benzyl-2-tert-
butyl-3-methylimidazolidin-4-one (0.002 mM) and trifluoroacetic acid (0.0002 
mM) in chloroform was then added (100 µL), and the reaction wells sealed 
for 24 hours. LC-MS analysis was obtained, and compared to that of the 
same reaction performed in a flask on a 50 fold higher scale. NMR analysis 
of the purified product of the flask-based reaction was obtained, and the 
crude LC-MS analyses compared. 
 
 
Format LC-MS Trace Retention 
Time 
(Mins) 
Mass 
Found 
Flask 
 
0.78 (1) 
 
588.35 
 
 
Isolated 
Product 
0.78 (1) 217.73 
Plate 0.78 (1) 588.33 
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Plate Based Synthesis of Compound 31 
 
 
Crotonaldehyde (1 M solution in CHCl3, 10 µL) and 3-phenyl-1λ⁶,2-
benzothiazole-1,1-dione (1 M solution in CHCl3, 20 µL) were added to a 300 
µL reaction vial, and the solutions were allowed to evaporate. A solution of 
2-Mesityl-2,5,6,7-tetrahydropyrrolo[2,1-c][1,2,4]triazol-4-ium chloride (0.0006 
mM) and 1,8-diazabicyclo(5.4.0)undec-7-ene (0.00012 mM) in DCM was 
then added (100 µL), and the reaction wells sealed for 24 hours. LC-MS 
analysis was obtained, and compared to that of the same reaction performed 
in a flask on a 50 fold higher scale. NMR analysis of the purified product of 
the flask-based reaction was obtained, and the crude LC-MS analyses 
compared. 
 
 
Format LC-MS Trace Retention 
Time (Mins) 
Mass 
Found 
Flask 
 
0.60 (1) 
 
313.96 
 
 
Isolated 
Product 
0.59 (1) 
 
313.94 
 
Plate 0.60 (1) 313.95 
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Plate Based Synthesis of Compounds 25a and 25b 
 
 
Cinnamaldehyde (1 M solution in CHCl3, 10 µL) and methylisatin(1 M 
solution in CHCl3, 20 µL) were added to a µL reaction vial, and the solutions 
were allowed to evaporate. A solution of 1,3-Bis(2,4,6-
trimethylphenyl)imidazolium chloride (0.0006 mM) and 1,8-
diazabicyclo(5.4.0)undec-7-ene (0.00012 mM) in THF was then added (100 
µL), and the reaction wells sealed for 24 hours. LC-MS analysis was 
obtained, and compared to that of the same reaction performed in a flask on 
a 50 fold higher scale. NMR analysis of the purified product of the flask-
based reaction was obtained, and the crude LC-MS analyses compared. 
 
 
Format LC-MS Trace Retention 
Time 
(Mins) 
Mass 
Found 
Flask 
 
0.59 (1) 
 
294.14 
 
Isolated 
Product 
0.59 (1) 
 
293.93 
 
Plate 0.59 (1) 294.14 
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6.4 Procedures for Post-Reaction Protocol Development 
 
Reduction with Sodium Borohydride 
 
The standard, 1,2,4-trichloro-5-methoxybenzene (7.4 mg, 0.035 
mmol), and the selected carbonyl substrate (0.035 mmol) were weighed into 
a vial. Deuterated chloroform (400 L) was added, and the solutions 
transferred into NMR tubes. Following an initial 1H NMR experiment to 
obtain a spectrum of the reaction components, 40 μL (0.0525 mmol, 1.5 
equiv.) of a solution of sodium borohydride (11.9 mg in 240 μL of methanol) 
was added into the NMR tube and the solution left for one hour. A final 1H 
NMR (400 MHz) spectrum was obtained, and the integral ratios of the initial 
and final spectra compared to determine percentage conversion. 
 
Reductive Amination with Secondary Amines 
 
The standard, 1,2,4-trichloro-5-methoxybenzene (7.4 mg, 0.027 
mmol), and carbonyl substrate (0.027 mmol) were weighed into vial. 
Deuterated chloroform (400 L) was added, and the solutions transferred 
into NMR tubes. Following an initial 1H NMR run to obtain a spectrum of the 
reaction components, the appropriate amine (0.030 mmol) was added to the 
NMR tubes, followed by 40 μL (0.0405 mmol, 1.5 equiv.) of a solution of 
tetramethylammonium triacetoxyborohydride (63.9 mg, 0.243 mmol) in 
acetic acid (240 μL). The mixture was left for 24 hours before obtaining a 1H 
NMR spectrum, and then another 1H NMR (400 MHz) spectrum after 48 
hours. The integral ratios of the spectra were compared to determine 
percentage conversion, and LC-MS analysis confirmed the presence of the 
expected products. 
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6.5 Procedures for Assembly of ADS Reaction Arrays 
 
6.5.1 Stock Solutions of Reaction Components 
 
Stock solutions of components were made up to enable the efficient 
setup of ADS reaction arrays. Solutions varied in their concentrations, and 
their addition volumes to the reaction vial to make up a 100 μL scale 
reaction (Table 6.1). 
 
Component Stock Solution Volume 
(μL) 
Reaction 
Concentration 
Substrate 1 M 
(in chloroform) 
10 100 mM 
Co-substrate 1 M 
(in chloroform) 
20 200 mM 
Catalyst 
System 
10 mM 
(chloroform for amine 
catalysts, THF for NHCs; 
concentration relative to 
catalyst) 
100 10 mM 
 
6.5.2 Mock Array 
 
Mock arrays were executed to determine the activity of the individual 
components at the same concentration at which the array was to be 
screened. This array was carried out on components that had been 
subjected to the work-up procedures, and their relative bioactivities relative 
to the testosterone positive control were determined. Components exhibiting 
biological activity at the reaction array screening concentration were 
identified and removed from the array to prevent interference so bioactive 
Table 6.1 – An outline of the solutions used in reaction array setup, 
their concentrations, addition volumes and their final reaction 
concentration. 
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mixtures as a result of productive reaction combinations could readily be 
identified. The mock array protocol is outlined graphically in Figure 3.5, and 
concentrations and volumes required of solutions are defined in Table 6.1. 
 
1. For the desired component, add the specified volume of solution to 
reaction vial. 
2. Allow evaporation.  
3. Add either: 
a. 50 μL of chloroform, followed by 50 μL of a 0.62 M solution of 
sodium borohydride in ethanol. 
b. 75 μL of a 0.4 M solution of Me2NH in chloroform, and sealing the 
vessel for 45 minutes. Following this, 25 μL of a 0.62 M solution of 
Me4N.BH(OAc)3 in AcOH is added. 
4. After 4 hours, add 25 μL of a 5 M solution of acetaldehyde in chloroform 
to quench unreacted reductant. 
5. Leave the plate to evaporate, before further evaporation in a GeneVac 
apparatus for 4 hours. 
6. Follow single-point assay protocol specified in Section 6.6.3 to obtain 
bioactivity % of reduced component relative to testosterone. 
 
6.5.3 Reaction Arrays 
 
The full reaction array protocol is outlined graphically in Figure 3.8, 
and was used for both the exhaustive and targeted reaction arrays. 
Concentrations of solutions are defined in Table 6.1 
 
1. For the desired reaction in each well, add first 10 μL of the substrate 
solution, followed by 20 μL of the co-substrate solution. 
2. Allow evaporation.  
3. Add 100 μL of the desired catalytic system, before sealing the reaction 
vial. Leave to react for 24 hours. 
4. Remove lids to vials, leave to evaporate. 
5. Add either: 
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a. 50 μL of chloroform, followed by 50 μL of a 0.62 M solution of 
sodium borohydride in ethanol. 
b. 75 μL of a 0.4 M solution of Me2NH in chloroform, and sealing the 
vessel for 45 minutes. Following this, 25 μL of a 0.62 M solution of 
Me4N.BH(OAc)3 in AcOH is added. 
6. After 4 hours, add 25 μL of a 5 M solution of acetaldehyde in chloroform 
to quench unreacted reductant. 
7. Leave the plate to evaporate naturally, before evaporation in a GeneVac 
apparatus for 4 hours. 
8. Follow single-point assay protocol specified in Section 6.6.3 to obtain 
bioactivity % of crude product mixture relative to testosterone. 
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6.6 Assay Experimental Procedures 
 
6.6.1 General Assay Procedure 
 
The assay kit was purchased from Fischer Scientific and used as 
instructed in black 384-well Corning assay plates (#4514). The kit contained: 
 
• AR-LBD GST: Rat AR-LBD in a buffer pH 7.5, containing 
protein, stabilising reagents and glycerol, concentration batch 
dependent. 
• Fluorescein-tagged peptide: 100 μM in 50 mM HEPES 
buffer, pH 7.5, sequence: VESGSSRFMQLFMANDLLT. 
• Tb3+ anti-GST antibody: Concentration batch dependent. 10 
mM HEPES buffered saline 137 mM NaCl, 2.7 mM KCl, pH 
7.5. 
• TR-FRET co-regulator buffer: proprietary buffer, pH 7.5, 20% 
glycerol.  
• DTT: 1 M in water. 
 
The 1M DTT solution was diluted to 5 mM in TR-FRET co-regulator 
buffer. This solution was then used as the buffer for all other assay 
components. 
 
The final DMSO concentration for all ligands screened was 1%. The 
assay included three additions per well, in which 2.5 μL of AR-LBD was 
added to 5 μL of the ligand in buffer (1% DMSO), followed by the addition of 
2.5 μL of a pre-mixed fluorescein-tagged peptide/Tb3+ anti-GST antibody 
solution. 
 
A 20 μM solution of testosterone was prepared for use as the positive 
control, by adding 5 μL of a 5000 μM solution to 45 μL of DMSO to make a 
500 μM (100 x final screening concentration) solution. 1 μL of the 500 μM 
solution was then diluted with 49 μL of the prepared buffer to make a 20 μM 
solution, of which 5 μL was added to the assay plate in triplicate to give a 
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final assay concentration of 10 μM. For the negative control, 5 μL of the 
prepared buffer (2% DMSO) was added to each well, leading to a final 
DMSO concentration of 1% when screened. 
 
Other ligands to be assayed were diluted to a concentration twice that 
of the desired screening concentration with a solution of prepared buffer (2% 
DMSO). Dilution of the controls or ligands with the other assay components 
would lead to a final concentration of 1% DMSO in all assay wells. 
 
A solution of the AR-LBD was prepared, diluting with the prepared 
buffer, the concentration of which was dependent upon the batch of protein 
used during the assay. 2.5 μL of a solution that was four times the final 
desired screening concentration was added to the well to be assayed. 
 
A solution of the Tb3+ anti-GST antibody and the fluorescein-tagged 
peptide was prepared, diluting with the prepared buffer. Both these 
components in the solution were 4x the final concentration to be used in the 
assay: 2000 nM for the fluorescein-tagged peptide, and either 40 or 20 nM of 
the Tb3+ anti-GST antibody, depending on the requirements of each batch of 
antibody used. 2.5 μL of this solution was added to all wells, leading to final 
concentrations of 500 nM, and either 10 or 5 nM, for the fluorophore and 
antibody components respectively. 
 
The plate was then left to incubate for 4 hours, and read using a 
Perkin-Elmer Envision 2103 Multilabel reader, equipped with a 320 nM 
excitation filter (14 nM bandwidth, excites Tb3+), and 495 nM (14 nM 
bandwidth, detects Tb3+ fluorescence) and 520 nM (10 nM bandwidth, 
detects fluorescein fluorescence) emission filters. A 400 nM dichroic mirror 
with a delay window of 100 μs and an integration window of 200 μs were 
used to detect the fluorescence at an excitation light percentage of 50%. 3 
repeat measurements were obtained, and the results of each measurement 
averaged during processing. 
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Three repeat measurements were obtained, and the results of each 
measurement averaged, before combining to generate the final data. In the 
rare case of there being a clear inconsistent outlier within the three points, it 
was deleted to create a duplicate point. Each data point was normalised 
relative to the controls, obtaining percentage activity relative to the 10 μM 
testosterone positive control (EC50 = 17 nM). 
 
6.6.2 Procedure for Dose-Response Assay 
 
DMSO solutions of compounds to be tested were prepared at a 
concentration 100 times that of the desired final screening concentration. 
This solution was then subject to serial dilution with DMSO across 12 points 
in either a three-fold or four-fold manner (see specific dose response assay 
for detail). The 100x solutions were then diluted to 2x that of the final 
screening concentration with the prepared buffer, before addition of 5 μL to 
the desired wells in triplicate. The general assay procedure specified in 6.6.1 
was then followed, and the data analysed to produce the observed results. 
 
 
6.6.3 Procedure for Single Point Assays 
 
DMSO solutions of the product mixtures were made relative to the 
concentration of the armed substrate in the reaction array (Σ[𝑃𝑛] = 100 mM). 
This solution was diluted to 100x the final screening concentration with 
DMSO, before preparation of a 2x the final screening concentration solution 
of each with the prepared buffer. 5 μL of each solution was added to the 
assay plate in triplicate. The general assay procedure specified in 6.6.1 was 
then followed, and the data analysed to produce the observed results. The 
relevant final screening concentration is described in the main text relevant 
for each single-point assay executed. 
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6.7 Structural Data used for Cheminformatics Pipeline 
 
  
The cheminformatics workflow enabled a library of 250,000 
commercially available compounds from Sigma-Aldrich and Fluorochem to 
be filtered, allowing selection of suitable co-substrates for ADS reaction 
arrays. The compounds selected had desirable structural motifs with 
potential for organocatalytic reactions, in addition to possessing desirable 
physiochemical parameters (Figure 3.4). The structural motifs used to filter 
the library are shown in Figure 6.1: they demonstrate good diversity with 
regard to their potential reactivity with both secondary amine and NHC 
catalyst classes. 
 
Figure 6.1 – Structural motifs that were used to filter for potential co-
substrates for the first round of exhaustive ADS. 
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6.8 Full Data for Round 1 Exhaustively Designed ADS Arrays 
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Figure 6.2 – Assay data for reactions involving substrate A1 with the sodium 
borohydride reduction protocol, screened at 𝚺[𝑷𝒏] = 10 μM. 
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Figure 6.3 - Assay data for reactions involving substrate A1 with the 
reductive amination protocol, screened at 𝚺[𝑷𝒏] = 10 μM.  
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Figure 6.4 - Assay data for the reactions involving substrate A2 with the 
sodium borohydride reduction protocol, screened at 𝚺[𝑷𝒏] = 10 μM. 
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Figure 6.5 - Assay data for reactions involving the substrate A2 with the 
reductive amination protocol, screened at 𝚺[𝑷𝒏] = 10 μM.   
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Figure 6.6 - Assay data for reactions involving A3 with the sodium borohydride 
reduction protocol, screened at 𝚺[𝑷𝒏] = 10 μM. 
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Figure 6.7 - Assay data for reactions involving the substrate A3 with the 
reductive amination protocol, screened at 𝚺[𝑷𝒏] = 10 μM.   
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Figure 6.8 - Assay data for reactions involving substrate A4 with the sodium 
borohydride reduction protocol, screened at 𝚺[𝑷𝒏] = 10 μM. 
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Figure 6.9 - Assay data for reactions involving the substrate A4 with the 
reductive amination protocol, screened at 𝚺[𝑷𝒏] = 10 μM.   
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Figure 6.10  - Assay data for reactions involving substrate A5 with the 
sodium borohydride reduction protocol, screened at 𝚺[𝑷𝒏] = 10 μM. 
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Figure 6.11 - Assay data for reactions involving the substrate A5 with the 
reductive amination protocol, screened at 𝚺[𝑷𝒏] = 10 μM.   
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6.8.1 Round 1 Validation Study 
 
The following data shows the validation arrays for the hits identified 
from the first round reaction arrays using organocatalytic ADS. The reactions 
were repeated identically to the first round reactions and screened again 
using the single-point assay protocol at a screening concentration of Σ[𝑃𝑛] = 
10 μM. Reactions that were highlighted to develop a new reaction array are 
highlighted, and summarised in Table 3.2.   
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A4B16C3
A5B31C3
A2B15C4
A2B18C4
A4B3C4
A4B16C4
A5B5C4
A5B15C4
A1B4C4
A2B23C1R
A4B28C2
A5B28C2
A3B31C3
0
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Pos
Neg
A2B20C1
A3B4C1
A3B6C1
A3B8C1
A5B3C1
A5B7C1
A5B12C1
A5B18C1
A1B12C2
A1B28C2
A2B1C2
A3B6C2
A5B7C2
A1B2C3
A1B3C3
A1B4C3
A1B19C3
A2B1C3
A2B10C3
A2B20C3
A4B20C3
A5B3C3
A5B12C3
A5B23C3
A1B1C4
A2B1C4
A2B10C4
A5B4C4
A4B34C1
A2B21C2
A1B35C4
A3B19C4
A5B10C4
0
5
0
1
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6.9 Design of Round 2 ADS Reaction Arrays 
 
Substrates for Round 2 are shown in the following tables. For each 
active combination identified from the first round of the exhaustive reaction 
arrays, up to 7 structurally-related analogues of the co-substrate were 
selected with the aid of cheminformatics tools such as Pipeline Pilot and 
Knime. The co-substrates had favourable properties, in addition to exhibiting 
structural similarity to the co-substrate present in the original active 
combination.  
 
Additionally, each new reaction featured both catalysts within the 
class that was used in the original hit. For example, if NHC catalyst system 
was used in the original hit, both NHC systems (C3 + C4) were used in the 
new reaction. The substrate and work-up protocol in each reaction remained 
the same for each new combination. 
 
A1B31C1R 
 
A1 
 
B31 
 
+ ent, 1 equiv. NEt3 
CHCl3 
C1 
 
D1 
 
D2 
 
D3 
 
D4 
 
D5 
 
D6 
 
D7 
 
As the hit reaction used a secondary amine catalyst system, both secondary amine 
catalysts (C1 + C2) were used in all new combinations, with D1-D7 replacing B31. 
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A5B31C3R 
 
A5 
 
B31 
 
DBU, THF 
C3 
D1 – D7 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with D1-D7 replacing B31. 
 
A4B16C3R 
 
A4 
 
B16 
 
DBU, THF 
C3 
D1 – D7 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with D1-D7 replacing B31. 
 
A4B16C4R 
 
A4 
 
B16 
 
DBU, THF 
C4 
D1 – D7 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with D1-D7 replacing B31. 
 
A3B19C1R 
 
A3 
 
B19 
 
+ ent, 1 equiv. NEt3 
CHCl3 
C1 
 
E1  
E2 
 
E3  
E4 
181 
 
E5 
   
 
 
As the hit reaction used a secondary amine catalyst system, both secondary amine 
catalysts (C1 + C2) were used in all new combinations, with E1-E5 replacing B19. 
 
A3B8C2R 
 
A3 
 
B8 
 
+ ent, CHCl3 
C2 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
As the hit reaction used a secondary amine catalyst system, both secondary amine 
catalysts (C1 + C2) were used in all new combinations, with F1-F7 replacing B8. 
 
A5B28C2R 
 
A5 
 
B28 
 
+ ent, CHCl3 
C2 
 
G1 
 
G2 
 
G3 
 
G4 
182 
 
G5 
   
As the hit reaction used a secondary amine catalyst system, both secondary amine 
catalysts (C1 + C2) were used in all new combinations, with G1-G5 replacing B28. 
 
 
A4B3C4R 
 
A4 
 
B3 
 
DBU, THF 
C4 
 
H1 
 
H2 
 
H3  
H4 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with H1-H4 replacing B3. 
 
 
A5B5C4R 
 
A5 
 
B5 
 
DBU, THF 
C4 
 
I1 
 
I2 
 
I3 
 
I4 
 
I5 
 
I6  
I7 
 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with I1-I7 replacing B5. 
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A5B15C4R 
 
A5 
 
B15 
 
DBU, THF 
C4 
 
J1 
 
J2 
 
J3 
 
J4 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with J1-J4 replacing B15. 
 
 
A2B20C1RA 
 
A2 
 
B20 
 
+ ent, 1 equiv. NEt3 
CHCl3 
C1 
 
K1 
 
K2 
 
K3 
 
K4 
 
K5 
 
K6 
 
K7 
 
As the hit reaction used a secondary amine catalyst system, both secondary amine 
catalysts (C1 + C2) were used in all new combinations, with K1-K7 replacing B20. 
 
A4B20C3RA 
 
A4 
 
B20 
 
DBU, THF 
C3 
K1-K7 
As the hit reaction used an NHC catalyst system, both NHC catalyst systems (C3 + 
C4) were utilised for all new combinations, with K1-K7 replacing B20. 
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6.10 Methods for Evaluation and Scale-Up 
 
To evaluate reactions that indicated bioactivity in the ADS reaction 
arrays, a number of methods were used to identify both reaction conversion 
and bioactivity of components, that are outlined in Section 1.1. 
 
6.10.1 NMR Analysis Reaction Tracing Experiments 
 
Reactions were recreated as they were carried out in the original 
reaction arrays, albeit on a scale five times larger, and utilising deuterated 
solvents to facilitate NMR analysis. Analysis of the reactions was only 
carried out prior to execution of the work-up conditions, as this would allow 
validation that any products that were formed were the result of 
intermolecular organocatalytic reactions. 
 
1. Obtain 13C NMR (125 MHz) analyses for the separate components in 
deuterated solvents. 
2. For the desired reaction in each well, add first 50 μL of the substrate 
solution, followed by 100 μL of the co-substrate solution. 
3. Allow evaporation.  
4. Add 500 μL of the desired catalytic system in deuterated solvent, before 
transferring to an NMR tube and sealing. 
5. 13C NMR (125 MHz) was carried out at 6 hour, 24 hour and 48 hour 
intervals to allow observation of changes in reaction mixture composition. 
 
Analyses for the reaction mixtures A5G5C1R and A1TB20C3R are 
shown in Figure 3.20 and Figure 3.21 respectively. Analysis for the reaction 
mixture A2TB20C3R can be observed below. 
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Armed Substrate Co-Substrate Catalyst/Additive 
 
  
in d8-THF 
 
 
 
6.10.2 Crude Dose-Response Experiments 
 
The reaction mixtures from the NMR analysis were subjected to the 
relevant work-up protocols, before evaporating to obtain the residue of the 
crude product mixture. This crude product mixture was then assayed using 
the dose-response protocol outlined in Section 6.6.2, with the concentration 
screened at remaining relative to the limiting substrate. 
Cl
Cl
H
O
O
O
HO
Table 6.2 - Analysis of the A2TB20C3R combination via 500 MHz 13C-NMR 
demonstrated conversion of both substrate and co-substrates, and 
formation of new peaks prior to being subjected to the sodium borohydride 
reduction. Blue dots indicate new peaks in NMR spectra. 
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6.10.3 Fractionation of Reactions 
 
The reactions outlined in Table 3.3 and Table 3.4 were repeated as 
they had been in the reaction arrays, albeit in a round-bottomed flask and 
scaled up by a factor of 50. Following execution of the work-up, the product 
mixtures were evaporated under reduced pressure, and subsequently 
fractionated via flash column chromatography, eluting with slow-running 
solvent systems to attempt to isolate individual components within the 
reaction mixture. All columns were flushed with DCM–MeOH (98:2) following 
the fractionation to obtain any remaining polar fractions from the column. 
The fractions were then evaporated under reduced pressure, and each 
fraction of the reaction screened using the single-point assay procedure 
outlined in Section 6.6.3 at a concentration of 20 μM relative to the limiting 
substrate.  
 
Reaction Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 6 Fraction 7 
A5G5C1R 30 60 45 16 5 13  
A2K1C1RA 3 1 1 11 8 15 9 
A4K1C3RA 6 6 -1 19 0   
A5J4C3R 12 5 -2 7 -3 1  
A4D5C4R 7 14 8 3 -6 -9  
A4H4C4R 6 7 7 1 -5 -9  
A1TB6C1R 5 3 7 19 18 0  
A1TB20C3R 2 14 24 8 2   
A1TB22C3R -17 11 7 6 14   
A2TB20C3R 19 28 14 18 5   
A2TB22C3R 9 11 7 6 14   
 
 The results from the NMR reaction tracking by 13C NMR, the crude-
dose response curves and the fractionation (Table 6.3) were interpreted to 
indicate that bioactive components were in the product mixtures A5G5C1R, 
A1TB20C3R and A2TB20C3R. The 1H NMR analysis of the relevant 
fractions indicated that they were the same as compounds 35, 36 and 37 
respectively, each of which were synthesised via an independent method.  
Table 6.3 – Bioactivity (% value relative to that of testosterone (10 μM)) of 
the fractions at a 20 μM screening concentration  
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Figure 6.12  - 1H NMR spectrum (500 MHz) of the bioactive Fraction 2 of 
A5G5C1R – the NMR is the same as observed for 35a. 
Figure 6.13 - 1H NMR spectrum (500 MHz) of the bioactive Fraction 2 of 
A5G5C1R – the NMR is the same as observed for 35b. 
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Figure 6.14 - 1H NMR spectrum (500 MHz) of the bioactive Fraction 2 of 
A1TB20C3R – the NMR is the same as observed for 36. 
Figure 6.15 – 1H NMR spectrum (500 MHz) of the bioactive Fraction 2 of 
A2TB20C3R – the NMR is the same as observed for 37. 
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